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Summary  
 
Folliculin (FLCN) is a tumour suppressor protein with unclear cellular function. Inactivating 
germline mutations in FLCN lead to Birt-Hogg-Dubé (BHD) syndrome. BHD patients have an 
increased risk of developing renal cell carcinoma (RCC). Unlike other genetic disorders with 
a predisposition to RCC, BHD patients are prone to all tumour subtypes (Khoo et al. 2003; 
Hudon et al. 2010). FLCN acts as a classical tumour suppressor in that a ‘second-hit’, 
deactivating mutation in the second allele, is required for cellular transformation. FLCN has 
been implicated in numerous signalling pathways and cellular processes. Most notably it is 
involved in mTOR, AMPK and HIF signalling, mitochondrial biogenesis, autophagy and 
membrane trafficking (Klomp et al. 2010; Tee and Pause 2013; Dunlop et al. 2014; Yan et al. 
2016a). Despite this breadth of function, its currently unclear how FLCN loss contributes to 
the development of RCC. Therefore, to better define the tumour suppressor role of FLCN a 
protein-protein interaction assay, using FLCN as bait, was carried out. This revealed that 
FLCN interacts with numerous proteins involved in DNA-damage response and/or cell cycle 
regulation. To explore this further, RNAi was used to generate FLCN knockdown in human 
proximal tubule kidney cells. In this study, FLCN was demonstrated to interact with DNA-
dependent protein kinase catalytic subunit (DNA-PKcs); the apical protein in non-
homologous end joining repair (NHEJ) of double strand DNA breaks (DSB). The association of 
FLCN with DNA-PKcs was shown to weaken when cells are subjected to DNA damage (via 
ionising radiation). As a direct consequence of FLCN knockdown evidence suggest kidney 
cells accumulate double-strand DNA damage. Furthermore, FLCN-deficient cells display 
perturbed G1/S checkpoint and it is thought these cells prematurely commit to cellular 
division. Ultimately, this thesis highlights a novel role of FLCN within renal cell tumorigenesis 
and suggests it could function to maintain genomic stability. Our basic understanding of RCC 
within the general population is limited. Nevertheless, genetic conditions (such as BHD) that 
predispose individuals to cancer, provide valuable insights into somatic tumour 
development. By using BHD syndrome as a model of genetic instability, further work should 
focus on mechanistically establishing FLCN’s role in genomic integrity and will provide 
valuable insight into sporadic renal cancer within the general population. 
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Chapter 1: Introduction  
 
1.1 A putative tumour suppressor protein; folliculin  
 
Birt–Hogg–Dubé syndrome (BHD) is an autosomal dominant disorder predisposing 
individuals to lung cysts, spontaneous pneumothorax, fibrofolliculomas, and renal cell 
carcinoma (Nickerson et al. 2002; Zbar et al. 2002). BHD was first described in 1977 (Birt et 
al. 1977), however, it wasn’t until 2002 that the gene encoding folliculin (FLCN) was 
identified, and its mutations associated with the disease (Nickerson et al. 2002). FLCN is a 
putative tumour suppressor, of which the cellular function is currently undefined. 
 
1.1.1 The folliculin gene 
FLCN was first mapped by genome wide linkage analysis, using polymorphic microsatellite 
markers, linking the gene to chromosome 17p12-q11.2 (Khoo et al. 2001; Schmidt et al. 
2001). The FLCN gene was identified shortly after when the critical region was narrowed to a 
700 kb segment on 17p11.2 (Nickerson et al. 2002). This genomic region is rich in unstable, 
low-copy number repeat elements. These are often subject to aberrant recombination 
events, resulting in deletions and duplications of the region (Stankiewicz and Lupski 2002). 
Deletions within this region cause Smith-Magenis Syndrome (Lucas et al. 2001), while 
duplications cause Charcot-Marie-Tooth Syndrome (Patel et al. 1992). Curiously, while 
the FLCN gene is often heterozygously deleted in Smith-Magenis Syndrome, patients do not 
seem to develop any BHD associated symptoms (Truong et al. 2010).  
The FLCN gene contains 14 exons spanning approximately 30 kb of genomic DNA 
(Figure 1.1) (Nickerson et al. 2002). To date 194 different FLCN mutations have been 
identified; 149 of which are thought to be pathogenic (Fokkema et al. 2011).  Most of the 
mutations are predicated to introduce a premature stop codon and result in a C-terminal 
truncated FLCN protein (Nickerson et al. 2002; Schmidt et al. 2005). Exon 11 is a mutation 
hotspot and contains a mononucleotide tract of eight cytosines (C8). Over half the 
mutations identified in exon 11 involve either a cytosine insertion or deletion; probably 
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caused by a slippage-mediated mechanism during DNA replication (Khoo et al. 2001; 
Nickerson et al. 2002; Schmidt et al. 2005). More recently, a second mutational hotspot was 
described within the non-coding region of exon 1. This region contains the FLCN promoter 
and the identified mutations were predicted to dramatically reduce FLCN expression 
(Benhammou et al. 2011).  
 
Figure 1.1 The mutation spectrum of the folliculin (FLCN) gene. Abbreviations: pMET = proposed 
deletion of initiator codon; MS = missense; FS = frameshift; NS = nonsense; AADel = amino acid 
deletion in-frame; SS = splice site. Image adapted from (Schmidt and Linehan 2015; Zhang et al. 
2016). 
 
1.1.2 The folliculin protein 
The human FLCN protein is 579 amino acids long (64 kDa), comprising of a short 
hydrophobic N-terminal sequence, a single N-glycosylation site, three myristoylation sites 
and a glutamic acid-rich coiled coil domain located centrally in the protein (Nickerson et al. 
2002). While FLCN is a highly evolutionarily conserved protein, the sequence has no 
significant homology to any known protein (Nickerson et al. 2002). It does, however, share 
domain similarities with proteins involved in cell trafficking. X-ray crystallography of FLCN’s 
C-terminal domain (PDB ID: 3V42, figure 1.2A) shows a β-sheet with helices on one side, 
followed by an all helical region (Nookala et al. 2012). This formation is akin to differentially 
expressed in normal and neoplastic cells (DENN) domain proteins (figure 1.2B). The DENN 
domain is a poorly characterised protein component. Proteins that contain a DENN domain 
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typically function as Rab guanine nucleotide exchange factors (GEFs) (Marat et al. 2011) and 
facilitate the recruitment of effectors that control multiple aspects of membrane trafficking. 
To date, the N-terminal domain of FLCN remains uncharacterised. Work is currently ongoing 
to establish the crystal structure of this region; it has been computationally predicted to 
form the longin domain. Longin domains seem to be important for regulating membrane 
trafficking and are typically present in other DENN-domain containing proteins. The N- and 
C-terminal domains of FLCN are connected by a 40 amino acid flexible linker region, 
containing a bipartite tryptophan (WD-WQ) motif, sharing similarity with a binding motif 
present in the intracellular trafficking protein, kinesin light chain 1 (Dodding et al. 2011). 
Collectively, early studies into its structure suggest FLCN may play a role in membrane 
trafficking.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 The folliculin (FLCN) protein. A) Crystal structure of C-terminal domain of FLCN at 2Å 
resolution. Two FLCN molecules are present in the asymmetric unit. The N-terminus of the FLCN 
molecule is blue and the C-terminus is red. B) C-terminal domain of FLCN is structurally similar to the 
DENN domain of DENN1B protein. C-terminal domain of FLCN is shown in blue and DENN domain of 
DENN1B is shown in magenta. Images A and B taken from (Schmidt and Linehan 2018). C) Post-
translational modification sites of FLCN. Single letter amino acid code used to denote amino acid 
that is modified, S = serine; T = threonine; K = lysine; R = arginine. Posttranslational modification 
sites were identified using PhosphositePlus® online resource, blue text = phosphorylation, green text 
= ubiquitination, red text = methylation. 
 
A) B) 
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1.1.2.1 Post-translational modifications  
Several post-transcriptional modification sites have been identified on FLCN; the majority of 
which are phosphorylation events (figure 1.2C). Of note, serine 62 (Ser62) phosphorylation 
is indirectly up-regulated by 5′-AMP activated protein kinase (AMPK) (Wang et al. 2010) and 
phosphorylation at Ser302 by an unknown kinase(s) downstream of mTORC1 (Piao et al. 
2009). Given that mTORC1 is known to be down regulated by AMPK, this process could be a 
feedback mechanism that regulates mTOR signalling. Furthermore, mTORC1 has been 
shown to phosphorylate Ser62 and Ser73 of FLCN (Yu et al. 2011). Interestingly, 
phosphorylation of these sites appears to be cell-cycle related, where Ser62 and Ser73 of 
FLCN become phosphorylated as the cell cycle progresses, with the maximum number of 
phosphorylated protein seen during the mitotic phase (Dephoure et al. 2008; Laviolette et 
al. 2013). These modifications correlated with a reduction in FLCN stability (Laviolette et al. 
2013). Additionally, the Ser302 site is maximally phosphorylated during G1 phase (Dephoure 
et al. 2008), but it is unclear why. 
ULK1 inhibits FLCN’s interaction with GABARAP by phosphorylating three sites in the 
C-terminus of FLCN; Ser406, Ser537 and Ser542. However, ULK1 was still able to block the 
interaction of GABARAP and a triple serine-to-alanine FLCN mutant in vitro, meaning other 
phosphorylation sites in FLCN, GABARAP and/or the FNIP proteins (see section 2) are 
important for this interaction (Dunlop et al. 2014). Two other ULK1 phosphorylation sites 
were identified at Ser316 and Thr317, but these are not well conserved between species 
(Dunlop et al. 2014). 
Additional post-translational modifications include: phosphorylation events on 
Thr244, Ser298, Ser558, and Ser571 (Sharma et al. 2014; Parker et al. 2015); ubiquitination 
on lysine residues lys206, lys272 and lys559 (Wagner et al. 2011; Udeshi et al. 2013); and 
monomethylation at arginine 477 (Larsen et al. 2016) (figure 1.2C). The relevance of these 
post-translational FLCN modifications have yet to be determined.  
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1.2 Interacting partners of FLCN 
 
1.2.1 Folliculin-interacting protein 1 (FNIP1) 
Due to its lack of homology with known functional domains, efforts to define FLCN’s 
function have shifted from structural studies to looking for interacting partners to define 
FLCN’s role. The first protein partner identified through co-immunoprecipitation studies was 
‘folliculin interacting protein 1’ (FNIP1), a 130 kDa protein also without recognisable 
functional domains. FNIP1 is expressed in a similar pattern to FLCN (Baba et al. 2006), and 
binds to FLCN’s C-terminus (Baba et al. 2006). FNIP1 was found to interact with AMPK, a 
heterotrimeric Ser/Thr protein kinase that serves as a critical energy sensor in cells and a 
negative regulator of mTOR complex 1 (Baba et al. 2006; Shackelford and Shaw 2009). FLCN 
interacted with the FNIP1/AMPK complex in vitro but was not essential for the FNIP1/AMPK 
interaction. FNIP1 preferentially binds the phosphorylated form of AMPK, and both FLCN 
and FNIP1 can be phosphorylated by AMPK (Baba et al. 2006). FNIP1 immunoprecipitates 
are enriched with the phosphorylated forms of FLCN (Baba et al. 2006). Mutation of Ser62 
within FLCN does not affect FNIP1 binding to FLCN, but slightly reduces FLCN’s binding to 
the AMPKα1 subunit. Therefore, it is thought that FLCN phosphorylation at Ser62 may 
stabilise or enhance the association of the AMPK/FNIP1/FLCN protein complex (Wang et al. 
2010). 
 
 
1.2.2 Folliculin-interacting protein 2 (FNIP2) 
A second folliculin-interacting protein, FNIP2 was identified through bioinformatic analysis 
of sequence databases for FNIP1 homologs (Hasumi et al. 2008; Takagi et al. 2008). FNIP2 
has 49% identity and 74% similarity to FNIP1 (Hasumi et al. 2008). The tissue expression 
of FNIP2 mRNA is similar to both FNIP1 and FLCN, suggesting that both FNIP1 and FNIP2 
may have redundant function to regulate FLCN. Preferential FNIP2 expression is found in fat, 
liver, kidney and pancreas, which may imply a more specific function of FNIP2 in metabolic 
tissues (Hasumi et al. 2008). Similar to FNIP1, FNIP2 also interacts with the C-terminus of 
FLCN and is directly phosphorylated by AMPK (Hasumi et al. 2008; Takagi et al. 2008).   
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1.2.3 Functional studies in FNIP1/FNIP2-deficient in vivo models 
Although identified as FLCN-binding partners, FNIP1 and FNIP2 are themselves newly 
discovered proteins, and studies are ongoing to determine how FNIP1 and FNIP2 function 
with FLCN. So far, mice knockout models on Fnip1 show B-cell deficiency due to a block in B-
cell development. Two models suggest this phenotype was caused by caspase-induced cell 
death and was rescued by expression of the anti-apoptotic protein Bcl2 (Baba et al. 2012; 
Siggs et al. 2016). A third mouse model showed Fnip1 deficiency resulted in increased AMPK 
and peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α) 
expression leading to increased mitochondrial biogenesis and dysregulation of pre-B cells 
(Park et al. 2012). Furthermore, Fnip1-deficient mice were also reported to develop 
cardiomyopathy (Hasumi et al. 2015; Siggs et al. 2016). A switch from type 2 “fast twitch” to 
type 1 “slow twitch” skeletal muscle fibre, and an increase of AMPK activation and 
expression of its target PGC1α leading to increased mitochondrial biogenesis (Reyes et al. 
2015) was also observed.  The significance of these findings remains uncertain. BHD patients 
with germline FLCN mutations do not develop B-cell or muscle tissue manifestations 
highlighted by the Fnip1-deficient mice, suggesting FNIP1 has function independent of FLCN.  
 
Mice with kidney-targeted Fnip1 and Fnip2 double inactivation develop cystic 
kidneys, that express elevated levels of PGC1α and display increased mitochondrial 
biogenesis (Hasumi et al. 2015), mimicking the phenotype of kidney-targeted Flcn knockout 
mice (Baba et al. 2008; Chen et al. 2008). In addition, both heterozygous inactivation of 
Fnip1 or homozygous inactivation of Fnip2 causes renal tumours in mice. Therefore, at least 
within the kidney, these proteins are somewhat redundant in function (Hasumi et al. 2015).  
 
Interestingly, FNIP1 and FNIP2 were shown to form homodimers and heterodimers 
with each other. FLCN and AMPK subunits were present in all immunoprecipitates 
containing these FNIP1/FNIP2 multimeric complexes (Hasumi et al. 2008). The functional 
significance of the varying FNIP1/FNIP2 multimeric complexes awaits further investigation 
to clarify their impact on FLCN function, and on cellular signalling. 
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1.3 Pathways and cellular processes associated with folliculin function  
Since its identification in 2002, several genetic and biochemical studies have attempted to 
understand the molecular function of FLCN. To date FLCN has been implicated in a number of 
diverse cellular processes; however, there are inconsistencies in the roles found for FLCN. 
Therefore, the tumour suppressor function of FLCN remains unclear. Recognised functions of 
FLCN are discussed below. 
1.3.1 Membrane trafficking and GTPases function 
Initial studies suggested FLCN may have a role in membrane trafficking. Collectively, X-ray 
crystallography, fold recognition, and structure prediction software identified a DENN-like 
domain in the C-terminal of FLCN (Nookala et al. 2012). DENN domains are found within the 
Rab guanine exchange factor (GEF) protein family whose members function as regulators of 
membrane trafficking (Marat et al. 2011). GEFs activate Rab proteins by mediating the 
exchange of GDP for GTP. In vitro, the C-terminal domain of FLCN was shown to have GEF 
activity towards Rab35 (Nookala et al. 2012).  
 
FLCN has also been linked to another GTPase protein family; the Rag GTPases. These 
play an important role in amino acid signalling and FLCN was shown to interact with Rag 
proteins at the lysosome (Petit et al. 2013; Tsun et al. 2013).  Interestingly, FLCN may 
have a dual function, as it can also act as a GEF and a guanine activating protein (GAP) to 
members of the Rag GTPase family. One study suggested FLCN may have GEF activity for 
Rag A (Petit et al. 2013), while another showed FLCN may act as a GAP for Rag C/D (Tsun 
et al. 2013). FLCN’s role with Rag GTPases is discussed in section 1.3.2.1. Additionally, 
FLCN’s C-terminal domain has also been shown to bind with Rab7A, and wild-type FLCN is 
able to stimulate Rab7A GTP hydrolysis (Laviolette et al. 2017). Rab7A plays a central role in 
endosomal recycling and lysosomal degradation of epidermal growth factor 
receptor (EGFR). FLCN loss resulted in slower endocytic trafficking and an accumulation of 
EGFR in early endosomes, where the ligand-stimulated EGFR signalling cascade can still be 
active. EGFR activation is also observed in FLCN-deficient mouse tumours and BHD-
associated kidney tumours (Laviolette et al. 2017). FLCN has also been shown to interact 
directly, via its C‐terminal domain, with the Rab34 effector RILP. This interaction promotes 
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the loading of active GTP-bound Rab34 onto RILP during nutrient withdrawal and causes 
peri‐nuclear clustering of lysosomes (Starling et al. 2016). Collectively, the experimental 
evidence to date reveals that FLCN likely has dual functionality, acting as both a GAP and 
GEF for small GTPase in order to regulate vesicle trafficking linked to nutrients.  
 
1.3.2 mTOR signalling pathway 
The mammalian target of rapamycin (mTOR) signalling pathway serves as a central regulator 
of cell metabolism, proliferation, and survival. It is commonly dysregulated in many cancers 
(Rad et al. 2018). FLCN’s involvement in mTOR signalling is complicated and the literature 
has contradictory findings. Flcn heterozygous knockout mice develop kidney tumours with a 
long latency (> 10 months) only after having lost the wild type Flcn allele. Within these FLCN 
deficient tumours, increased activation of AKT, a substrate of mammalian target of 
rapamycin complex 1 and 2 (mTORC1 and mTORC2) can be observed (Hasumi et al. 2009). 
When Flcn knockdown is targeted to mice kidneys, mice die by 3 weeks of age due to 
enlarged polycystic kidneys and renal failure (Baba et al. 2008; Chen et al. 2008). When 
analysed, the renal cysts displayed elevated levels of phosphorylated AKT (p-AKT), 
phosphorylated mTOR (p-mTOR) and phosphorylated ribosomal protein S6 (p-RPS6, a 
downstream effector and surrogate marker of mTOR activity) demonstrating 
hyperactivation of the mTORC1 pathway in Flcn-deficient mice kidneys (Baba et al. 2008; 
Chen et al. 2008). Furthermore, when targeted exclusively to the proximal tubules in the 
kidney of mice, FLCN deletion led to renal cysts and early onset renal neoplasms (≥ 6 
months) with high tumour penetrance (Chen et al. 2015). These growths also displayed 
elevated levels of p-AKT, p-mTOR, and p-RPS6. Furthermore, treatment with the mTOR 
inhibitor rapamycin limited the cystic formations and tumour growths in mice (Baba et al. 
2008; Chen et al. 2008; Chen et al. 2015). In humans, renal tumours from BHD patients with 
germline FLCN mutations also present hyperactivated mTORC1 signalling (Baba et al. 2008; 
Hasumi et al. 2008).  Increased p-mTOR and p-RPS6 were found in cyst-lining epithelial cells 
from BHD patient lungs, and increased p-RPS6 protein levels were seen in human lung-
derived cells with FLCN knockdown (Khabibullin  et al. 2014).  
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Collectively, these data support a role for FLCN in suppressing mTORC1 activation. 
Nonetheless, there also exists evidence to suggest FLCN may have an activating role in the 
mTORC1 pathway. In the yeast model, Schizosaccharomyces pombe (S. pombe), deletion of 
the Flcn homolog, bhd, resulted in hypersensitivity to rapamycin suggesting that bhd 
activates the yeast Tor (van Slegtenhorst et al. 2007). In mice, two in vivo Flcn knockdown 
models showed additional evidence that FLCN may positively regulate mTORC1 signalling. In 
the first model, mice developed micro-cysts and presented with a low frequency of 
oncocytic tumours. These oncocytic tumours displayed a reduction in their p-
RPS6 immunostaining,  suggesting less mTORC1 activity (Hartman et al. 2009). The second in 
vivo Flcn knockdown model developed numerous renal cysts and adenomas over a wide age 
range. p-RPS6 immunostaining was variable and depended on cyst size and number; 
showing elevated expression in large, multilocular cysts and weak to no p-RPS6 staining in 
small, single cysts (Hudon et al. 2010). Reduced p-RPS6 has also been observed in several 
mammalian cell lines with transient downregulation of FLCN (Takagi et al. 2008; Hartman et 
al. 2009; Bastola et al. 2013). 
This conflicting data suggests FLCN loss, particularly with the regards to renal 
tumours, is more complex than a simple activation of mTORC1, and may depend upon cell 
type and knockdown method (Khabibullin  et al. 2014). Mice models that revealed that FLCN 
inhibits mTORC1 signalling where created using a Cre/LOX system, whereas models 
supporting an activating role were created using gene trap vector technology. It could also 
be dependent on nutritional/energy status of cells (See section 3.2.1 for more information) 
(Hudon et al. 2010; Tsun et al. 2013). Equally, FLCN loss may affect additional signalling 
pathways, such as Raf-MEK-ERK signalling, that in turn can affect mTORC1 signalling (Baba 
et al. 2008). 
 
1.3.2.1 Interaction with Rag GTPases for amino acid-dependent mTORC1 activation on lysosomes 
 
FLCN is selectively recruited to the lysosome after amino acid starvation and may have a 
role in nutrient-dependent lysosome-associated regulation of mTORC1 (Petit et al. 2013; 
Tsun et al. 2013). mTORC1 integrates cellular signals from nutrients, growth factors and 
energy to drive cellular proliferation and inhibit nutrient scavenging. Nutrients, such as 
amino acids, glucose and lipids, drive the recruitment of mTORC1 to the lysosomes via 
10 
 
the Rag GTPases (Bar-Peled and Sabatini 2014). The ‘inactive’ combination of guanosine 
diphosphate (GDP)-loaded Rag A/B and guanosine triphosphate (GTP)-loaded Rag C/D 
cannot bind to mTORC1, which remains indolent in the cytoplasm. The ‘active’ GTP-
loaded Rag A/B and GDP-loaded Rag C/D complex, on the other hand, engage mTORC1 to 
the lysosomal surface (Bar-Peled and Sabatini 2014).  
FLCN’s interacting partners, FNIP1 and FNIP2, have been shown to interact with Rag 
proteins and are necessary for starvation-induced localisation of FLCN to the lysosomes. In 
turn, the FLCN-FNIP1/2 complex allows the dissociation of mTORC1 from the lysosomes 
(Tsun et al. 2013). It is unclear if FLCN functions as a GAP or GEF, and how FNIP1/2 are 
required for this process. In vitro purified FLCN-FNIP2 complexes stimulated GTP hydrolysis 
by Rag C and Rag D, but not by Rag A or Rag B (Tsun et al. 2013) suggesting FLCN-FNIP2 acts 
as a GAP complex for Rag C/D and promotes mTORC1 localisation to the lysosomal surface. 
However, another study reports that FNIP1, not FNIP2, facilitated this process (Petit et al. 
2013). Furthermore, FLCN has been shown to preferentially bind the inactive or GDP-loaded 
Rag A through its GTPase domain (Petit et al. 2013). This is a property commonly seen in 
GEFs, suggesting it may function as a GEF towards RagA/B. In both cases, FLCN was 
selectively recruited to the lysosome after amino acid depletion and interacted with Rag 
GTPase heterodimers. These data underscore the role of the FNIP proteins in facilitating the 
nutrient-dependent lysosome association of FLCN. Consistently, FLCN was required for the 
recruitment and activation of mTORC1 in response to amino acids. However, taking into 
account previous work on mTOR signalling, it is still not clear if FLCN’s ability is to either 
inhibit or activate mTORC1. 
Furthermore, the cellular signals that send FLCN to the lysosome under nutrient-
depleted conditions remain uncertain. In Hela and  FLCN-deficient/FLCN-restored UOK257 
renal tumour cells, FNIP1 and FNIP2 are thought to be unstable when nutrients are 
abundant and mTORC1 is active (Nagashima et al. 2017). Given that FNIP1/FNIP2 were 
shown to be necessary for starvation-induced localisation of FLCN on the lysosomes and for 
dissociation of mTORC1 from the lysosomes, FLCN nutrient-dependent lysosomal 
association is likely facilitated by the FNIP proteins. 
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1.3.3. Adenosine monophosphate (AMP)-activated protein kinase (AMPK) pathway signalling  
Similar to mTOR, AMPK is considered a master regulator of energy homeostasis within the 
cell. AMPK directly regulates energy by phosphorylating metabolic enzymes and nutrient 
transporters, and indirectly regulates energy production by promoting the transcription of 
genes involved in mitochondrial biogenesis and function. AMPK acts upstream of mTOR, 
which both function as energy sensors responding to and maintaining energy balance within 
tissues. AMPK phosphorylates and activates ULK1, which is a negative regulator of mTOR 
(Dunlop et al. 2014). Furthermore, AMPK can directly phosphorylate Tuberous Sclerosis 
Complex 2 (TSC2) (Inoki et al. 2003), which switches Rheb to an inactive GDP-bound state to 
turn off mTOR (Tee et al. 2003). The interplay of AMPK and mTOR allows cells to coordinate 
an appropriate response to environmental conditions and helps the cell maintain energy 
homeostasis. Activated AMPK turns on catabolic pathways to enhance ATP production, 
while turning off anabolic pathways that consume ATP.  mTOR responds to energy 
availability through AMPK, and in turn determines the rate of cell growth and proliferation. 
Cellular levels of ATP increase mTOR signalling, as AMPK is switched off.  
 
FLCN has been shown to interact with AMPK through its protein partners FNIP1 and 
FNIP2 (Baba et al. 2006; Hasumi et al. 2008; Lim et al. 2012; Possik et al. 2014). Both FLCN 
and FNIP1 serve as substrates for AMPK in vitro (Baba et al. 2006). The association of FLCN, 
FNIP1/2, and AMPK in immunoprecipitates from multiple cell types suggests that they exist 
in a complex. As previously mentioned, investigations into the functional relationship 
between FLCN, FNIP1/2 and AMPK in vitro and in vivo have been ambiguous (see section 2). 
FLCN deficiency has been shown to facilitate AMPK activation in a variety of models 
including; nematodes, FLCN-null  thyroid carcinoma cells, mouse embryonic fibroblasts 
(MEFs), the kidneys of mice and in BHD-associated renal tumours (Possik et al. 2014; Yan et 
al. 2014) Loss of FLCN results in the activation of AMPK and, through Hypoxia Inducible 
Factor (HIF) signalling, leads to large metabolic changes consistent with the Warburg effect 
(Possik et al. 2014; Yan et al. 2014).  AMPK is a key regulator of glycogen metabolism. Acute 
activation of AMPK leads to the phosphorylation and inhibition of glycogen synthase, and 
favours glycogen degradation for supply of short-term energy (Wojtaszewski et al. 2002; 
Miyamoto et al. 2007). However, chronic AMPK activation results in glycogen accumulation 
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via glucose-6-phosphate-dependent allosteric activation of glycogen synthase bypassing the 
inhibitory effect of the AMPK-mediated phosphorylation (Hunter et al. 2011). An important 
role for glycogen is in organismal survival during stress. Indeed, flcn-1 deficiency in 
nematodes supported a higher resistance to hyperosmotic stress due to increased glycogen 
storage by AMPK (Possik et al. 2014).  Glycogen is often used by tumour cells to survive 
harsh microenvironments, such as hypoxia (Favaro et al. 2012; Zois et al. 2014). Indeed, 
glycogen accumulation occurs in many cancer types (Zois et al. 2014). 
 
Conversely, FLCN loss has also been shown to decrease AMPK signalling. FLCN-
deficient UOK257 cells, Flcn-null primary mouse alveolar epithelial cells (AEC), and siRNA-
induced Flcn knockdown in mouse epithelial NMuMG cells all display reduced AMPK 
activation under nutrient deprivation (Goncharova et al. 2014).  Within the lungs of mice, 
loss of FLCN results in cell apoptosis as a result of impaired AMPK activation and increased 
cleavage of caspase3. Treatment with AICAR, an AMPK activator, or constitutively active 
AMPK-mutant improved cell survival, lung surface tension and reduced an inflammatory 
response (Goncharova et al. 2014). Nevertheless, FLCN has been shown to have highly cell-
type-specific outcomes. In the same study, knockdown of FLCN in human bronchial 
epithelial (HBE) cells decreased the phosphorylation of acetyl-CoA (p-ACC), a marker of 
AMPK activation, while downregulation of FLCN in small airway epithelial (SAEC) cells 
increased the activity of AMPK (Khabibullin  et al. 2014). Collectively, the majority of the 
published literature supports FLCN acting as a negative regulator of AMPK. While it remains 
unclear exactly how FLCN regulates AMPK, FLCN appears to be required for a cell to respond 
appropriately to energy supply, where loss of function of FLCN can lead to metabolic 
transformation. 
 
 
1.3.3.1. PPARGC1A/PGC1α regulation and mitochondrial biogenesis driven by AMPK signalling 
 
AMPK activates signalling pathways that promote mitochondrial biogenesis and energy 
bioavailability, such as peroxisome proliferator–activated receptor gamma coactivator–1α 
(PGC-1α). PGC-1α is the principal transcription factor for mitochondrial biogenesis, and 
transactivates nuclear respiratory factors 1 and 2 (NRF1 and NRF2). In turn NRF1 and NRF2 
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increase the expression of the transcription factor A (TFAM), leading to mitochondrial gene 
transcription (Marin et al. 2017).  
 
Loss of FLCN in MEFs results in elevated PGC-1α expression, mitochondrial 
biogenesis and ATP production though the increased activity of AMPK. This leads to reactive 
oxygen species (ROS)-dependent activation of HIF-1α and a metabolic switch to aerobic 
glycolysis (Yan et al. 2014). Furthermore, Flcn knockdown in Ampk-deficient MEFs did not 
change PGC-1α expression or ROS levels, suggesting AMPK activation is the driving force for 
the PGC-1α-initiated metabolic switch following the loss of FLCN (Yan et al. 2014). Similarly, 
chronic hyperactivation of AMPK in vivo sequentially lead to PGC-1α-driven mitochondrial 
biogenesis, which then enhanced oxidative metabolism and metabolic reprogramming (Yan 
et al. 2016a). When targeted to mouse adipose tissue, Flcn inactivation led to a “browning” 
of white adipose tissue due to AMPK-dependent PGC-1α-, TFE3-, and mTORC1-dependent 
transcriptional control of energy metabolism (Wada et al. 2016; Yan et al. 2016a). When 
targeted to mouse kidney and muscle, Flcn inactivation again led to elevated PGC-1α gene 
expression, an increased number of mitochondria, and enhanced flux through the Krebs 
cycle (Hasumi et al. 2012). Notably, inactivation of PGC-1α reversed the PGC-1α driven 
metabolic phenotypes, and limited cystic growth in Flcn-deficient mice kidneys (Hasumi et 
al. 2012). When targeted to mice heart cells, Flcn inactivation caused dilated 
cardiomyopathy and mice die by 3 months of age. However, the Flcn-deficient hearts display 
increased mitochondria, ATP levels, and PGC-1α levels (Siggs et al. 2016). BHD-associated 
renal tumours demonstrate upregulation of both PGC-1α and TFAM transcription factors, 
along with a subset of PGC-1α regulated genes, all of which are known drivers 
of mitochondrial biogenesis (Klomp et al. 2010).  
 
Collectively, the evidence emphasises a central role for FLCN as a negative regulator 
of PGC-1α and mitochondrial biogenesis and suggests that AMPK activity causes an 
enhanced metabolic state upon the loss of FLCN. Tumour development in BHD may be 
driven, at least in part, by dysregulation of the PGC1α-TFAM axis. 
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1.3.4 Regulation of cell-cell adhesion, cell polarity, and RhoA activity 
FLCN has been linked to cell-cell adhesion through a direct interaction with p0071 
(PKP4/plakophilin) (Medvetz et al. 2012; Nahorski et al. 2012; Khabibullin  et al. 2014). 
p0071 is a member of the armadillo repeat containing protein family that also includes beta‐
catenin (β-catenin). p0071 binds E‐cadherin at adherens junctions and regulates the activity 
of the small GTPase RhoA in the cytoplasm (Hanna and El-Sibai 2013). RhoA signalling 
controls cytoskeletal remodelling, and regulation of focal adhesion that is required for cell 
migration (Hanna and El-Sibai 2013). FLCN has been shown to regulate RhoA signalling in a 
number of cell lines, where loss of FLCN enhanced cell-cell adhesion (Medvetz et al. 2012; 
Nahorski et al. 2012; Khabibullin  et al. 2014).  This suggests the FLCN-p0071 protein 
complex acts as a negative regulator of cell-cell adhesion. Interestingly, FLCN-deficient 
thyroid cancer cells displayed a more migratory phenotype when compared to wild-type 
controls, whereas data from BHD-RCC derived kidney cells suggested a migratory delay. 
Furthermore, FLCN was shown to negatively regulate cell-cell adhesions in three-
dimensional cell cluster assays (Medvetz et al. 2012). Despite conflicting roles as to whether 
loss of FLCN upregulates or down regulates RhoA signalling, the data supports a role for the 
interaction of FLCN and p0071 in the regulation of cell-cell adhesion.  
FLCN knockdown in polarised mouse inner medullary collecting duct (IMCD-3) cells 
resulted in a reduction of E-cadherin immunostaining (Nahorski et al. 2012). These cells had 
a delay in tight junction formation, which led to a disruption of cell polarity. A reduction in 
E-cadherin has also been noted in primary mouse lung AECs, (Goncharova et al. 2014). 
Interestingly, loss of E-cadherin is a common event in epithelial cancers, and loss of the RCC 
tumour suppressor gene, Von Hippel-Lindau, is associated with the down-regulation of E-
cadherin expression (Esteban et al. 2006).  
 
1.3.5. Regulation of autophagy 
Autophagy is a highly controlled process of degrading and recycling damaged organelles 
and macromolecules to replenish cellular energy and amino acid supply. Within the 
cytoplasm, materials are sequestered in specialised double membrane vesicles 
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called autophagosomes. Autophagosomes then fuse with lysosomes and the material is 
enzymatically degraded (Choi et al. 2013).  
 
FLCN knockdown in a human kidney cell line (HK2), FLCN-deficient MEFs and BHD-
associated kidney tumour tissue all show an accumulation of the autophagic marker 
sequestosome1 (SQSTM1/p62), which can be reversed with FLCN reintroduction (Dunlop et 
al. 2014). In addition, increased endogenous levels of GABA(A) receptor-associated protein 
(GABARAP), a component of mature autophagosomes, was observed in FLCN-
deficient HEK293 and HK2 cells, along with impaired maturation of autophagosomes 
(Dunlop et al. 2014). The FLCN-GABARAP interaction in mammalian cells was shown to be 
dependent on FNIP1 and FNIP2 association but displayed a preference for FNIP2. In 
addition, Unc-51 like autophagy activating kinase 1 (ULK1) is an activator of the autophagic 
process and a GABARAP interactor. ULK1 was shown to phosphorylate FLCN at three serine 
sites; Ser406, Ser537, Ser542 and the kinase activity of ULK1 was required for FLCN-FNIP2 
dissociation from GABARAP (Dunlop et al. 2014). Furthermore, BHD-patient derived FLCN 
mutations interacted more strongly with ULK1 than the wild type FLCN protein, showed 
impaired binding to GABARAP, and were not able to reverse SQSTM1/p62 levels as 
efficiently as wild-type FLCN (Dunlop et al. 2014) suggesting FLCN may be a positive 
modulator of autophagy.  
 
On the other hand, studies exploring the relationship between AMPK and FLCN in 
the flcn deficient Caenorhabditis elegans model, flcn-1(ok975), support an opposing role of 
FLCN in autophagy. In this model, loss of flcn-1 increased numbers of autophagic vacuoles 
and elevated resistance to oxidative stress through the AMPK ortholog, aak-2 (Possik et al. 
2014). This resistance was shown to be from increased autophagy and not ROS-related 
pathways. Furthermore, higher autophagic activity was shown to be aak-2 dependent and 
required for resistance to oxidative stress. Flcn-1 mutants showed an autophagy-driven 
increase of ATP levels which, in turn, protected against apoptosis. Similar findings have been 
noted in Flcn −/− MEFs and in thyroid carcinoma cells lacking FLCN (Possik et al. 2014). 
Overall, loss of FLCN in worm, mouse and human in vivo models resulted in activation of 
AMPK, elevated autophagy and increased ATP levels conferring resistance to metabolic 
stress. More in-depth studies will be required to understand these divergent results 
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regarding a role for FLCN in regulating autophagy. In addition, it is unclear how impaired 
autophagy may contribute to the BHD syndrome phenotype. 
 
 
1.3.6. Ciliogenesis and cilia-dependent flow sensory mechanisms 
Patients with both von Hippel-Lindau (VHL) and tuberous sclerosis complex (TSC) diseases 
have similar clinical manifestations to those with BHD, and all are susceptible to renal 
tumour growths. Both VHL and TSC have previously been linked to dysfunctional primary 
cilia (Esteban et al. 2006; Hartman et al. 2009). Therefore, a possible role for FLCN in cilia 
formation was explored. Cilia function as flow sensors and down regulate mTORC1 signalling 
through flow-mediated activation of Liver Kinase B1 (LKB1). LKB1 in turn phosphorylates and 
activates AMPK, which negatively regulates mTORC1 via phosphorylation and activation of 
TSC2 (Boehlke et al. 2010). FLCN was demonstrated to localise to primary cilia in several cell 
types, with both wild type and mutant forms of FLCN binding to the basal body during early 
ciliogenesis (Luijten et al. 2013). FLCN knockdown resulted in delayed development of cilia 
in serum starved cells (Luijten et al. 2013). Primary cilia restrict canonical Wnt signalling by 
sequestration of β-catenin in the basal body (Lancaster et al. 2011), and abnormal Wnt/β-
catenin signalling has been attributed to renal cyst formation (Kotsis et al. 2013). Elevated 
levels of un-phosphorylated (active) β-catenin and its downstream targets were observed in 
cultured mouse Flcn-deficient cells, suggesting Flcn deficiency may lead to kidney and lung 
cyst formation through defective ciliogenesis, resulting from an inappropriate activation of 
the canonical Wnt/β-catenin pathway (Luijten et al. 2013). In addition, FLCN was shown to 
recruit LKB1 to cilia and induce its association with AMPK for activation in response to flow 
stress (Zhong et al. 2016). Flow stress has been shown to reduce mTORC1 signalling in 
FLCN–expressing HKC-8 and FLCN-restored UOK257 cells in a cilium-dependent manner, but 
not in FLCN-deficient cells (Zhong et al. 2016). In the FLCN-deficient cells, increased AMPK 
activity and AMPK-mediated phosphorylation of TSC2 were attributed to mTORC1 inhibition. 
Furthermore, Kinesin Family Member 3A (KIF3A) has been identified as a FLCN-interacting 
protein(Zhong et al. 2016). KIF3A is one of two motor subunits that make up the kinesin-2 
motor required for primary cilium assembly and maintenance (Kim and Dynlacht 2013). 
These results support a role for FLCN as part of the mechanosensory machinery that 
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controls LKB1 and AMPK activation resulting in mTORC1 pathway inhibition through primary 
cilia.  
 
1.3.7 Regulation of gene transcription  
FLCN is thought to have negative regulatory effects on a broad range of gene transcription 
(Hong et al. 2010a; Betschinger et al. 2013; Gaur et al. 2013; Petit et al. 2013). In Drosophila, 
dBHD interacts with Rpt4, a known regulator of ribosomal RNA (rRNA) transcription (Gaur et 
al. 2013). Loss of dBHD resulted in upregulation of rRNA synthesis. Whereas an 
overexpression of dBHD reduced rRNA transcription by preventing the association of Rpt4 
with the ribosomal DNA locus (Gaur et al. 2013). Similarly, Rpt4 knockdown impedes the 
growth of FLCN-deficient human renal cancer cells in mouse xenografts (Betschinger et al. 
2013).  
FLCN has been linked to two key members of the MiT/TFE transcription factor family, 
TFEB and TFE3 (Hong et al. 2010a; Petit et al. 2013). The MiT/TFE transcription factor family 
are regulators of cell survival and energy metabolism, through the promotion of genes 
involved in lysosomal regulation, oxidative metabolism and the oxidative stress response 
(Slade and Pulinilkunnil 2017). TFEB and TFE3 are considered oncogenes and are often 
implicated in the development of sporadic renal cell carcinomas (RCC), clear cell sarcomas, 
and malignant melanoma (Argani et al. 2003; Kauffman et al. 2014). Specifically, TFEB is a 
master regulator of lysosomal biogenesis (Raben and Puertollano, 2016). Loss of FLCN 
results in an increase of nuclear TEFB (Petit et al. 2013). Previous work shows the nuclear 
localisation of TFEB is controlled by mTORC1-dependent phosphorylation of TFEB 
on serine 211 (Ser211) and inhibits its nuclear localisation when lysosome function is 
sufficient. TFEB Ser211 phosphorylation was reduced in FLCN-deficient cells, and along with 
elevated nuclear levels of the protein, an increase in lysosomal proteins was identified (Petit 
et al. 2013). Furthermore, FLCN has also been shown to be important for the cellular 
localisation of TFE3. Similar to TFEB, FLCN-deficient cells display a decrease in 
phosphorylation and elevated nuclear accumulation of TFE3, resulting in the increased 
expression of target genes (Hong et al. 2010a). In addition, expression of GPNMB, a 
surrogate for TFE3 activity, was found to be high in BHD-associated kidney tumours and in 
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kidney tumours from Flcn heterozygous knockout mice (Hong et al. 2010a; Furuya et al. 
2015). The nuclear sequestration of TFE3 in FLCN-deficient cells is thought to be due to the 
loss of mTORC1-dependent phosphorylation of TFE3 allowing localisation to the nucleus and 
activation of its target genes (Wada et al. 2016). FLCN’s roles in the regulation of gene 
transcription seem to centre around the trafficking of transcription factors, ensuring nuclear 
shuttling only when appropriate.  
1.3.8 Summary  
In addition to the known functions of FLCN described above, a number of published reports 
support roles for FLCN in other signalling pathways and cellular processes and 
include: JAK/STAT signalling (Singh et al. 2006), TGF-β signalling (Singh et al. 2006; Hong et al. 
2010b; Cash et al. 2011), Matrix Metalloproteinase signalling (Hayashi et al. 2010; Pimenta et 
al. 2012), regulation of HIF-1α transcriptional activity (Preston et al. 2011; Yan et al. 2014), the 
cell cycle (Kawai et al. 2013; Laviolette et al. 2013), and an interaction with HSP90α 
(Woodford et al. 2016).  Collectively, these studies suggest a multitude of cell-type- and/or 
tissue-specific functions for FLCN that are highly dependent on biological context. As such, 
FLCN is perhaps better thought of as a globalised regulator of cellular homeostasis rather than 
having a distinct cellular purpose. 
 
1.4 About Birt-Hogg-Dubé 
1.4.1 Epidemiology  
Birt-Hogg-Dubé (BHD) syndrome, is a rare genetic disorder resulting from the loss of 
function of FLCN (Schmidt et al. 2005; Toro et al. 2008) and is characterised by 
fibrofolliculomas (benign skin tumours), pulmonary cysts, spontaneous pneumothorax (lung 
collapse), and a predisposition to develop RCCs.  As of January 2017, it is conservatively 
estimated that 613 families worldwide have been diagnosed with BHD. The true incidence 
of BHD is not known. Due to its rarity and the highly variable penetrance of clinical 
manifestations, it is speculated to be underdiagnosed (Steinlein et al. 2018). At present 
there is no clear evidence of a genotype-phenotype correlation between FLCN mutations 
and the symptoms of BHD (Schmidt et al. 2005; Toro et al. 2008). Limited evidence suggests 
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a correlation between mutation location and pneumothoraces. Mutations within exon 9 and 
exon 12 are associated with an increase in lung cyst size and number (Toro et al. 2007). 
Furthermore, mutations within the splice-site of intron 9 (thought to cause skipping of exon 
9) have been linked with a higher frequency of renal tumours (Schmidt et al. 2005). These 
two independent studies suggest that exon 9 may have functional importance, however, 
more work is needed to confirm these observations.  
1.4.2 Diagnosis  
Initially, BHD was defined by the presence of at least 5 to 10 fibrofolliculomas, of which at 
least one papule was diagnosed histologically. The identification of FLCN defects in families 
with BHD led to new insights into the penetrance and clinical variability of this syndrome.  
Diagnostic criteria are based on DNA testing for FLCN mutations in addition to clinical 
manifestations. It is worth noting, of those who satisfy diagnostic criteria, 7–9 % do not 
have an identifiable FLCN mutation (Tong et al. 2018). Any individual with early-onset renal 
cancer, unexplained cystic lung disease (with or without a history of pneumothorax), a 
familial history of cystic lung disease or renal cancer, or any combination of spontaneous 
pneumothorax and kidney cancer within the family are recommended for a clinical 
assessment, pedigree analysis, and FLCN genetic mutation analysis. Mutational assessment 
is recommended even when the clinical diagnosis of BHD is unambiguous. Detection of a 
pathogenic FLCN mutation not only confirms the diagnosis in the index patient, but also 
permits pre-symptomatic testing of at-risk relatives. Due to the clinical variability of BHD, 
genetic testing is imperative; adult at-risk relatives without fibrofolliculomas or pulmonary 
symptoms can carry the familial mutation. Surveillance in FLCN mutation carriers usually 
begins at 20 years of age. In most centres, pre-symptomatic diagnosis is postponed until the 
age of 16–18 years to allow for counselling and informed consent before genetic testing. 
However, earlier testing and surveillance might be used in rare circumstances; for example, 
families with a history of very early onset of pneumothorax or renal cancer (Tong et al. 
2018). 
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1.4.3 Clinical manifestations  
1.4.3.1 Fibrofolliculomas 
 
Around 90% of BHD patients develop benign skin tumours, clinically known as 
fibrofolliculomas. These appear as small, whitish papules, primarily on the face and neck, 
usually after 20 years of age (Menko et al. 2009). The number of fibrofolliculomas per 
individual can range from less than ten to over a hundred (Toro et al. 1999) and likely arise 
from sebaceous glands (Vernooij et al. 2013). Almost 25% of BHD carriers do not have skin 
symptoms at the time of diagnosis (Nikolaidou et al. 2016). This is especially true in Asian 
BHD carriers, where more than half do not report having cutaneous lesions (Furuya et al. 
2016). The lesions do not cause any physical problems. Patients, however, often report a 
psychological burden from having numerous facial lesions. 
1.4.3.2 Pulmonary cysts and pneumothorax 
Around 90% of BHD patients develop pulmonary cysts and have an increased risk of 
pneumothorax (spontaneous lung collapse) (Zbar et al. 2002; Predina et al. 2011). Lung 
anatomy in BHD patients appears normal, and despite the presence of multiple cysts, lung 
function is not often affected (Toro et al. 2007; Tobino et al. 2012). The size of pulmonary 
cysts can vary from a few millimetres to over 2cm, and from 30-400 in number (Agarwal et 
al. 2011; Tobino et al. 2012). Cysts are thought to arise due to defects in cell-cell adhesion in 
the absence of FLCN leading to repeated respiration-induced stress and, over time, 
expansion of alveolar spaces (Kennedy et al. 2016).  
BHD patients have a 50-fold increase in the risk of pneumothorax and a mean age for 
the first event of 36 years (Houweling et al. 2011). Pneumothoraces have been reported in 
BHD patients as young as seven and as old as 73; suggesting the age of onset is highly 
variable (Bessis et al. 2006; Gunji et al. 2007; Okura et al. 2013; Johannesma et al. 2014b). 
Pneumothorax is strongly correlated with the number of lung cysts present, and it is thought 
that the pulmonary cysts increase the risk of pneumothorax by rupturing and releasing air 
into the chest cavity (Furuya and Nakatani 2013; Johannesma et al. 2014a).  Pneumothorax 
typically occurs in the lower regions of the lung in BHD patients, it is thought that the cysts 
in the lower region of the lung have more chance of rupturing due to it being a region of 
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high mechanical stress (more compression) and can be instigated by changes in air pressure, 
such as flying and scuba-diving. 
1.4.3.3 Renal Cell Carcinoma  
The most life threatening complication of BHD is predisposition to RCC, where renal cancer 
is 7-fold more likely to occur in a BHD patient than the general population (Zbar et al. 
2002). Haploinsufficiency is enough for the benign skin lesions and lung cysts to develop; 
however a ‘second-hit’ in the other FLCN allele is required for RCC to develop (Vocke et al. 
2005). This suggests, at least in the kidneys, that FLCN acts as a classical tumour 
suppressor.  
BHD-associated RCC has an average diagnosis age of 50.7 years, 10-15 years earlier 
than sporadic cases (Pavlovich et al. 2005; Toro et al. 2008; Houweling et al. 2011). Around a 
third of BHD patients will develop RCC. Estimates of RCC prevalence among BHD patients, 
however, are varied between reported studies. A study on a small Dutch cohort reported 
that 12% of BHD patients developed renal cancer and further analysis of 22 BHD families of 
Dutch origin suggest a lifetime risk for RCC to be 16% (Houweling et al. 2011), however, two 
larger American cohorts found a prevalence of RCC to be 27% and 34% respectively 
(Pavlovich et al. 2005; Toro et al. 2008). Similarly, a more recent French study found the 
prevalence to be 27% (Benusiglio et al. 2014). The difference in these estimates may be due 
to population differences between cohorts, or, more likely, ascertainment bias. The patients 
in the Dutch study were recruited via dermatology clinics, whereas the cohorts in the 
American and French studies were recruited via dermatology and urology clinics. Due to 
these differences, the Houweling et al estimation is likely to be low, whilst the Pavlovich et 
al, Toro et al and Benusiglio et al estimations may be high. Therefore, the risk of developing 
RCC is estimated to be between 12-34%.  
RCC is not a single disease; it has a number of specific subtypes of renal tumours that 
can occur within the kidney. Each subtype has a different histology that is used as a 
diagnostic tool to help define them. The renal tumour subtypes response to different 
therapies as they are often associated with mutations in specific tumour suppressors and 
oncogenes (Linehan 2013). Unlike other genetic disorders predisposing individuals to renal 
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tumours, those associated with BHD are histologically diverse (table 1.1). BHD patients are 
susceptible to all renal tumour subtypes. BHD-associated tumours often display hybrid 
histologies, are multifocal, and can affect both kidneys (bilateral) (Pavlovich et al. 2002; 
Houweling et al. 2011; Benusiglio et al. 2014). Most renal tumours in BHD are hybrid 
tumours comprised of features from both renal oncocytoma and chromophobe RCC 
(HOCT, 50%), but other BHD-associated sub-types are chromophobe renal cell carcinoma 
(34%), clear cell renal cell carcinoma (9%), oncocytoma (5%) and papillary renal cell 
carcinoma (2%) (Hasumi et al. 2015). Tumour progression is usually slow, and tumours 
rarely metastasise. Nevertheless, 12 deaths have been reported in BHD patients due to 
metastatic renal cancer (Pavlovich et al. 2005; Toro et al. 2008; Houweling et al. 2011; 
Hasumi et al. 2015). Given the high percentage of chromophobe tumours, it was initially 
believed that tumours arise from the distal nephron (Pavlovich et al. 2002). Subsequent 
research in mice, however, demonstrated Flcn expression in the proximal tubules of murine 
kidneys, which are now regarded as the site of origin for BHD-associated RCC (Chen et al. 
2008; Hudon et al. 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1 Summary of BHD-associated renal cell carcinoma (RCC) histological subtype prevalence. 
Information obtained from (Pavlovich et al., 2002, Pavlovich et al 2005, Linehan WM 2004). 
Photomicrograph RCC subtype % BHD associated 
RCC 
% subtype of 
sporadic RCC 
 
 Chromophobe RCC 34% 5%  
 Oncocytoma 5% 3-5%  
 Papillary RCC    
(type 1 & 2) 
2% 10%  
 Clear cell 9% 75%  
 HOCT 50% <5%  
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1.4.3.3.1 Sporadic kidney cancer  
RCC is the seventh most common cancer in men, tenth in women, and the tenth most 
common cause of cancer-related deaths worldwide (Wong et al. 2017). It constitutes 90–
95 % of all kidney neoplasms (Ljungberg et al. 2011),  and 25–30 % of patients have 
metastatic disease upon diagnosis (Gupta et al. 2008; Wong et al. 2017). The majority of 
RCC are sporadic. Factors such as smoking, obesity, and hypertension are known to 
contribute to its development. Somatic FLCN mutations have been reported in 3-7 % of 
sporadic RCC cases (Khoo et al. 2003; Gad et al. 2007) indicating that FLCN mutations may 
cause a small percentage of sporadic RCCs.  
While BHD-associated renal tumours are histologically diverse, there is a marked 
difference in prevalence of each subtype when compared to sporadic cases (table 1.1). A 
marker panel to discriminate BHD tumours from sporadic RCC is currently ongoing (Table 
1.2). BHD-associated hybrid tumours show decreased expression of CK7 compared to 
sporadic chromophobe RCCs but increased expression of Ksp-cadherin and CD82 compared 
to sporadic oncocytomas (Iribe et al. 2015). Tumours from BHD patients show increased 
expression of Transmembrane glycoprotein NMB (GPNMB )(Furuya et al. 2015) and BHD-
chromophobe RCC and HOCTs retain chromosome 17 disomy unlike sporadic tumours which 
are typically monosomic (Kato et al. 2016). So far, these markers are only able to distinguish 
between some of the sporadic and BHD-associated tumour subtypes. The identification of 
further markers will allow for greater understanding of the underlying biology but also more 
accurate RCC subtype diagnoses and, hopefully, a more targeted therapy for the treatment 
of BHD. 
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Table 1.2 Summary of current work to generate a biomarker panel to distinguish BHD-associated 
renal tumours from sporadic renal tumours. Reference code *Furuya et al 2015, ** Kato et al 2016, 
***Iribe et al 2001 
 
1.4.3.4 Other clinical manifestations 
 
Fibrofolliculomas, pulmonary cysts, pneumothorax and RCCs are the only recognised clinical 
features of BHD syndrome. Emerging evidence suggests FLCN mutations could also play a 
role in several other manifestations, including an increased risk of other types of cancer. 
These additional risk factors associated with BHD have yet to be confirmed in bigger case 
studies, as many reports have only a very limited amount of clinical evidence with a small 
cohort of patients. Nevertheless, they are summarised in table 1.3, and briefly discussed 
below.  
1.4.3.4.1 Melanoma 
Melanoma has been associated with BHD in numerous cases studies (Toro et al. 1999; Khoo 
et al. 2002; Menko et al. 2009; Cocciolone et al. 2010; Houweling et al. 2011; Mota-Burgos 
et al. 2013). However, studies attempting to prove a definitive link have been too small in 
patient numbers and failed to prove a correlation. FLCN negatively regulates the mTOR 
pathway through FNIP1, FNIP2 and AMPK complexes, to limit cell proliferation and tumour 
growth (Karbowniczek et al. 2008; Takagi et al. 2008; Cocciolone et al. 2010). The 
dysregulation of the mTOR pathway is associated with the benign and malignant tumours 
found in BHD but is also commonly activated in melanomas (Mota-Burgos et al. 2013). 
Whether patients with BHD have a greater risk of melanoma or it is just a coincidence is 
hard to establish; skin cancer is very common, and BHD is a rare disease.  
Sporadic RCC subtype BHD-associated RCC 
subtype 
Distinguishing markers 
Chromophobe RCC Chromophobe RCC ↓FLCN*, ↑GPNMB*, 17q/2p/6p disomy** 
Chromophobe RCC HOCT ↓CK7***, ↓FLCN*, ↑GPNMB*, 17q/2p/6p 
disomy** 
Oncocytoma HOCT ↑Ksp-Cadherin***, ↑CD82***, ↓FLCN*, 
↑GPNMB 
Papillary RCC papillary RCC ↓FLCN*, ↑GPNMB* 
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Clinical manifestation  Reference  
Benign 
Multinodular goiter (Schmidt et al. 2005) 
Parathyroid adenoma  (Chung et al. 1996) 
Colorectal polyp and adenoma (Le Guyadec et al. 1998; Khoo et al. 2002; da Silva et al. 2003) 
Neural-tissue tumour (Hornstein and Knickenberg 1975) 
Trichoblastoma (Chung et al. 1996) 
Connective-tissue nevus (Liu et al. 2000) 
Focal-cutaneous mucinosis (Lindor et al. 2001) 
Adenoma of adrenal gland (Toro et al. 2008; Kunogi et al. 2010)  
Lipoma (Toro et al. 1999) 
Angiolipoma (Chung et al. 1996) 
Cutaneous leiomyoma (Imada et al. 2009) 
Rhabdomyoma (Toro et al. 2008; Bondavalli et al. 2015) 
Myoma (Kunogi et al. 2010) 
Thyriod nodules (Kluger et al. 2010; Benhammou et al. 2011) 
Ovarian cyst  (Godbolt et al. 2003) 
Malignant 
Breast cancer (Toro et al. 2008; Kunogi et al. 2010) 
Colorectal cancer (da Silva et al. 2003) 
Sarcoma of the leg (Menko et al. 2009) 
Squamous cell carcinoma  (Toro et al. 2004) 
Tonsillar cancer (Warren et al. 2004) 
Lung cancer (Gunji et al. 2007; Furuya and Nakatani 2013; Nishida et al. 2015) 
Melanoma (Toro et al. 1999; Khoo et al. 2002; Cocciolone et al. 2010; 
Houweling et al. 2011; Mota-Burgos et al. 2013)  
Basal and squamous-cell skin cancer (Leter et al. 2008; Toro et al. 2008) 
Dermatofibrosarcoma protuberans (Menko et al. 2009) 
Hodgkin lymphoma  (Toro et al. 2008) 
Uterine cancer (Toro et al. 2008) 
Prostate cancer (Toro et al. 2008) 
Cutaneous leiomyosarcoma (Toro et al. 2008) 
Adrenal carcinoma (Raymond et al. 2014) 
 
Table 1.3 Reported tumours noted in the literature that may be associated with BHD and/or FLCN 
loss of function. A direct or causative relationship between FLCN and these tumours have NOT been 
conclusively demonstrated. Adapted from (Menko et al. 2009). 
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1.4.3.4.2 Pulmonary cancer 
 
A handful of case studies where BHD patients have developed pulmonary tumours have 
been reported (Gunji et al. 2007; Furuya and Nakatani 2013; Nishida et al. 2015). These 
however correlate to a history of smoking and no heterozygous loss of FLCN was reported. 
 
1.4.3.4.3 Colorectal cancers 
Initial studies suggested a link between BHD and colorectal neoplasis due to a high 
occurrence of colorectal polyps and colorectal cancer in BHD patients (Birt et al. 1977; 
Schulz and Hartschuh 1999; Khoo et al. 2002). Interestingly, one study noted that BHD 
patients who developed colonic polyps had mutations within the exon 11 (c.1285delC) 
hotspot (Khoo et al. 2002). Furthermore, somatic frameshift mutations in the FLCN exon 11 
C8 mononucleotide tract were detected in 23% of sporadic colorectal cancers with 
microsatellite instability, suggesting that FLCN inactivation might contribute to colorectal 
tumorigenesis (Nahorski et al. 2010). However, subsequent studies containing a larger 
cohort of patients failed to confirm an association between BHD and colonic polyps or 
colorectal cancer (Zbar et al. 2002).  
1.4.3.4.4 Thyroid and Parotid  
Two case studies have described BHD patients with thyroid cancer (Benusiglio et al. 2014; 
Yamada et al. 2015). Both report a loss of heterozygosity of FLCN in the tumour, but state 
other genetic lesions that may have contributed to the development of thyroid cancer. 
Therefore, causality between FLCN and thyroid cancer cannot be established. A study of 
French families with BHD noted 65 % of cases exhibited thyroid nodules or cysts (Kluger et al. 
2010). No thyroid carcinomas were detected. The high prevalence of thyroid nodules in this 
study is interesting, but the study lacked an appropriate control group and the authors were 
not able to assess the significance of these results. 
To date, eight cases of parotid tumours have been reported in patients with a germline 
FLCN mutation (Liu et al. 2000; Schmidt et al. 2005; Maffe et al. 2011; Lindor et al. 2012; 
Pradella et al. 2013). Interestingly, the parotid tumours were oncocytic, a trait frequently seen 
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in BHD kidney tumours, however, there is not sufficient statistical evidence to associate 
parotid tumours with BHD syndrome. 
1.5 Management and current therapies  
There is currently limited treatment available for BHD syndrome, and none are curative. More 
clinical research and a better understanding of the basic biology involved in FLCN loss will 
facilitate the development of therapies to treat BHD and its symptoms. Screening drug 
libraries could identify novel therapeutic compounds already known to target a relevant 
pathway (such as mTOR signalling) or those used in a phenotypically similar disorder could be 
tested. Once demonstrated effective, FDA-approved drugs could be rapidly repurposed. 
Granted, therapies that target the mTOR pathway have not been successful in treating BHD-
associated fibrofolliculomas, lung cysts, or pneumothorax (Gijezen et al. 2014). mTOR 
inhibitors have, however, shown early promise with regards to BHD-associated RCCs (further 
information in section 1.5.3). Gene therapy is a promising treatment for a vast variety of 
genetic disorders. Preliminary studies show FLCN function can be successfully restored 
in FLCN-null cells (Wong and Harbottle 2013). In the future it may be possible to re-introduce 
a functional copy of the FLCN gene into FLCN-null or -heterozygous cells, either preventatively 
or curatively. These technologies are still very much in their infancy, and there is currently 
only one FDA-approved gene therapy, Glybera, to treat lipoprotein lipase deficiency, which is 
currently available. However, a great number of gene therapy clinical trials are currently 
ongoing. 
1.5.1 The skin  
Therapies for fibrofolliculomas are very limited and current options include ablative laser, 
electrocoagulation and excision, and are highly invasive. After such abrasive therapies, 
regrowth of the fibrofolliculomas is common. This high recurrence rate (typically returning 
within 2-3 years) is one issue with therapy and there are also significant risk of complications 
such as scaring, inflammation, and hypo- or hyperpigmentation (Gambichler et al. 2000; Jacob 
and Dover 2001; Kahle et al. 2001; Gijezen et al. 2014). Given that the animal models 
demonstrate deregulation of mTOR signalling, topical treatment using a clinically effective 
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mTOR inhibitor, rapamycin, was trialled for fibrofolliculoma, but found no cosmetic 
improvement in BHD patients (Gijezen et al. 2014).  
1.5.2 The lungs  
The management of BHD pulmonary symptoms largely focuses on the treatment of 
pneumothoraces. BHD lung cysts typically do not result in respiratory failure, however 
periodic measurement of pulmonary function and CT monitoring of cysts are recommended 
(Gupta et al. 2013). Although limited, data on smoking and the risk of pulmonary cysts and 
pneumothorax in BHD suggest smoking may increase the risk of these manifestations and 
should be avoided (Fabre et al. 2014; Park and Lee 2017). 
1.5.3 The kidneys  
Due to the high prevalence of RCC, BHD patients with a confirmed germline mutation, and 
at risk relatives in families with clinical BHD, undergo kidney surveillance. There are no 
widely established guidelines for BHD-associated RCC surveillance. The age to start 
surveillance, how regularly patients are monitored, and the method of examination can vary 
between establishments (Toro et al. 2008). Most institutes start surveillance at around 20 
years of age, as BHD-associated RCC typically present between the ages of 25-75. This also 
allows the individual to receive genetic counselling at an appropriate age. Common methods 
used include, renal ultrasonography, computed tomography (CT), and magnetic resonance 
imaging (MRI). Each approach has its strengths and weaknesses as discussed by Choyke et 
al. (Choyke et al. 2003); briefly, ultrasonography is relatively insensitive, detecting only 58 % 
of small lesions (15–20 mm) when compared to CT and MRI, which detects 100 % of similar 
sized lesion. Frequent CT scanning, however, would lead to unacceptably high cumulative 
radiation dose, and MRI, while radiation free, is not widely available at all centres (Hall and 
Brenner 2008; Sodickson et al. 2009). Annual renal ultrasonography is offered to those with 
germline confirmed FLCN mutations. Even though the sensitivity of this method in detecting 
small renal tumours is limited, renal growth removal isn’t recommended until lesions are 
sized 25–30 mm. These size tumours can be readily detectable by ultrasonography, which is 
available at the majority of healthcare centres (Choyke et al. 2003).  
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There are no BHD-associated RCC specific treatments. When diagnosed, patients 
follow the treatment options available for sporadic RCC cases. Complete removal of tumour 
lesions by partial or full nephrectomy is the best course of action, with partial removal being 
preferred, allowing surgery to be as nephron sparing as possible. BHD patients, however, 
are at risk of synchronous and multiple kidney cancers throughout their lifetime. Therefore, 
the balance of oncological eradication and postoperative renal function is one of the most 
critical elements for the quality of life and overall survival of BHD patients. Tumour size at 
the time of removal is essential for minimising the number of surgeries in a lifetime, as well 
as post-operative renal function. Therefore, it is common practice to operate on BHD-
associated renal tumours when the diameter of the largest tumour reaches 3 cm (Ather and 
Zahid 2018). This concept parallels that of Von Hippel-Lindau (VHL) and Tuberous Sclerosis 
Complex (TSC)-associated renal tumours.   
In recent years, there have been attempts to find specific chemotherapeutics for 
BHD-associated RCC. The antibiotic mithramycin, for example, was shown to inhibit the 
growth of FLCN-null RCC cells (Lu et al. 2011). Likewise, a combination of autophagy 
inhibition and Paclitaxel treatment selectively promoted apoptosis in FLCN-null cells (Zhang 
et al. 2013). The mTOR inhibitor, rapamycin, effectively reduced the number and size of 
renal tumours in Flcn-deficient mouse models (Baba et al. 2008; Chen et al. 2008; Wu et al. 
2015). Furthermore, a handful of case studies have reported a good response in BHD 
patients with metastatic RCC who have been treated with systemic small molecule tyrosine 
kinase and/or mTOR inhibitors (summarised in (Benusiglio et al. 2014)). The mTOR inhibitor 
everolimus, which is a rapamycin analogue, went into a clinical trial in 2015 (NCT02504892). 
Everolimus is an approved treatment for sporadic metastatic RCC but has not been 
specifically trialled in BHD-associated and sporadic chromophobe RCC. The phase 2 trial was 
terminated April 2018 due to slow, insufficient accrual. 
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1.6 DNA damage overview  
 
Genome instability is described as one of the hallmarks of cancer and the most universal 
characteristic of tumour cells (Hanahan and Weinberg 2011). Human DNA is continuously 
challenged by a host of processes that can alter cellular DNA (Jackson and Bartek 
2009). Cells have evolved a complex series of mechanisms that govern genomic integrity. 
These mechanisms - known collectively as the DNA damage response (DDR) - can be divided 
into a set of distinct, but functionally overlapping pathways; defined mainly by the type of 
DNA lesion they repair (Jackson and Bartek 2009; Ciccia and Elledge 2010). A summary of 
the types of DNA damage, their causing factors, and dedicated repair mechanisms are 
outlined in figure 1.4. 
 
1.6.1 Types of damage  
DNA can be subjected to a large array of insults, both exogenous and endogenous in origin 
(Jackson and Bartek 2009). Exogenous sources of DNA damage are environmental agents 
external to the cell, such as ultraviolet light (UV), ionising radiation (IR), and chemicals, 
including those in cigarette smoke and chemotherapeutics. Endogenous causes of DNA 
damage arise internally from cellular activities, such as metabolism that produces reactive 
oxygen species (ROS), or errors from faulty DNA replication. Damage to DNA includes 
mismatched base pairs, insertion or deletion of nucleotides (indels), the addition of bulky 
adducts, inter- and intra-strand links, single-strand DNA breaks (SSBs), and double-strand 
DNA breaks (DSBs) (Jackson and Bartek 2009). 
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Figure 1.4 Summary of the types of DNA damage, their usual causes, repair mechanisms, and key 
proteins involved in DNA repair. Various types of DNA damage can occur within cells, caused by 
both endogenous and exogenous agents. These agents can cause base modifications, helix-distorting 
lesions or DNA strand cross-links, and single-stranded, or double-stranded DNA breaks, that are 
repaired by biochemically distinct DNA repair pathways. (Ciccia and Elledge 2010; O'Connor 2015). 
Abbreviations; UV, ultraviolet radiation; ROS, reactive oxygen species; IR, ionising radiation; GG-NER, 
global genome-nucleotide excision repair; TC-NER, transcription coupled-nucleotide excision repair. 
 
 
 
 
32 
 
1.6.2 DNA damage repair  
In response to DNA lesions, cells activate an elaborate signalling network, the DDR. DDR can 
be divided into three main phases that translate the signal of DNA damage into an 
integrated cellular response (Jackson and Bartek 2009). In the first phase, the “sensors” of 
DNA lesions detect abnormally structured DNA and initiate the signalling response. The key 
DDR sensors known to date in mammalian cells are DNA-dependent protein kinase (DNA-
PK), ataxia telangiectasia-mutated protein kinase (ATM), and ATM-Rad-3-related protein 
kinase (ATR). Upon activation, these sensors phosphorylate “mediator” proteins that further 
recruit “transducer” proteins, such as p53, checkpoint kinase 1 (Chk1) and checkpoint kinase 
2 (Chk2), to amplify the DDR signal. Once activated, the transducer kinases phosphorylate 
“effector” proteins who elicit multiple mechanisms of cell fate including DNA repair, cell 
cycle arrest, and/or cellular death (Marechal and Zou 2013; Yan et al. 2016b). 
There are several distinct repair pathways, specialised for different types of DNA 
lesions (summarised in figure 1.4). Base excision repair (BER) corrects small, non-helix-
distorting base lesions, by the removal of the damaged base only. This covers damage which 
arises from hydrolysis, alkylation or oxidation of nucleotides, that could otherwise cause 
mutations by mispairing or lead to DNA breaks during replication (Krokan and Bjoras 2013). 
Nucleotide excision repair (NER), on the other hand, co-ordinates the repair of DNA adducts. 
Large helix-distorting base lesions, intercalated agents, and strand cross links are removed 
by the excision of a short string of nucleotides and replaced as directed by the undamaged 
template strand. Recently NER has been divided into two distinct modes; global genome 
NER (GG-NER) and transcription coupled NER (TC-NER). GG-NER repairs damage in both 
transcribed and un-transcribed DNA strands throughout the genome and is initiated by XPC-
RAD23B. CT-NER focuses on repairing lesions within the transcribed strand of active genes 
and is initiated by RNA polymerase at a stalled replication fork (Scharer 2013). Mismatch 
repair (MMR) detects non-commentary base pairings, errors that commonly occur due to 
polymerase mis-incorporation, or chemical and/or physical damage to nucleotides (for 
example, oxidation or deamination) (Jiricny 2013).  
DSBs are among the most destructive DNA lesions and are repaired through two 
pathways; homologous recombination (HR) and non-homologous end-joining (NHEJ). HR is 
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an accurate process that uses information from genetically identical DNA molecules to 
repair damaged DNA. Several genes with tumour-suppressor activity are crucial to this 
process, including BRCA1, BRCA2, PALB2 and RAD51, and their functioning is essential for an 
error-free repair (Moynahan and Jasin 2010).  NHEJ, on the other hand, recruits DNA-PK to 
bring about the direct ligation of two dsDNA molecules, regardless of whether the ends 
come from the same chromosome. As such, NHEJ is far more error-prone and has increased 
mutagenic potential. NHEJ itself is therefore a potential source of carcinogenic 
transformation within cells.  
Typically, it is the phase of the cell cycle that determines the dominant pathway of 
DSB repair. Highly compact chromatin restricts access to homologous sequences. As such, it 
is thought NHEJ is the dominant DSB repair pathway when cells aren’t replicating and during 
early phases of the cell cycle (Branzei and Foiani 2008). Cell cycle checkpoints occur at the 
G1/S and G2/M cell cycle boundaries to prevent cells from proliferating in the presence of 
DNA damage (figure 1.5). Co-ordination of DNA repair within cycling cells is controlled 
through cyclin-dependent kinases (CDKs). CDKs regulate cell cycle transitions by inducing 
degradation of inhibitory proteins and are systematically activated by their regulatory cyclin 
subunits, which are differentially expressed in a phase dependant manner (Branzei and 
Foiani 2008). 
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Figure 1.5 The DNA damage response (DDR) key proteins during the cell cycle.  DDR targets are 
shown for each cell-cycle checkpoint. Adapted from (O'Connor 2015). Abbreviation; DNA-PK, DNA-
dependent protein kinase ATM, ataxia-telangiectasia mutated; ATR, ataxia-telangiectasia and Rad3-
related; CHK1, Checkpoint kinase 1; CHK2, Checkpoint kinase 2; WEE1, Wee1-like protein kinase. G1, 
gap/growth phase 1; S, DNA replication phase; G2, gap/growth phase 2; M, mitosis (cell division 
phase).  
 
1.6.3 Telomere maintenance  
Telomeres are specialised nucleoprotein complexes. They protect the natural ends of linear 
chromosomes from being recognised as intra-chromosomal DSBs and exposure to the DDR 
(Longhese 2008). Telomere shortening occurs with each round of DNA replication. In the 
absence of a compensatory mechanism this results in unmasked chromosome ends. As a 
consequence, DDR will activate and define the fate of cells; either engaging replicative 
senescence or apoptosis (Fumagalli et al. 2012). Dysfunctional telomeres are associated 
with an increased cancer risk. They promote tumorigenesis through chromosomal instability 
and influence tumour cell plasticity (Plentz et al. 2007; Tomasetti and Vogelstein 2015; 
Gunes et al. 2018). 
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1.6.4 Genomic instability in cancer  
Defects in DDR are associated with increased mutational load and genomic instability. They 
are well-established causes of neoplastic transformation and drive a variety of hereditary 
and sporadic tumours (Halazonetis et al. 2008; Negrini et al. 2010; Hosoya and Miyagawa 
2014). Both activation and inactivation of the DDR are found in various cancers. For 
example, TP53 (p53) is one of the most frequently altered genes in human cancers. While 
the reported occurrences of TP53 mutation vary among the different types of cancer, it is 
estimated that more than half of cancers involved inactivated p53 due to mutation, 
deletion, loss of heterozygosity, or decreased expression of the gene (Brosh and Rotter 
2009; Hosoya and Miyagawa 2014). Inactivating mutations are also commonly observed 
in ATM, BRCA1, and BRCA2 (Grasso et al. 2012; Koboldt et al. 2012; Cremona and Behrens 
2014), and cancers often display a decreased expression of ATM, Chk2, and RAD51 
suggesting aberration of the DDR is common feature of cancers (Angele et al. 2003; 
Verlinden et al. 2007; Dzikiewicz-Krawczyk 2008; Hosoya and Miyagawa 2014). On the other 
hand, inappropriate activation of DDR can also have tumorigenic effects and is linked to 
worse prognosis or therapy resistance (Ciccia and Elledge 2010). An increase in the gene 
expression of Chk1, Chk2, CDC25A, CDC25B, and CDC25C have been reported in numerous 
tumours (Boutros et al. 2007; Verlinden et al. 2007; Dzikiewicz-Krawczyk 2008; Hosoya and 
Miyagawa 2014). Furthermore, overexpression of DNA-PKcs, RAD51, BRCA1, and PARP1 
have all been associated with resistance to therapy in a variety of cancers (Taron et al. 2004; 
Kase et al. 2011; Bouchaert et al. 2012; Hosoya and Miyagawa 2014). 
DNA damage occurs daily by endogenous and exogenous sources. Erroneous repair 
or replicative bypass of these lesions can result in DNA mutations and chromosomal 
aberrations. When mutations affect tumour suppressor genes or oncogenes, cells may 
transform into cancer cells. DNA repair is therefore essential for preventing tumour 
development. However, once a cancer has developed, DNA damage can be exploited to 
reduce cancerous growth and evoke apoptotic demise of cancer cells. 
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1.7 Aims and objectives of this thesis 
 
Dispite numerous advances to understand its tumour suppressive function, FLCN is still a 
poorly characterised protein. To better define the cellular role(s) of FLCN in renal 
tumorigenesis, an unbiased protein-protein interaction study was performed. Manual 
evaluation found multiple associations between FLCN and components involved in DNA 
repair. From this, it was hypothesised that FLCN may preserve DNA integrity through the 
interaction and regulation of proteins involved in DNA damage repair. 
The aim of this study was to examine the role of FLCN in the context of genome 
maintenance. To do this the following objectives were carried out: 
• Analysis of the FLCN interactome and validation of novel FLCN interactors 
• Analysis of the transcriptomic effect of FLCN knockdown 
• Characterise the role of any novel FLCN interacting proteins and explore the 
effect of FLCN knockdown on DNA damage signalling pathways 
• Explore the effect of FLCN knockdown on cell cycling. 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
Chapter 2: Methods and Materials 
 
2.1 Mass spectrometry sample preparation, sequencing, and analysis   
 
An unbiased protein-protein FLCN interaction screen was performed to analyse proteins co-
purifying with FLCN. GST-FLCN was expressed in HEK293 cells, purified and run on an 
agarose gel. GST-FLCN and interacting proteins were stained and divided into 8 sections 
based on molecular weight. Protein identification was performed using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). GST-FLCN pull-down was 
previously carried out by Dr Elaine Dunlop, with LC-MS/MS analysis performed by Peter 
Doubleday and Dr Bryan Balliff (University of Vermont)  
Sample preparation and analysis were performed as follows: Protein gel bands were 
excised and reduced with 10 mM DTT for 30 min at 50 ˚C and then alkylated with 12 mM 
iodoacetamide at room temperature in the dark for 1 h. Gel pieces were then washed three 
times with a 50:50 mixture of 100 mM ammonium bicarbonate and acetonitrile. Gel pieces 
were then rehydrated with 100 mM ammonium bicarbonate and 150 ng of trypsin was 
added. Tryptic digest proceeded overnight at 37˚C. Peptides were extracted by the addition 
of 50 % [v/v] acetonitrile (MeCN)/ 5 % [v/v] formic acid (FA) followed by 90 % [v/v] MeCN / 5 
% [v/v] FA. Peptides were dried by vacuum centrifugation.  
For LC-MS/MS analysis, dried peptides were re-suspended in 2.5 % [v/v] MeCN, 2.5 
% [v/v] FA and were loaded for nanoscale microcapillary LC–MS/MS in a LTQ-Orbitrap mass 
spectrometer (Thermo Electron, Waltham, MA) fitted to a Finnigan Nanospray II 
electrospray ionization source, a Surveyor HPLC pump plus, and a Micro AS autosampler (all 
from Thermo Electron, Waltham, MA). After isocratic loading for 15 min in solvent A (2.5 % 
[v/v] MeCN, 0.15 % [v/v] FA), peptides were separated on an increasing MeCN gradient 
(2.5–35 %) containing 0.15 % [v/v] FA from 15 to 60 min on a 100 μm internal diameter, in-
house prepared, 13 cm long, MagicC18 reverse phase column (5 μm, 200 Å; Michrom 
Bioresources, Auburn, CA). Data acquisition was performed with a full scan (365-2000 m/z) 
followed by data-dependent scans on the 10 most abundant precursors. Dynamic exclusion 
was enabled with a repeat count of 3 and a repeat cycle of 120 s. Lock mass was enabled 
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and set to calibrate on the mass of a polydimethylcyclosiloxane ion [(Si(CH3)2O)5 + H+]+, 
m/z = 371.10120. 
Mass spectra were searched using SEQUEST (Thermo Electron V26.12) against the 
human forward and reverse IPI database (human IPI v3.60) using a target-decoy approach 
and allowing for variable oxidation of methionine (+15.99429), and the fixed modification of 
carbamiodomethylation to cysteine (+57.02146 Da). Peptide quantification was performed 
using Vista-based software taking the integral values of the chromatographic monoisotopic 
peaks generated from full MS1 scans. MS runs were pooled and filtered below a 0.5% false 
discovery rate using an automated linear discriminant analysis weighted by XCorr, ΔCn2, 
MS2 ion intensity, missed tryptic cleavages, precursor ppm and peptide length. 
2.2 Construction of the FLCN-bound interactome  
 
The STRING protein–protein interaction database (Szklarczyk et al. 2017) was used to create 
a FLCN interactome. Of the 650 FLCN interacting proteins identified by LC-MS/MS, 613 were 
successfully mapped within the network. Enrichment analysis of Gene Ontology biological 
processes (GO-BP) was then used to classify the identiﬁed proteins into 8 major functional 
categories. The following categories were chosen as they have either not previously been or 
are only weakly associated with FLCN; telomere maintenance, chromatin structure, 
ubiquitination, DNA damage repair and response, DNA replication, cell cycle, transcription 
and translation, and other. Enrichment in Gene Ontology cellular component (GO-CC) was 
also produced in STRING. The interactome was then imported into Cytoscape (v3.6.1,(Lopes 
et al. 2010) making use of the aesthetic freedom of the software to produce a more 
informative network. 
2.2.1 Topological analysis of the FLCN interactome 
The topological analysis of the FLCN interactome was performed using the Network 
Analyzer plugin (v2.7) for Cytoscape. The following topological properties of the network 
were analysed, where a node refers to a protein and an edge denotes the interaction 
between two proteins. The degree (k) represents the connectivity of a node or the number 
of other nodes that it is connected to, i.e., the number of interactions a protein has to other 
proteins within the network. The clustering coefficient signifies the connectedness of a node 
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to other nodes and represents the overall tendency of the nodes to form clusters. The 
average clustering coefficient of all the nodes in the network is represented as the network 
clustering coefficient. The shortest path length is measured by the number of edges 
occurring within the shortest path between two nodes averaged over all pairs of nodes in a 
network, i.e., the fewest steps between any two proteins within the network. It corresponds 
to the typical separation between two proteins in a network and is indicative of the 
navigability of the network. The network diameter is defined as the maximum length of the 
shortest path between two nodes. Closeness centrality (CC) indicates nodes with the 
minimum average distance to all other nodes. It is defined as the inverse of the average 
lengths of the shortest paths to and from all other nodes in the network. Betweenness 
centrality (BC) is a fundamental parameter of the network. It is measured by the fraction of 
shortest paths that pass through a node and corresponds to the number of times that a 
node lies on the shortest path between two other nodes. In essence, it measures how often 
a node acts as a bridge between other nodes.  
2.2.2 Creation of a backbone network  
To identify proteins integral to the flow of information through the FLCN interactome, 
proteins that have a k and BC value more than two standard deviations from mean values 
were extracted from the giant network to form a backbone network.  
 
2.3 RNA sample preparation, sequencing, and analysis 
 
RNA sample preparation and sequencing were performed by Dr Elaine Dunlop (Cardiff 
University, UK) in conjunction with Wales Gene Park (Cardiff University, UK). 
For each cell line, cells were cultured in separate 60mm plates. Three plates were 
grown per cell line (n=3). After plates reached ≥90% confluency, media was removed, and 
cells were washed with phosphate buffered saline (PBS). Plates were treated with 0.5 ml of 
RNAprotect® (QIAGEN) reagent to stabilise RNA, plates were then scraped, and the mixture 
pipetted into separate eppendorfs. RNA extraction was performed using the RNeasy® Plus 
Mini kit (QIAGEN), with the homogenisation step being performed with QIAshredder® 
(QIAGEN). Purified RNA was stored at -80°C. Maintenence of FLCN knockdown was 
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confirmed by real time PCR prior to RNA sequencing. Total RNA quality and quantity was 
assessed using RNA Nano 6000 kit and 2100 Bioanalyser™ (both Agilent Technologies, 
Waldbronn, Germany). 100-900 ng of total RNA with a RIN value >8 was used as the input 
and the sequencing libraries were prepared using the Illumina® TruSeq® RNA sample 
preparation v2. (Illumina Inc.).  All steps where followed as described by the manufacturer’s 
instructions.  
Differentially expressed transcripts were identified using DeSeq2 package in R (Love 
et al. 2014). Analysis was carried out on all pairwise comparisons in the dataset. P-values 
were corrected for multiple testing using the Benjamini–Hochberg false discovery rate (FDR) 
method.  Differential gene expression was performed by Dr Marc Naven (Wales Gene Park, 
Cardiff, UK).  
Genes where split into biological processes using gene lists generated from the 
following GO list; GO:0006974 (Cellular response to DNA damage stimulus); GO:0007049 
(Cell cycle); GO:0006351 (Transcription, DNA-templated); GO:0006412 (Translation); 
GO:0006260 (DNA replication); GO: 0016567 (Protein ubiquitination); GO:0006302 (Double-
strand break repair); GO: 1902807 (Negative regulation of cell cycle G1/S phase transition); 
GO: 1902808 (Positive regulation of cell cycle G1/S phase transition) from AmiGo 2 
(Ashburner et al. 2000). The E2F target gene list was taken from (Bracken et al. 2004). 
AMPK gene list was gifted from Dr Henry McCann.  
All heatmaps were creating using the R pHeatmap package (Kolde 2019). Density 
plot was produced in R using the ggplot2 package (Ginestet 2011). All other graphical 
visualisation (bar graphs, scatter plot and volcano plots) were produced using GraphPad 
Prism 4.00. 
2.3.1 Correlation of log2 fold change between FLCN knockdown cell lines 
To explore the effects of differentially expressed genes (DEGs) upon FLCN knockdown four 
pairwise comparisons were made; (1) low passage wild type vs low passage knockdown cells 
(LP-WT vs LP-KD), these represent the direct effect of FLCN knockdown; (2) high passage 
wild type vs high passage knockdown cells (HP-WT vs HP-KD), these represent the effect of 
FLCN knockdown in aged cells; (3) low passage wild type vs high passage wild type cells (LP-
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WT vs HP-WT), these represent changes that normally occur upon cellular aging; and (4) low 
passage knockdown vs high passage knockdown cells (LP-KD vs HP-KD), these represent 
changes occurring due to continuous FLCN knockdown. Where indicated Pearson’s 
correlation coefficient (PCC) was performed, using GraphPad Prism 4.00, to understand the 
statistical relevance of gene correlation.  
2.3.2 Functional analysis of differentially expressed genes 
To investigate the biological mechanisms related to the DEGs, enrichment analysis was 
performed using REACTOME online resource tool (Fabregat et al. 2017). Figures were 
adapted using Inkscape v0.92.4.  
 
2.4 Validation of RNA sequencing   
 
2.4.1 Reverse transcription  
Reverse transcription of purified RNA to create cDNA was undertaken using QuantiTect® 
Reverse Transcription Kit (QIAGEN). 1 µg of template RNA was used per sample. 
Temperature and length of reactions on heat block were as follows: 2 min at 42 ⁰C for 
genomic DNA elimination reaction, 30 mins at 42 ⁰C for reverse transcription reaction and 3 
min at 95 ⁰C to inactivate Quantiscript® Reverse Transcriptase (QIAGEN). cDNA was stored 
at -20 ⁰C until needed. 
2.4.2 Real-time quantitative Polymerase Chain Reaction (qPCR)  
qPCR was carried out using Taqman® chemistry (Applied Biosystems). For each gene being 
assayed, 20 µL reactions per sample were set up in triplicate on a 96-well PCR plate. Each 
reaction consisted of 10 µL of Taqman Master Mix (2X), 1 µL primer/probe mix, 1 µL of 
cDNA and 8 µL of RNase-free water. RNase-free water was used in place of cDNA as a 
negative control. Plates underwent a qPCR reaction using a 7500 Real Time PCR system 
(Applied Biosystems). The thermal cycling conditions were as follows: 2 min at 50 ⁰C, 10 min 
at 95 ⁰C, then 40 cycles of both 15 s at 95 ⁰C and 1 min at 60 ⁰C. ACTB (β-actin) was used as 
the control gene which CT values were normalised against. Genes were assayed in five 
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experiments. The following primer/probe mixes were sourced from Applied Biosystems; 
CCND1 (Assay ID= Hs00765553_m1), TP53 (Assay ID= Hs01034249_m1), FOXN3 (Assay ID= 
Hs00758121_m1), ACTB (Assay ID= Hs01060665_g1), RPA (Assay ID= Hs00161419_m1), JUN 
(Assay ID= Hs01103582_s1), TGFA (Assay ID= Hs00608187_m1), PPARGC1A (Assay ID= 
Hs00173304_m1). qPCR of FLCN, CCND1, TP53 and FOXN3 were carried out by Mr Jesse 
Champion under my guidance. qPCR of FLCN, RPA, JUN, TGFA, and PPARGC1A were carried 
out by Dr Elaine Dunlop.  
 
2.6 Cell culture and treatment  
 
Human embryonic kidney 293 (HEK293) and human proximal epithelial kidney (HK2) cell 
lines were propagated in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, 
11995065) and supplemented with 10 % [v/v] foetal calf serum (Life Technologies, 10270-
106), 100 U/ml penicillin and 100 µg/ml streptomycin (Life Technologies, 15070- 063) in a 
humidified incubator containing 5 % CO2 at 37 °C.  
FLCN shRNA plasmid (pLKO.1-puro-shRNA5968, Sigma-Aldrich-Aldrich) and non-
target shRNA plasmid (pLKO.1-puro-NonTaget, Sigma-Aldrich) used to generate stable FLCN 
knockdown in HK2 cells.  HK2 are a non-disease associated human proximal kidney cell line 
and were chosen as the proximal tubules are thought to be the origin cells of BHD 
associated renal tumours (Chen et al. 2008; Hudon et al. 2010). ‘Low passage’ refers to cells 
grown in culture for less than 2 months, while ‘high passage’ signifies cells gown 
continuously for one year. Cells where kept under selection with 2 µg/ml puromycin 
(Gibco™). 
All transfections were performed using Lipofectamine 2000 according to the 
manufacturer’s protocol (Life Technologies, 11668019). Where specified, cells were exposed 
to ionising radiation (IR) using Gammacell 1000 Elite (Nordion International Inc).  
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2.7 Cell lysis  
 
HEK293 cells were lysed in ‘BHD lysis buffer’ (20 mM Tris, 135 mM NaCl, 5 % [v/v] glycerol, 
50 mM NaF, 0.1 % [v/v] Triton X-100) containing the protease inhibitors pepstatin (1 ug/ml); 
antipain (2 uM); leupeptin (10 uM); benzamaidine (1 mM); phenylmethylsulfonyl fluoride 
(0.1 mM) and the phosphatase inhibitor, sodium orthovanadate (1 mM).  
HK2 cells were lysed in 1x NuPAGE LDS sample buffer (Invitrogen) containing 62.8 
mM Tris, 10 % [v/v] glycerol, 2 % [w/v] SDS, 0.1 % [w/v] bromophenol blue. 50 mM 
dithiothreitol (DTT) was added just before use.  
 
2.8 Protein quantification  
 
Where appropriate, protein quantification of cellular lysates was carried out using Bradford 
protein assay. 750 µl of Bradford reagent was added to 12 µl of lysate, and light 
absorbances were measured using a Genova life sciences spectrometer (Janeway) at 
595 nm. 
 
2.9 GST pull down and co-immunoprecipitation 
 
For GST-pull down assays, HEK293 cells were transfected with either GST-FLCN in pDEST27 
empty vector (Life Technologies, 11812013) or pcDNA3.1 empty vector (Invitrogen, 
V79020). 150 µl of lysate was incubated with pre-blocked Glutathione-Sepharose 4B beads 
(GE Healthcare) at 4 °C in a rotary shaker for 3 h. Beads were washed five times in BHD lysis 
buffer in the presents of protease inhibitors with a final NaCl concentration of 300 mM for 
DNA-PKcs and washes three times with 250 mM NaCl for all other proteins. Bound proteins 
were eluted using 10 mM glutathione in Rheb storage buffer (20 mM HEPES, 200 mM NaCl, 
5 mM MgCl2, pH 8). Bound proteins were stored in 1xNuPAGE LDS sample buffer containing 
100 mM DTT with a final volume of 40 µl. Where indicated, aliquots were removed for 
immunoblots of whole cell lysates. 
For co-immunoprecipitation assays of patient-derived FLCN mutations, HEK293 cells 
were transfected with either HA-FLCN wild type, HA-FLCN Y463X, HA-FLCN H429X in pN3HA 
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backbone (kindly gifted from Professor Maurice Van Steensel, Maastricht University, 
Netherlands) or pcDNA3.1 empty vector. 150 µl of lysate was incubated with unblocked 
protein G-Sepharose beads (GE Healthcare Life Sciences, 17-0618-05) for 1 h at 4 °C in a 
rotary shaker. This ‘pre-clear’ step was to remove any tenacious proteins. Lysates were spun 
down for 3 min, 3,000 rpm at 4 °C to removed unblocked beads. Lysates were then 
incubated with anti-HA antibodies (1:150, #1186742300; Roche) for 2 h at 4 °C in a rotary 
shaker before the addition of pre-blocked protein G-Sepharose beads (GE Healthcare Life 
Sciences, 17-0618-05) for further 2 h. Beads were washed as described for GST-pull downs 
above. Bound proteins were stored in 40 µl 1xNuPAGE LDS sample buffer containing 100 
mM DTT. Where indicated, aliquots were removed for immunoblots of whole cell lysates. 
Endogenous-endogenous interaction was explored by immunoprecipitating FLCN using Anti-
FLCN antibody gifted from Prof Arnim Pause (McGill University, Canada) at 1:50 dilution.  
Both Glutathione-Sepharose 4B beads and protein G-Sepharose beads were blocked 
in 2 % [w/v] BSA in PBS for at least 1 h at 4°C in a rotary shaker. 
 
2.10 In vitro DNA-PK kinase assay  
 
To assess if FLCN could be a DNA-PK substrate, DNA-PK Kinase Enzyme System (Promega, 
#V4106) was used. Following the manufacturer's protocol, 25 Units/reaction of purified 
DNA-PK holoenzyme, 150 ng/reaction of either purified GST–FLCN or GST-p53, was 
prepared on ice. p53, a well characterised substrate of DNA-PK (Goodwin and Knudsen 
2014), was used as a positive control. ddH2O was used as a substrate negative control. The 
assay was activated with 100 mM ATP containing 1 μCi γ-[32P] ATP. Reactions were 
incubated for 45 min at room temperature. Kinase activity was stopped with the addition of 
1x NuPAGE LDS sample buffer (Invitrogen) supplemented with 100 mM DTT (Sigma-Aldrich-
Aldrich). Samples were separated by SDS-PAGE (Invitrogen). Gels were vacuum-dried and 
[32P]-incorporation was measured by autoradiography.  
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2.11 Western blot  
 
Protein samples were separated on SDS-PAGE (Invitrogen) at 150 V for 1 h and 5 min, after 
which, proteins were electrophoretically transferred to a polyvinylidene difluoride (PVDF) 
membrane at 25 V for 2 h 10 min. Membranes were blocked with 5 % [w/v] non-fat milk in 
TBS-T (10 mM Tris, 150 mM NaCl, 0.1 % [v/v] Tween-20, pH7.6) for 1 h at room 
temperature. Required primary antibodies were diluted (as listed below) in 2 % BSA [w/v] in 
TBS-T and incubated at 4 °C overnight. After three washes with TBS-T, secondary antibodies 
conjugated with horseradish peroxidase (HRP) were applied. Membranes were analysed by 
using enhanced chemiluminescence (Luminata Classic [WBLUC0500], Crescendo 
[WBLUR0500], Forte [WBLUF0500]; Millipore) as required.  
2.11.1 Antibodies  
Unless stated otherwise, antibodies were purchased from Cell Signalling Technologies. The 
following total protein antibodies were used for western blotting;, β-actin (1:1000, #84573 
(D6A8)); p53 (1:1000, DO-1; Bethyl); GST (1:1000, #DAM1411332; Millipore); HA (1:1000, 
#1186742300; Roche); DNA-PKcs (1:250, #D00148436; Calbiochem); p21 (1:1000, 12D1), 
CDC37 (1:1000, ab108305, Abcam), CDK4 (1:1000, 11026-1-AP, Proteintech), Histone 3 
(1:1000, ab1791, Abcam), EGFR (1:1000, #2232), LDHA (1:1000, ab53292, Abcam), SP1 
(1:1000, #9389 (D4C3). 
 
The following additional phospho-specific proteins were used; p-ATR s428 (1:1000, #2853p); 
p-Chk1 Ser345 (1:1000, #2348p (13D3)); p-H2AX Ser139 (1:1000, #9718P (S) (20E3)); p-Chk2 
Thr68 (1:1000, #2661P); p-ATM Ser1981 (1:1000, #5883P (D6H9)); p-BRCA1 Ser1524 
(1:1000, #9009P); p-p53 Ser15 (1:1000, #9286P (16G8)); p-RB Ser780 (1:1000, D59B7); p-
DNA-PK Ser2056 (1:5000, Ab124918; Abcam).  
 
2.12 Cell viability assay  
 
1x105 low passage HK2 cells were seeded onto a 60 mm plate and incubated overnight. Cells 
were subjected to 10 Gy IR, trypsininsed and 10µL of suspended cells were loaded onto a 
NC-Slide A8. DNA was stained with Solution 18™ (chemoetic) to identify live vs total cells 
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and the viability of harvested HK2 cells were measured by using a NucleoCounter NC-3000 
(Copenhagen, Denmark), according to the manufacturer's instructions. 
 
2.13 Subcellular fractionation  
 
Cells were treated with either 5 or 10 Gy IR and after 1 hour lysed using the Subcellular 
Protein Fractionation Kit for Cultured Cells™ (ThermoFisher Scientific) as stated in the 
manufacturer’s protocol. The following proteins were used as fraction controls; lactate 
dehydrogenase (LDHA) for the cytoplasmic fraction; epidermal growth factor receptor 
(EGFR) for the membrane-bound fraction; transcription factor Sp1 (SP1) for the soluble 
nuclear fraction; and histone 3 (His3) for the chromatin-bound fraction. 
 
2.14 Flow cytometry 
 
For all experiments, cells were seeded at 1x105 in 35 mm plates. Where specified, cells were 
subjected to IR.  To quantify DNA content, 20 µM DRAQ5™ (BioStatus) was added to 
samples 10 min before FACS analysis using a BD FACSCalibur™ (BD Biosciences). Data were 
quantified by using Flow Jo v10 Software (Tristar). 
2.14.1 Cell cycle analysis following DNA damage 
Low passage HK2 cells were subjected to 2 Gy IR, after which fresh media was added. Cells 
were washed once with 1 mL PBS and fixed with ice-cold 70 % [v/v] ethanol on ice for 45 
min. Fixed cells were stored at 4 °C in PBS until analysed.  
2.14.2 G2/M phase block 
Low passage HK2 cells were subjected to 2 Gy IR and fresh media was added containing 60 
ng/mL colcemid (Gibco). Cells were washed once with 1 mL PBS and fixed with ice-cold 70 % 
[v/v] ethanol on ice for 45 min and stored at 4 °C in PBS until analysed.  
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2.14.3 Quantifying S phase cells 
The thymidine analogues; 5-bromo-2'-deoxyuridine (BrdU) and 5-ethynyl-2´-deoxyuridine 
(EdU), were trialled in an attempt to quantify cells entering S phase. 
For Brdu treatment, cells were treated with 30 µM BrdU and fixed with ice-cold 70 % 
[v/v] ethanol on ice for 45 min. Once fixed, DNA was denatured by incubating cells in 1 mL 3 
M HCL at room temperature for 30 min and washed with 1 mL of 0.1 M sodium borate 
(Sigma-Aldrich-Aldrich) to stop acid depurination. Samples were centrifuged for 10 min at 
1000 rpm and supernatant was removed. Cells were re-suspended in 180 µl 0.5 % [v/v] 
Tween 20 and 1 % [w/v] BSA in PBS and incubated at room temperature for 15 min. 20 µl 
Anti-BrdU, antibody (clone B44, 347580 Becton Dickinson Biosciences) was added and 
samples were incubated for 1 h at room temperature. Cells were washed once with 3 mL 
PBS before being incubated with Alexa 488-conjuated secondary antibody (1:500, 
Invitrogen) in 100 µl 0.5% [v/v] Tween 20 and 1 % [w/v] BSA in PBS for 1 h at room 
temperature in the dark. Cells were stored at 4 °C in PBS until analysed.  
For EdU treatment, the Click-iT® EdU Alexa Fluor® 488 Flow Cytometry Assay 
Kit (ThermoFisher Scientific) was used as described in the manufacturer’s protocol. The 
concentration of EdU used was lowered from 10 µM to 8 µM for longer incubation time, as 
recommended by manufacturer.  
 
2.15 Data handling and statistical analysis  
 
Where appropriate Student’s t-test was performed in Microsoft Excel and two-way ANOVA 
was performed in GraphPad Prism 4.00. 
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Chapter 3: Analysing the FLCN interactome; a novel FLCN/DNA-PKcs 
interaction  
 
3.1 Introduction  
 
Cellular functions are not carried out by single proteins, but rather by protein networks that 
act together. Recent advances in biological techniques such as yeast-2-hybrid, tandem 
affinity purification, and mass spectrometry, have led to a large amount of publicly available 
protein-protein interaction (PPI) data. PPI networks represent the cross talk among groups 
of proteins and provide valuable information to help understand cellular function, biological 
processes, and mechanisms of disease aetiology (Barabasi and Oltvai 2004; Kann 2007; 
Safari-Alighiarloo et al. 2017).  There are limitations to PPI networks. For instance, PPI 
networks do not explore spatial or temporal aspects that might influence protein 
interactions within the network, i.e., due to interactions in different cellular compartments. 
Consequently, PPI networks may not accurately reflect the actual situation in a cell. 
Nevertheless, the organisational principles discovered by analysing the topological features 
in these networks can be used to provide an insight into cellular interactions that exist 
under defined conditions (Barabasi and Oltvai 2004). Topological characteristics in PPI 
networks allow you to determine the key elements within a network (Barabasi and Oltvai 
2004; Safari-Alighiarloo et al. 2017). Centrality is an important part of the topological 
characteristics of any given PPI network and there are many centrality parameters are 
defined for network analysis (Barabasi and Oltvai 2004), some prove more informative than 
others. ‘Degree’ (k) and ‘betweenness centrality’ (BC) are the two most commonly applied 
topological attributes explored in PPI networks.  Proteins with a high number of 
interactions, as determined by their k value, are known as hubs; while proteins with high BC 
are termed bottlenecks (Barabasi and Oltvai 2004). Proteins that have both a high number 
of interactions and a high BC are often referred to as hub-bottlenecks. These proteins are 
often crucial for the PPI network integrity (Barabasi and Oltvai 2004) and are useful for 
understanding the flow of information around the network. 
To better understand the tumour suppressor role of FLCN, an unbiased protein 
interaction screen for FLCN was carried out. To do this, GST-tagged FLCN was expressed in 
HEK293 cells and then purified on glutathione-Sepharose beads. Proteins that co-purified 
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with GST-FLCN were resolved on SDS-PAGE and subjected to mass spectrometry. This 
identified over 650 potential FLCN-interacting proteins, 613 of which were successfully 
mapped to form a FLCN interactome using the STRING protein–protein interaction database 
(Szklarczyk et al. 2017). The dense protein interaction network was then imported into 
Cytoscape (v3.6.1 (Lopes et al. 2010) to explore the topology and form a more meaningful 
network (Figure 3.1A). A full list of proteins identified by mass spectrometry can be found in 
appendix 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Network image of the FLCN interactome.  A) FLCN interactome containing all proteins as 
determined by GST-FLCN pull down. The network contains 613 proteins coloured according to the 
biological processes they are involved in. Node size corresponds to the number of interactions with 
other FLCN-bound proteins (k) with larger sized circles representing a higher number of interactions. 
B) Node colour key indicating what biological process each protein is involved in. A more detailed 
functional break down of the FLCN interactome can be found in figure 3.4.  
 
A) 
Ubiquitination Other (function(s) not referenced)  Cell cycle 
DNA replication 
DNA damage 
2 or more functions  
Transcription & Translation  
Chromatin structure
  
B)     Colour Key 
Telomere maintenance 
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3.2 Results and discussion  
 
3.2.1 FLCN interactome network modelling  
Within PPI networks, the number of edges that connect to a given node is referred to as its 
degree (k), i.e., the number of interactions a protein has to other proteins within the 
network. The largest degree in the FLCN interactome was 169, while the average degree for 
the network is 32.28 (Figure 3.2A).  The degree distribution (Figure 3.2B) of a network is the 
probability distribution of node degrees over the whole network (Barabasi and Oltvai 2004). 
Within a biological setting, most proteins within a network participate in only a few 
interactions, while a few proteins participate in many. These proteins are referred to as hub 
proteins. Hubs typically represent proteins that have a crucial role for the cell. They function 
as control centres connecting many cell processes (Barabasi and Oltvai 2004; Han et al. 
2004). Depending on the nature of the protein, the degree could indicate a central role in 
amplification (kinases), diversification and turnover (small GTPases), signalling module 
assembly (docking proteins), or gene expression (transcription factors). Hubs identified 
within the FLCN interactome include TP53, HSP90AA1, CDK1, PPP2CA, PPP2R1A, PCNA, and 
XOP1, and all are involved in DDR, cell cycle regulation, or have been linked to 
tumorigenesis. These proteins are discussed further in sections 3.3 and 3.5; and summarised 
in table 3.1. 
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Figure 3.2 Topological parameters of the FLCN interactome. A) A summary of the FLCN protein-
protein interaction (PPI) network topological parameters. B) The distribution of node degree within 
the FLCN interactome. Red line indicates power of fit and has a degree exponent γ =0.-855. C) The 
distribution of cluster coefficient within the FLCN interactome. D) The distribution of shortest path 
length within the FLCN interactome. 
 
Within the FLCN interactome, the degree distribution decreases following a power-law (P(k) 
∼kγ), where k is the number of partner proteins, and γ is the degree exponent (figure 3.2B). 
This indicates that the network has scale-free properties. Most biological networks are 
scale-free. In a scale-free network, the probability of a node (protein) being highly 
connected is statistically more significant than in a random network (Barabasi and Oltvai 
2004). In random networks most of the nodes have almost the same number of edges 
(interactions) (Barabasi and Oltvai 2004). The value of γ can determine characteristics of the 
Summary of PPI topological parameters 
Parameter Score 
Number of nodes 613 
Average Clustering coefficient 0.401 
Connected components 1 
Average shortest path length 2.475 
Maximum node degree 169 
Average node degree 32.277 
Network density 0.053 
Network heterogeneity 0.931 
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network. The smaller the value of γ, the more important the role of hubs are. For γ>3 the 
hubs are not relevant, and a scale-free network behaves like a random one. When 2< γ <3 
there is a hierarchy of hubs, with the most connected hub being in contact with a small 
fraction of all nodes. When γ=2, a hub-and-spoke network emerges, with the largest hub 
being in contact with a large fraction of all nodes. Furthermore, γ<3 networks typically 
possess a high level of robustness against accidental node failures. This means the network 
can respond to changes in external conditions or internal organisation while maintaining 
comparatively normal behaviour (Albert et al. 2000). Within a biological context, disabling 
an extensive number of proteins will result in a functional dissolution of a network; 
however, cell signalling networks can withstand the incapacitation of many of their 
individual components. Even if 80 % of randomly selected nodes fail, the remaining 20 % are 
usually still able to form a compact cluster with a path connecting any two nodes. On the 
other hand, the reliance on hub proteins for information flow is an area of vulnerability for 
scale-free networks. Removing a only few key hub proteins can break the network into small 
isolated clusters (Albert et al. 2000). Proteins involved in cancer often form hubs and are 
good examples of the limitations of scale-free networks. p53, for instance, has over 300 
protein interactors (Maslon and Hupp 2010). A mutation in any one of these 300 proteins 
would likely have minimal effect on the cell. However, loss of p53 itself is linked to the 
deregulation of numerous cell systems and the progression of many cancers (Maslon and 
Hupp 2010). The FLCN interactome has a degree exponent of 0.855, (figure 3.2B) similar to 
that of other biological networks following a scale-free distribution (Barabasi and Oltvai 
2004). The R2 value was 0.754, verifying the scale-free property of the network. Together 
the γ and R2 value establish an important role for the hub proteins in maintaining the 
network integrity (Barabasi and Oltvai 2004).  
The clustering coefficient, on the other hand, signifies a node’s connectedness to 
other nodes. The clustering coefficient was used to identify the overall organisation of the 
network (Barabasi and Oltvai 2004). The average clustering coefficient of the nodes 
decreases as the number of interactions per protein increases, demonstrating the potential 
of the network to adopt a hierarchical organisation. The average clustering coefficient of the 
FLCN interactome was 0.401 (figure 3.2C). This parameter was also measured in 100 random 
networks generated by rewiring edges in the FLCN interactome while preserving the 
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degrees of the respective nodes. In the random networks, the average clustering coefficient 
was 0.176 (SD± 0.004), supporting the idea that the FLCN interactome behaves like a real-
world network. 
The shortest path length describes the distance between two nodes having the 
minimum edge length, i.e., the shortest route between any given two proteins. The shortest 
path length distribution can indicate small-world properties, the information transfer 
eﬃciency, and the overall navigability of the network (Barabasi and Oltvai 2004). In the 
FLCN interactome, the average shortest path length was 2.475. The shortest path length 
distribution (Figure 3.2D) shows the majority of paths are short (<3) suggesting that 
information can spread rapidly from any given node to all other nodes in the network.  
The overall structure and topological properties of the network indicate that it is a 
strongly connected, scale-free network.  Thus, it represents a solid and specific network of 
interactions from the human PPI. 
 
3.2.2 Identifying important proteins within the FLCN interactome 
The global centrality measures (closeness centrality and betweenness centrality) have been 
used in many studies to find essential proteins within PPI networks. Closeness centrality (CC) 
is the average length of the shortest path between the node and all other nodes. The more 
central a node is, the closer it is to all other nodes. It is a measure of how fast information 
spreads from a given node to other reachable nodes in the network (Barabasi and Oltvai 
2004). CC can be interpreted as the probability of a protein to be functionally relevant for 
several other proteins within the network, but with the possibility to be functionally 
irrelevant for few other proteins. The higher a CC value is, the closer it is to all other nodes 
(figure 3.3A). Recently it has been demonstrated that CC does not reliably deduce the 
essentialness of a protein within a network, and instead betweenness centrality (BC) should 
be favoured (Raman et al. 2014). BC measures how frequently nodes are on the shortest 
pathway between any two nodes (figure 3.3B) (Barabasi and Oltvai 2004). The BC of a node 
reflects the amount of control that a node exerts over the interactions of other nodes in the 
network (Yoon et al. 2006). Nodes with a high BC are of interest because they function as 
bottlenecks, i.e., they lie at the intersection of communication paths and can control 
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information flow. In biology, these nodes represent important proteins in signalling 
pathways (Girvan and Newman 2002; Barabasi and Oltvai 2004; Han et al. 2004). Within the 
FLCN interactome the node with the highest BC was TP53, a major tumour suppressor that 
is heavily mutated in cancer progression.  
A backbone network was constructed from nodes with both a high degree and high 
BC, termed hub-bottleneck nodes. These were determined by values that are 2 standard 
deviations above respective means. A total of 18 hub-bottleneck nodes were identified in 
the FLCN interactome (Figure 3.3C), whose functions are summarised in table 3.1. Of these, 
p53, HSP90AA1, CDK1, PPP2CA, PPP2R1A, PCNA, and XPO1 have all been previously been 
linked to DDR and cell cycle control and are often altered in tumorigenesis.  
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Figure 3.3 Important proteins within the FLCN interactome. A) Distribution of closeness centrality 
(CC) scores within the FLCN interactome. B) Distribution of betweenness centrality (BC) scores within 
the FLCN interactome. C) The backbone network of the FLCN interactome showing proteins that 
contain both a high degree (k) and high a BC score as determined by values that are 2 standard 
deviations above their respective means. These are considered hub-bottleneck nodes.  Purple nodes 
= proteins with a role in the DNA-damage response (DDR); orange nodes = proteins with a role in the 
cell cycle; mauve nodes = proteins with a role in both DDR and cell cycle; black nodes = have either 
3+ functions, or do not function in DDR and/or cell cycle. 
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Table 3.1 Table summarising the backbone network of the FLCN interactome. Listed proteins contain both high degree and high betweenness centrality 
(BC), as determined by values that are 2 standard deviations above their respective means and are considered hub-bottleneck nodes. The proteins are 
ordered based on degree values (k), highest value first. 
Protein 
Name 
Function k BC 
p53 
Tumour suppressor; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Negatively regulates 
cell cycle regulation. Involved in signal transduction following DNA damage. 
169 0.05376 
HSPA8 
Molecular chaperone for in a wide variety of cellular processes. Ensures correct folding of newly synthesized polypeptides.  Activates 
proteolysis of misfolded proteins. Acts in response to stress. 
161 0.03225 
HSP90AA1 
Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved in 
cell cycle control and DNA damage response signal transduction. 
153 0.0401 
UBC Polyubiquitin-C has a role in a diverse range of biological processes, including DNA repair.  150 0.03059 
CDK1 Plays a key role in cell cycle control. Regulates G1 progression and G1-S transition. Also promotes G2-M transition.  145 0.02768 
GAPDH 
Modulates cytoskeleton. Has a role in glycolysis. Participates in nuclear events including transcription, RNA transport, DNA replication and 
apoptosis. Nuclear functions are due to the nitrosylase activity; nuclear target proteins include SIRT1, HDAC2 and DNA-PKcs. 
142 0.02650 
CAD This protein is a "fusion" protein encoding four enzymatic activities of the pyrimidine pathway (GATase, CPSase, ATCase and DHOase) 132 0.02412 
PPP2CA 
PP2A is the major phosphatase for microtubule-associated proteins (MAPs). PP2A can modulate the activity of phosphorylase B kinase 
casein kinase 2, mitogen-stimulated S6 kinase, and MAP-2 kinase. Can dephosphorylate p53. Activates pro-proliferation pathways via RAF1.  
125 0.01821 
EPRS Multifunctional protein, primarily part of aminoacyl-tRNA synthetase multienzyme complex. Is an effector of the mTOR signalling pathway. 118 0.01377 
ACLY ATP-citrate synthase is responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Has a central role in de novo lipid synthesis. 117 0.02287 
ACTB Β-actin involved in various types of cell motility, major component of the cytoskeleton. 116 0.02172 
IMPDH2 
Catalyses inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP). Regulates of cell growth. Possible role in malignancy and 
progression of some tumours. 
114 0.01698 
POLR2B DNA-dependent RNA polymerase catalyses the transcription of DNA into RNA. 113 0.02123 
EEF1A1 This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis. 112 0.01379 
PPP2R1A 
The PR65 subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a 
variable regulatory B subunit. Required for proper chromosome segregation and for centromeric localization of SGO1 in mitosis. 
110 0.01305 
PCNA 
Auxiliary protein of DNA polymerase delta. Involved in controlling DNA replication. Plays a key role in DNA damage response (DDR) 
coordinating DNA replication with repair at the replication folk. Acts as a loading platform to recruit DDR proteins. 
105 0.01447 
HSPD1 Chaperone implicated in mitochondrial protein import and macromolecular assembly. 102 0.01438 
XPO1 Mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) – such as cyclin D1  101 0.01931 
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3.2.3 Functional role of the FLCN interactome 
To gain insights into the biological roles of the components of the FLCN interactome, gene 
ontology (GO) category enrichment was analysed using the STRING-db. The GO categories; 
cellular component (GO-CC) and biological process (GO-BP) were used to organise the 
constituents of the FLCN interactome and indicate possible functions for FLCN. GO-CC terms 
describe subcellular structures and macromolecular complexes and may be used to 
annotate cellular locations of gene products, and by extension give clues as to its biological 
function. GO-CC term enrichment for the FLCN interactome suggest FLCN interacts with 
proteins that function in every aspect of the cellular substructures (figure 3.4), but suggest 
the nucleus may be the most important compartment of FLCN interactors (Roncaglia et al. 
2013).  
 
Figure 3.4 Cellular component enrichment of the FLCN interactome. Bar graph showing enrichment 
P-values corrected to multiple testing (FDR) for subcellular compartments in which components of 
the FLCN interactome function. Number of proteins in each compartment are bracketed. 
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Using a threshold of FDR<0.05, a total of 743 significant GO-BP terms were enriched (see 
appendix 2 for a full break down of terms and FDR corrected P-values). GO is a 
large bioinformatic initiative to unify the attributes of genes across all species. The project 
aims to maintain and develop a controlled vocabulary of gene attributes, and to assimilate 
and disseminate annotation data to enable functional interpretation of experimental data 
(Ashburner et al. 2000; Harris et al. 2008). GO is not static; additions, alterations, and 
corrections are advocated by both those directly involved in the GO project, and members 
of the research community (Harris et al. 2008; Lovering 2017). Over the years, similar and 
overlapping terms have emerged, giving a level of redundancy to the GO annotations. This 
can be considered a good thing as specific association between a GO term and gene can be 
made stronger by the availability of multiple annotations that reproduce an association 
using evidence from independent sources of data. However, GO term-gene associations are 
sometimes based on the same primary data and can result in a false impression, giving more 
emphasis on the association. Numerous ‘GO term/gene product’ associations can cause an 
annotation dataset to become unnecessarily large and cumbersome for data manipulation. 
For example, within the FLCN interactome the terms; cell cycle (GO.0007049, FDR 6.05E-32), 
mitotic cell cycle (GO.0000278, FDR 7.56E-35), mitotic cell cycle process (GO.1903047, FDR 
7.3E-34), and cell cycle process (GO.0022402, FDR 3.91E-33) are all vastly enriched, but all 
overlap in function and cover the same biological process. As such, GO terms where 
combined into 8 broad categories. These were telomere maintenance, chromatin structure, 
ubiquitination, DNA damage, DNA replication, cell cycle, and, transcription and translation. 
Everything else is categorised under ‘other’ (figure 3.5A). These categories were chosen as 
they either have no or very limited evidence linking FLCN to the biological process. 
Interestingly, there is a large degree of functional overlap between each category. 
Proteins within the FLCN interactome often have roles in multiple biological processes 
(figure 3.5B). This supports the concept that FLCN functions in co-coordinating multiple 
cellular responses and global homeostasis, rather than a defined cellular role.  
 
 
 
 59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Functional break down of the FLCN interactome. A) Pie chart showing merged Gene 
Ontology biological processes (GO-BP) terms enriched within the FLCN interactome that have either 
not previously been linked to, or only weakly associated with, FLCN. As determined by string-db.org. 
B) Venn diagram showing functional overlap of the FLCN PPI network. 
 
 
A) 
B) 
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3.2.4 A closer look at DDR and cell cycle components of the FLCN interactome  
Functional analysis of the FLCN interactome highlighted a role for FLCN in DDR and the cell 
cycle (figure 3.6). 99 proteins where identified to function within DDR, 157 within the cell 
cycle and 60 have a role in both (figure 3.6A).  As previously stated, a large proportion of 
proteins highlighted as integral for the function of the FLCN PPI network (figure 3.6B); p53, 
HSP90AA1, CDK1, PPP2CA, PPP2R1A, PCNA, and XPO1, have been linked to both DDR and 
the cell cycle. These are discussed in-depth below.  
 
3.2.4.1 Tumour suppressor p53   
 
TP53 gene encodes the tumour suppressor protein p53. p53 accumulates at times of cellular 
or genotoxic stress, when it functions to regulate transcriptional control at the G1/S phase 
checkpoint and promote cell cycle arrest, to co-ordinate DNA repair, to initiate and maintain 
senescence, or to promote apoptosis if the normal cellular conditions are not restored 
(Brosh and Rotter 2009). It functions to prevent conditions arising within the cell that can 
lead to the establishment of mutations and tumorigenic transformation of cells. More than 
50 % of human cancers have a mutation in p53 that allow cells to escape from p53-driven 
apoptosis and senescence. Interestingly, TP53 gene expression has been shown to 
correlate with the transition from precancerous lesions to malignancy (Bartkova et al. 
2005; Halazonetis et al. 2008; Brosh and Rotter 2009). Furthermore, overexpression of 
TP53 relates to poor patient prognosis in different cancer types (Haitel et al. 1999). 
Specifically in RCC, TP53 gene overexpression has been reported in up to 40% of tumours 
(Shiina et al. 1997; Haitel et al. 1999), but the role of TP53 overexpression in RCC is still 
debated (Zigeuner et al. 2004). Interestingly, data suggests that mutations within TP53 gene 
may not be linked to patient outcome, or progression in renal cancer, and that TP53 up-
regulation is not caused by gene mutation in most cases of RCC. Thus, the defect in TP53 
leading to its up-regulation in RCC likely reflects indirect and compensatory effects during 
the course of cancer progression (Noon et al. 2010). 
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Figure 3.6 A novel role of FLCN involved in DDR and the cell cycle. A) Venn diagram showing the 
number of proteins within the FLCN interactome that function within the DNA damage response 
(DDR) or the cell cycle. B) Network image showing proteins within the FLCN interactome that have a 
functional role in the DDR and/or cell cycle. Purple nodes = proteins with a role in the DDR; orange 
nodes = proteins with a role in the cell cycle; mauve nodes = proteins with a role in both DDR and 
cell cycle. Node size reflects the degree of each node. 
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3.2.4.2 Heat shock protein 90α 
 
Heat shock protein 90-alpha (Hsp90α) is a molecular chaperone required for correct protein 
folding. Unlike other chaperones, Hsp90α is not required for de novo protein folding, but 
rather facilitates the final maturation of specific proteins. Only once in the correct three-
dimensional native conformation can proteins successfully interact with their binding 
partners. As such, the Hsp90α chaperone machinery plays a key role in orchestrating the 
spatial and temporal order of protein interactions (Taipale et al. 2010; Makhnevych and 
Houry 2012). Protein specificity is facilitated through adapter co-chaperones such as Cdc37.  
The majority of identified Hsp90α protein clients are involved in signal transduction, 
and HSP90α has been heavily linked to DDR and the cell cycle (Burrows et al. 2004; Pennisi 
et al. 2015). HSP90α can be considered a regulator of the diverse DDR pathways as multiple 
components of the DNA DSBR machinery, including BRCA1, BRCA2, Chk1, DNA-PKcs, and 
p53, have all been described as HSP90α clients. Inhibition of HSP90α has been shown to 
lead to the altered stabilisation and localisation of DDR proteins after DNA damage (Pennisi 
et al. 2015). Interestingly, HSP90α  has been shown to facilitate telomere maintenance by 
regulating the switch between its capping and extending structures (DeZwaan et al. 2009). 
Inhibition of HSP90α was shown to decrease the activity of telomerases (Toogun et al. 
2008). Other clients include the cyclin-dependent kinases, CDK4, CDK6, and CDK2, which are 
essential to cell cycle G1/S phase progression. HSP90α mRNA levels are typically increased 
at G1/S phase transition and inhibition of HSP90 often leads to G1 cell cycle arrest (Burrows 
et al. 2004; Giraldez et al. 2017). Importantly, FLCN has already shown to interact with 
HSP90α (Woodford 2016). 
3.2.4.3 Cyclin-dependent kinase 1 
 
Cyclin-dependent kinase 1 (CDK1) is one of the master regulators of mitosis (Salaun et al. 
2008). The expression of CDK1 is constant throughout the cell cycle and regulation of its 
activity depends on its association with cyclins A and B, as well as on post-translational 
modifications such as phosphorylation. CDK1 activity is restricted from S-phase until mitosis 
due to the oscillating protein abundance of cyclins A and B, whose gene transcription, 
translation, and degradation cycles are highly regulated in a temporal manner (Draetta et al. 
1989; Hunt 1989; Salaun et al. 2008). CDK1 is bound to cyclin A during S- and G2-phases 
 63 
 
(Draetta et al. 1989). In G2, cyclin B is synthesised, allowing cyclin B-CDK1 complexes to 
form and activate CDK1 to initiate mitotic entry (Morgan 1995). Hyperactivation of CDK1 has 
been observed in many cancers and dysregulation of Cdk1 causes abnormal proliferation 
and genomic instability (Hall and Peters 1996; Malumbres and Barbacid 2009). 
3.2.4.4 Protein Phosphatase 2A (PP2A) –Scaffold subunit (PPP2R1A), and catalytic subunit 
(PPP2CA) 
 
The PP2A family of phosphatases are a major class of serine/threonine phosphatases. They 
have been associated with many cellular events such as the regulation of cell cycle, cell 
proliferation, and cytoskeletal remodelling (Janssens and Goris 2001). PP2A is a 
heterodimeric complex comprised of a scaffolding A subunit and a catalytic C subunit. This 
A/C unit interacts with a regulatory B subunit producing the PP2A heterotrimeric 
holoenzyme. To date, two different A (Aα and Aβ) and C (Cα and Cβ), and four different B 
subunits (B, B’, B”, and B”’) have been identified. The combination of all subunits (A, B, and 
C) is predicted to produce over 75 different trimeric holoenzymes depending on cell type. 
The A and C subunits are both ubiquitously expressed, while certain B subunits are only 
expressed in a tissue-specific manner and/or at particular stages of cellular development. It 
is thought that the variability of the B subunit dictates substrate specificity and/or 
subcellular localisation of a given PP2A holoenzyme (Janssens and Goris 2001).  
The scaffold subunit, PPP2R1A (Aα), and catalytic subunit PPP2CA (Cα) were identified 
within the FLCN interactome, and both were found to be hub-bottleneck proteins. 
Interestingly, it has been demonstrated that the small GTPases, Rab8 and Rab9, interact 
with PPP2R1A in a GTP-independent manner. It has previously been suggested that 
specific members of the Rab GTPase family play a role in the inhibition of the PP2A 
tumour suppressor. The interaction between Rab8/9 competes with PPP2CA to bind 
PPP2R1A, and weakens the assembly of the PP2A holoenzyme, resulting in its 
inactivation. Furthermore, it has been noted that numerous Rab proteins associate with 
PPP2R1A but not the catalytic subunit PPP2CA. This includes Rab34, Rab35, and Rab7a 
(Sacco et al. 2014). This is interesting as FLCN has already been shown to function as a 
GEF and GAP for Rab35 (Nookala 2012), and more recently with Rab7a (Laviolette et al. 
2017). Furthermore, the regulatory B subunits identified in the FLCN interactome are 
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PPP2R5C (B’γ), PPP2R5D (B’δ), PPP2R5E (B’ε). Specifically, the PP2A-B’γ holoenzyme is 
thought to dephosphorylate and activate p53, and play a role in DNA damage-induced 
inhibition of cell proliferation (Li et al. 2007). 
3.2.4.5 Proliferating cell nuclear antigen  
 
Proliferating cell nuclear antigen (PCNA) acts as a molecular platform to facilitate the 
numerous protein–protein and protein–DNA interactions that occur at the replication 
fork and is essential for the faithful replication of DNA. PCNA provides a central role co-
ordinating many replication-associated processes, including DNA damage repair, 
chromatin establishment, and correct sister chromatid cohesion. Due to a large number 
of proteins competing for a common surface, PCNA is able to modulate well controlled 
regulatory mechanisms. This allows a responsive interplay between appropriate proteins 
at different stages of DNA replication and associated processes (Strzalka and 
Ziemienowicz 2011; Mailand et al. 2013).  
3.2.4.6 Exportin 1  
 
Exportin 1 (XPO1, also known as CRM1) is one of the most well understood nuclear 
exporters. It is involved in the shuttling of over 200 cargo proteins (Xu et al. 2012). Crucially, 
it is the single nuclear exporter of several important cancer-related proteins (Turner et al. 
2012), including tumour suppressor proteins (p53, Rb, and BRCA1) (Jiao et al. 2006; Kanai et 
al. 2007; Brodie and Henderson 2012) and cell cycle regulators (such as p21 and cyclin 
D1) (Asada et al. 1999; Alt et al. 2000). XPO1 is elevated in many cancers and correlates with 
poor patient prognosis  (Cheng et al. 2014; Azmi et al. 2015; Muqbil et al. 2016; Azmi et al. 
2017). It’s likely that the enhanced export of tumour suppressor and regulatory proteins 
away from their targets due to XPO1 overexpression can lead to aberrant cellular growth 
signalling and prevents apoptosis (Turner and Sullivan 2008). Furthermore, XPO1 forms a 
complex with eukaryotic initiation factor 4E (eIF4E) and transports known oncogene mRNAs 
(such as cyclin D1 and MDM2) to the cytoplasm, promoting the synthesis of oncoproteins 
(Culjkovic-Kraljacic et al. 2012). FLCN was shown to interact with eIF4E within the FLCN-
interactome. 
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3.2.5 Validation of novel interactors  
Several proteins within the FLCN interactome were identified with known roles in 
maintaining genetic stability (Figure 3.7A). The PIKK family members, DNA-PK, ATM, and 
ATR were of particular interest as they are critically involved in DDR. All three are 
serine/threonine kinases and are recruited to the DNA lesion site (Lovejoy and Cortez 2009). 
DNA-PK was the most significant FLCN-interacting protein, with 66 unique peptides 
identified during MS (figure 3.7A). DNA-PK was confirmed to interact with GST-FLCN by 
western blot (figure 3.7B). ATR was not confirmed to interact, and ATM may be a very weak 
interactor. Limited evidence shows ATM interacted weakly with FLCN in two out of three 
replicates. For the sake of this thesis, ATM is not considered a true interactor with FLCN.   
Another protein of interest is telomere-associated protein RIF1 (RIF1). RIF1 is a key 
regulator of TP53BP1. It plays a role in promoting the repair of double-strand DNA breaks 
(DSBs) by non-homologous end joining (NHEJ) (Silverman et al. 2004; Drane et al. 2017). 
Furthermore, the yeast ortholog of RIF1 has a well-established role in maintaining telomere 
length (Shi et al. 2013). Mammalian RIF1 telomere function is still under debate (Xu and 
Blackburn 2004; Shi et al. 2013; Kumar and Cheok 2014). In addition, a number of other 
proteins involved in telomere maintenance were identified by MS (supplementary figure 1), 
such as TPP1, an important component of the telomeric shelterin complex. This led to the 
idea that FLCN may be involved in telomere conservation. While preliminary evidence 
suggested an increase in telomere length and telomere fusion events upon FLCN loss 
(supplementary figure 1), both RIF1 and TPP1 failed to be validated as FLCN interactors 
(figure 3.6C). In addition, time restrictions did not permit the exploration of FLCN in 
maintaining telomeric integrity.  
It is worth noting, overexpressed V5-tagged p53 was also transfected into HEK293 
cells alongside GST-FLCN. Upon western blotting the V5-tag could not be detected, nor 
could p53. This was only briefly explored and is worth further work to confirm if p53 directly 
interacts with FLCN.  
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Figure 3.7. Validation of candidate novel FLCN interactors. A) Table of candidate proteins identified 
by mass spectrometry. B) GST-tagged FLCN was overexpressed in HEK293 cells and used as bait 
protein to validate a protein interaction between FLCN and endogenously expressed DNA damage 
components (DNA-PKcs, ATM, ATR). C) GST-tagged FLCN was overexpressed in HEK293 cells and 
used as bait protein to validate a protein interaction between FLCN and endogenously expressed cell 
cycle components (CDK4, CDC37, CDKN2A). 
 
Protein Name # of Unique 
Peptides 
Total 
peptides 
DNA‐PKcs DNA‐dependent Protein Kinase, 
catalytic subunit 
66 
147 
RIF1 Rap1 interacting factor homology 7 
ATM Ataxia‐telangiectasia‐mutated 5 
ATR ataxia telangiectasia and Rad3‐related  2 
CDC37 Cell division cycle 37 6 
CDK4 Cyclin‐dependent kinase 4 5 
B) C) 
A) 
CDK4 
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Cell cycle associated proteins CDKN2A, CDC37 and CDK4 were also tested as 
potential FLCN interacting proteins. It’s worth noting both CDC37 and CDK4 function as 
clients of HSP90, a protein already confirmed to interact with FLCN (Burrows et al. 2004; 
Woodford et al. 2016). However, no evidence was found to validate CDKN2A, CDK4, or 
CDC37 as FLCN interactors. It’s worth noting lysis buffer was changed after this validation 
attempt. Details are discussed on page 104 but briefly, the lysis buffer used for GST-pull 
down assays may not sufficiently break down nuclear membrane. Therefore, the lack of 
biochemical interaction observed for nuclear DDR and cell cycle components such as ATM, 
ATR, CDK4, CDC37, and CDKN2A may be due to an inadequate lysis protocol. DNA-PKcs, on 
the other hand, is an extremely abundant protein and is commonly found in the cytoplasm 
(Anderson 1996; Huston et al. 2008).  
To further validate the protein interaction of DNA-PK with FLCN, endogenous DNA-
PK co-purified with immunoprecipitated endogenous FLCN (Figure 3.8A). In addition, DNA-
PK association was compared with either wild-type FLCN or two patient-derived mutants 
(Y463X and H429X) (Figures 3.8B). DNA-PK could associate with the two C-terminal 
truncated patient mutants, indicating that the C-terminus of FLCN is not crucial for DNA-PK 
binding. DNA-PKcs is a serine/threonine kinase responsible for instigating a DDR against 
dsDNA breaks. Therefore, DNA-PK’s protein interaction with FLCN following IR was explored 
to better understand the regulation of FLCN binding (figure 3.8C).  GST-FLCN expressing 
HEK293 cells were subjected to IR and showed a marked reduction in association with DNA-
PK upon 5 Gy, while no apparent association of FLCN with DNA-PK was observed with the 
higher dose of IR (10 Gy). DNA-PKcs autophosphorylates at serine 2056 (Ser2056) in 
response to dsDNA breaks (Smith and Jackson 1999) and phosphorylated H2AX is a well 
characterised surrogate marker of DSB. Both DNA-PK and H2AX were phosphorylated upon 
IR, confirming that IR was causing DNA damage. 
 
 
 
 
 
 68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Further validation of the novel FLCN/DNA-PKcs interaction. A) Endogenous DNA-PKcs co-
immunoprecipitation with endogenous FLCN from HEK293 cells. FLCN was used as the bait protein 
and immunoprecipitated using an antibody raised against the N-terminal of FLCN. B) Endogenous 
DNA-PKcs immunoprecipitation with overexpressed HA-tagged FLCN. HA-tagged FLCN constructs 
consisted of wild type FLCN (WT), and two patient derived C-terminal truncated mutants (Y463X and 
H429X). C) FLCN/DNA-PKcs interaction following induction of DNA-damage by ionising radiation (IR). 
GST-tagged FLCN was overexpressed in HEK293 cells and used as bait protein to validate a protein 
interaction between FLCN and endogenous DNA-PKcs. Cells where subjected to IR (5 or 10 Gy) and 
left for 1 hour prior to cellular lysis. 
 
 
 
 
B) 
 
B) 
A) 
 
A) 
C) 
 
C) 
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3.3 Conclusion  
 
The description of the topological characteristics of a network is often the first step in the 
analysis of network data (Assenov et al. 2008; Sanz-Pamplona et al. 2012). Proteins that 
have a large proportion of connections and high centrality measures within the network 
often play biologically important roles within in the studied system and are essential to the 
network’s viability (Barabasi and Oltvai 2004; He and Zhang 2006; Goh et al. 2007). Proteins 
that are traditionally associated with cancer tend to be implicated in several cellular 
processes and signalling pathways; they often work as protein hub-bottlenecks inside PPI 
networks (Kar et al. 2009). This was observed in the FLCN interactome. The proteins 
identified as most important for the network organisation and information flow (TP53, 
HSP90AA1, CDK1, PPP2CA, IMPDH2, PPP2R1A, PCNA, and XOP1) have all previously been 
linked to DDR, cell cycle control, and/or tumorigenesis (Haitel et al. 1999; Li et al. 2007; 
Malumbres and Barbacid 2009; Turner et al. 2012; Mailand et al. 2013; Pennisi et al. 2015). 
It is necessary to keep in mind that despite huge efforts, the human interactome is 
not complete. Well studied proteins have a higher probability of being included in such a 
network, resulting in some selection bias with respect to less studied proteins. Moreover, it 
is well known that the human interactome contains false positive interactions, so a careful 
interpretation of results is required (Chua and Wong 2008). Lack of spatial-temporal 
information is another obstacle to consider in the network elucidation process (Strogatz 
2001). Diseases like cancer are complex, consisting of cross-talk between neighbouring cells 
and the surrounding microenvironment, which is often missed in PPI networks (Kenny et al. 
2007; Hanahan and Weinberg 2011) . Despite this, information obtained is often valuable 
for hypothesis generation.  
Several proteins identified in the FLCN interactome have a role in DDR and/or the 
cell cycle. This led to the hypothesis that FLCN’s tumour suppressor functions may extend to 
genomic maintenance. Moreover, a novel FLCN interactor, DNA-PKcs, was identified and 
validated. This is an exciting finding. For the first time, FLCN has been linked to a role in 
genome integrity. The biological reason for this interaction is explored in subsequent 
chapters.  
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Chapter 4: Transcriptomic effects of FLCN knockdown 
 
4.1 Introduction 
 
RNA sequencing (RNA-seq) is a high-throughput technology used to provide a 
comprehensive and unbiased view of the complex nature of the transcriptome (Wang et al. 
2009). RNA-seq can be used to identify many features including fusion genes, disease-
associated single nucleotide polymorphisms (SNP), and differential gene expression across 
different groups or treatments (Wang et al. 2009). RNA-seq technology has emerged as a 
powerful tool for identifying functional genes and pathways in cancer research. Compared 
to previous hybridisation-based microarray and Sanger sequencing-based methods, RNA-
seq provides a higher resolution with less background noise (Wang et al. 2009).  In recent 
years, RNA-seq has become a very widely used technology for profiling transcriptional 
activity in biological systems. One of the most common uses of RNA-seq is to identify genes 
or molecular pathways that are differentially expressed between two or more biological 
conditions (Kukurba and Montgomery 2015). Changes in expression can then be associated 
with differences in biology and justify further enquiry to uncover mechanisms of action. 
Indeed, RNA-seq has led to the understanding of the molecular pathogenesis in many 
cancers (Wang et al. 2019; Zhou et al. 2019). For example, in clear cell RCC, RNA-seq was 
used to identify novel signalling pathways significantly affected in patient tumour samples 
(Yang et al. 2014). Similarly, gene expression from RNA-seq data has identified gene 
signatures that are associated with clear cell carcinoma aggressiveness, prognosis, and 
overall survival (Tan et al. 2011; Chen et al. 2014; Eckel-Passow et al. 2015; Chen et al. 
2016a). RCC is not a single disease. It contains several histologically defined cancers, each 
with different genetic drivers and therapeutic responses. RNA-seq has been used to 
evaluate the three major histologic subtypes, clear cell, papillary, and chromophobe RCC to 
reveal distinctive features of each RCC subtype and provide the foundation to develop 
subtype-specific therapeutic and management strategies for patients affected with these 
cancers (Ricketts et al. 2018). RNA-seq has also shown shared features among histological 
subtypes of RCC. For example, loss of CDKN2A, which encodes p16, was found in 16% of all 
RCC. Loss of CDKN2A correlated with poor survival in clear cell, papillary, and chromophobe 
renal cancers (Hamilton and Infante 2016) and demonstrates a universal feature in RCC that 
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is potentially druggable with CDK4/6 inhibitors that target the downstream effects of p16 
loss. 
Therefore, transcriptional profiling from RNA-seq of HK2 cells following FLCN 
knockdown was explored to understand FLCN’s tumour suppressive function or to identify 
potential mechanisms for cellular transformation following FLCN loss. The primary objective 
of this chapter was to have a broad understanding of transcriptional changes following FLCN 
loss. RNA preparations were carried out by Dr Elaine Dunlop, Cardiff University. Sequencing 
of the mRNA was performed by Wales Gene Park, Cardiff.  Differentially expressed gene lists 
were generated by Dr Marc Naven, Cardiff University. It’s worth noting RNA-seq was 
performed using a single clone per cell line in triplicate, therefore results represent 
means of technical repeats.  
 
4.2 Results and Discussion  
 
4.2.1 Overview analysis of the RNA sequencing data 
To get an overview of the effect that FLCN knockdown has on the transcriptome of HK2 
cells, a simple analysis compared the total number of significantly differentially expressed 
genes (DEGs) (figure 4.1A).  To do this, FLCN expression was knocked down in a human 
kidney proximal tubule epithelial cell line (HK2), as the proximal tubules are thought be to 
the origin cells for BHD-associated RCC (Chen et al. 2008; Hudon et al. 2010). HK2 cells were 
continually propagated, either with FLCN (wild type, WT) or without FLCN (knockdown, KD), 
for one year. This BHD cell line model was generated to reflect the effects of long-term loss 
of FLCN in kidney cells present within BHD patients. From this four pairwise comparisons 
were made; (1) low passage wild type vs low passage knockdown cells (LP-WT vs LP-KD), 
these represent the direct effect of FLCN knockdown; (2) high passage wild type vs high 
passage knockdown cells (HP-WT vs HP-KD), these represent the effect of FLCN knockdown 
in aged cells; (3) low passage wild type vs high passage wild type cells (LP-WT vs HP-WT), 
these represent changes that normally occur upon cellular ageing; and (4) low passage 
knockdown vs high passage knockdown cells (LP-KD vs HP-KD), these represent changes 
occurring due to continuous FLCN knockdown.  
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A lot of transcriptional dysregulation was detected from FLCN knockdown alone, 
with 1932 DEGs observed in the LP-WT vs LP-KD cells. Interestingly, this is a higher degree of 
change than ageing alone (1542 DEGs LP-WT vs HP-WT). Further changes in gene expression 
occur on ageing with FLCN knockdown with HP-WT vs HP-KD having 4773 DEGs and LP-KD vs 
HP-KD 4503 DEGs. This is again far above the number seen as part of normal cell ageing (LP-
WT vs HP-WT; 1541), suggesting an accelerated deregulation occurs in the absence of FLCN. 
Next, the direction of the differential expression was explored in response to FLCN 
knockdown (i.e., are genes up- or down-regulated). Upon normal ageing a similar amount of 
up regulation and down regulation can be observed (figure 4.1B). In both LP-WT vs LP-KD, 
and LP-KD vs HP-KD, FLCN knockdown resulted in an increase in the number of upregulated 
genes (figure 4.1C and 4.1D). However, when comparing the effect of FLCN knockdown in 
high passage cells to aged matched controls (HP-WT vs HP-KD), an increase in down 
regulated genes was observed (figure 4.1E). 
Typically, a fold change of 1.5 or 2 is considered a true effect in a change of gene 
expression. It’s often argued that small log-fold changes are not biologically relevant, but 
the exact definition of "small" is open to interpretation, and this thinking typically stems 
from the idea that larger log-fold changes are more robust and reliably detected across 
different technologies (e.g., RNA-seq, microarray, and qPCR). Indeed, selecting a threshold 
on this basis would depend on the sensitivities of the technologies involved (Wang et al. 
2009). Several studies have highlighted the functional importance of small gene expression 
changes (Flintoft 2007; St Laurent et al. 2013; Taugbol et al. 2014). Fold change on its own is 
not enough to select the DEGs. A log-fold change threshold doesn't tell you much about the 
error rate, as it doesn't account for the variability of the expression values. Statistics are 
employed to control the false discovery rate and ensures that the expected proportion of 
false positives in your data set of DEGs is below a certain threshold (usually 5%). While this 
itself may be an arbitrary threshold, the choice of this threshold is directly related to the 
probability of whether the genes are truly differentially expressed or not. The biological 
significance of a given fold-change is likely to depend on the gene and on the experimental 
context (McCarthy and Smyth 2009). Therefore, within the HK2 cells, genes were first 
selected on FDR Pvalue<0.05, and all genes were explored in subsequent analysis regardless 
of their fold change.  
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Figure 4.1 Exploring the transcriptomic changes following FLCN knockdown. A) The number of 
significantly differentially expressed genes (DEGs) in each pairwise comparison of low passage (LP), 
high passage (HP), wild type (WT), and FLCN knockdown (KD) cells. For each comparison the cell line 
labelled first represents the control cell line. B) Volcano plot showing normal age-related changes to 
the HK2 transcriptome (LP-WT vs HP-WT). C) Volcano plot showing upregulated and down regulated 
genes as a direct response to FLCN knockdown (LP-WT vs LP-KD). D) Volcano plot showing age 
related changes to the HK2 transcriptome following continued FLCN knockdown (LP-KD vs HP-KD). 
E) Volcano plot showing upregulated and down regulated genes following a year of continuous cell 
culture with FLCN knockdown compared to aged matched wild type FLCN cells (HP-WT vs HP-KD).  
-Log10FDR = log transformed Pvalue adjusted for multiple testing using the FDR method. Log2FC = 
log transformation of gene expression fold change.  
 
A) 
1882 2621 2620 2153 
868 674 885 1047 
B) C) 
D) E) 
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The distribution of statistically significant gene expression for each pairwise 
comparison is summarised in figure 4.2. Interestingly, FLCN knockdown did not produce 
large transcriptional changes in low passage cells (LP-WT vs LP-KD), only 9% of DEGs have a 
fold change ±2. The standard deviation of low passage cells was 1.30, meaning 95% of DEGs 
had a fold change between ±2.60. This increased slightly with normal ageing (LP-WT vs HP-
WT, SD 1.50, 95% of DEGs between ±3), and increased again in aged FLCN knockdown cells 
(HP-WT vs HP-KD, SD 1.72, 95% of DEGs between ±3.44; and LP-KD vs HP-KD, SD 1.75, 95% 
of DEGs between ±3.5). This suggests that FLCN knockdown may contribute to a larger 
occurrence of subtle changes, and these changes may become further deregulated with an 
even longer duration of FLCN knockdown.  
 
 
 
 
 
 
 
 
 
 
All differentially expressed genes 
 Total # DEGs SD log2FC # genes log2FC >±2 % genes log2 FC >±2 
LP-WT vs LP-KD 1932 1.30 175 9.06 
HP-WT vs HP-KD 4773 1.72 763 15.99 
LP-WT vs HP-WT 1541 1.50 213 13.82 
LP-KD vs HP-KD 4503 1.75 812 18.03 
 
Figure 4.2 Distribution of statistically differentially expressed genes (DEGs) A) Density plot showing 
the distribution of statistically differentially expressed genes (DEGs) following FLCN knockdown in 
each pairwise comparison. B) Table summarising the distribution of statistically differentially 
expressed genes (DEGs) following FLCN knockdown. For each pairwise comparison total number of 
DEGs, standard deviation (SD) of DEGs, total number of DEGs with a log2 fold change greater or 
smaller than 2, and percentage of total DEGs with a log2 fold change greater or smaller than 2 are 
shown. LP = low passage cells, HP = high passage cells; WT = wild type FLCN control, KD = FLCN 
knockdown. 
B) 
 
A) 
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Gene dysregulation is a hallmark of cancer. Cancer arises from genetic alterations 
that invariably lead to dysregulated transcriptional programs (Gonda and Ramsay 2015; 
Vinuela et al. 2018). These dysregulated programs can cause cancer cells to become highly 
dependent on certain regulators of gene expression (Vinuela et al. 2018). Transcriptional 
dysregulation arises in cancer from disease-defining genetic alterations, either indirectly via 
mutation of signalling factors converging on transcriptional control, or directly via genetic 
alterations in gene control factors themselves. Cancer-associated genetic alterations can 
affect proteins participating in nearly all levels of transcriptional control, including trans-
factors (transcription factors, signalling proteins, cofactors, chromatin regulators and 
chromosome structuring proteins) and cis-elements (enhancers, promoters and insulators) 
(Bradner et al. 2017). Indeed, the FLCN interactome highlighted several proteins with a role 
in transcription.  
Next, transcriptional changes upon FLCN knockdown in low passage cells were 
compared to their expression in high passage cells, focusing on genes with a role in DDR, cell 
cycle, and transcription and translation. DEGs were split into biological processes using Gene 
Ontology (GO) definitions for simplicity (figure 4.3). Blue dots indicate significant DEGs in 
low passage cells only, green dots indicate significant DEGs in high passage cells only, and 
black triangles indicate significant DEGs in both low and high passage cells. Genes that are 
differentially expressed in either low passage or high passage cells were included to 
highlight any potentially interesting patterns of gene expression changes during cell ageing. 
For example, in low passage cells, genes related to DDR could be collectively down regulated 
as a result of FLCN loss. This theoretically could represent a restricted response to DNA 
damage, enabling an accumulation of genetic mutations. DEGs present in high passage cells 
but not low passage cells represent acquired alterations due to FLCN knockdown. They may 
not be directly influenced by FLCN, but they could represent avenues of cellular 
transformation.  
Pearson’s correlation coefficient (PCC) calculations were performed to better 
understand the relationship of gene expression between the age status of the cells following 
FLCN knockdown. The PCC ranges from −1 to 1. A value of 1 implies that the linear equation 
describes the relationship between X axis and Y axis perfectly. As X increases, Y increases 
equally, and all data points lie on a line. A value of −1, on the other hand, implies that all 
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data points lie on a line for which Y decreases as X increases. A value of 0 implies that there 
is no linear correlation between the variables. A positive correlation within this data would 
suggest genes that are upregulated (or downregulated) following FLCN knockdown in low 
passage cells are also upregulated (or downregulated) in FLCN knockdown high passage 
cells. These changes in gene expression are likely to be directly, or near directly, influenced 
by FLCN. A negative correlation suggests genes that are upregulated (or downregulated) in 
low passage cells, become downregulated (or upregulated) upon ageing. These changes are 
likely to be indirectly influenced by FLCN or a result of complex feedback mechanisms. A 
summary of all correlation scores can be found in table 4.1.  
When comparing all DEGs no patterns in gene expression change can be seen in low 
passage cells only (figure 4.3A). However, in aged cells a very weak negative correlation can 
be observed (PCC -0.24, Pvalue <0.001, R2 0.057). Interestingly, DEGs in both low and high 
passage cells show a slightly stronger negative trend (PCC -0.43, Pvalue <0.001, R2 0.187). 
This suggests as cells age, over-expressed genes become under-expressed and/or vice versa. 
These results aren’t completely unexpected, as large transcriptional changes are commonly 
observed during cellular transformation (Bradner et al. 2017). Ultimately, however, this 
analysis provides little information with regards to molecular changes occurring as a result 
of FLCN knockdown. 
 
 
 
 
 
 
 
 
 
 
 
 77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Comparison of differentially expressed genes (DEGs) A) All common statistically 
significantly dysregulated genes. B) Shows transcriptome changes following FLCN knockdown for 
genes involved in DNA-damage response (DDR), list generated from GO 0006974. C) Shows 
transcriptome changes following FLCN knockdown for genes involved in cell cycle), list generated 
from GO 0007049. D) Shows transcriptome changes following FLCN knockdown for genes involved in 
transcription, and/or translation, list generated from GO 0006351 and GO 0006412 respectively. E) 
Shows transcriptome changes following FLCN knockdown for genes involved in DNA replication list 
generated from GO 0006260. F) Shows transcriptome changes following FLCN knockdown for genes 
involved in ubiquitination list generated from GO 0016567. Where appropriate, grey dots indicate 
not significant genes (NS), blue dots indicate significant DEGs in low passage cells only, green dots 
indicate significant DEGs in high passage cells only, and black triangles indicate significant DEGs in 
both low and high passage cells. Significance is indicated by FDR Pvalue<0.05. 
A) B) 
C) D) 
E) F) 
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Looking at the DDR genes (figure 4.3B); low passage cells only DEGs displayed a weak 
negative correlation (PCC -0.37, Pvalue 0.0001, R2 0.14). High passage only DEGs did not 
display a significant correlation. Collectively, for DEGs in both low and high passage cells, 
genes are upregulated in low passage cells and become downregulated upon ageing. They 
display a very strong negative correlation (PCC -0.90, Pvalue <0.001, R2 0.82). It is plausible 
that upon FLCN knockdown, cells experience an increase to DNA damage or at least an 
increase in the expression of DDR genes. It is also possible this upregulation in low passage 
cells may provide cells with a selective advantage where they are better able to tolerate 
harsh microenvironments (Di Micco et al. 2006; Broustas and Lieberman 2014). This 
phenomenon is commonly observed in human cancers (Chiang et al. 2003; Winnepenninckx 
et al. 2006; Kauffmann et al. 2008; Klein 2008; Broustas and Lieberman 2014). However, it’s 
not clear the extent these changes play in the early stages of cellular transformation. Once 
aged, these genes are expressed less than the aged matched control. Interestingly, it is 
common in cancer for DDR genes to be downregulated (Curtin 2012,2013). For cell cycle 
linked genes, on the other hand, FLCN knockdown had a smaller effect on gene expression 
changes as indicated by genes being more tightly clustered (figure 4.2C). Low passage only 
(PCC -0.45, Pvalue <0.0001, R2 0.20), high passage only (PCC -0.45, Pvalue <0.0001, R2 0.20), 
and DEGs in both (PCC -0.45, Pvalue 0.0001, R2 0.20) all display limited correlation. Based on 
this evidence it’s hard to hypothesise the effect on proliferative drive these expression 
changes have. Differential gene expression of DDR and cell cycle genes are explored more 
later in this chapter (see figure 4.5-4.8).  
For genes involved in transcription and/or translation; high passage only cells display 
no significant correlation. Low passage only cells have a very weak negative correlation (PCC 
-0.46, Pvalue <0.0001, R2 0.21), while DEGs present in both have a strong negative 
correlation (PCC -0.84, Pvalue <0.0001, R2 0.71). For DNA replication, the only significant 
correlation was found in the low passage cell DEGs with a moderately weak correlation (PCC 
-0.46, Pvalue 0.0004, R2 0.21). Low passage only DEGs for ubiquitination showed similarly 
weak negative correlation (PCC -0.44, Pvalue <0.0001, R2 0.19). High passage cells, on the 
other hand, showed strong positive correlation (PCC 0.83, Pvalue <0.0001, R2 0.69), an 
increase or decrease in expression correlates well with cell ageing. However, for DEGs in 
 79 
 
both low and high passage cells, no significant correlation can be seen, suggesting the 
changes seen in high passage cells may have more to do with ageing, then FLCN loss per se.  
 
All DEGs 
 Low passage only High passage only Both 
PCC -0.06127 -0.2389 -0.4320 
Pvalue NS 0.0001 0.0001 
R2 0.00375 0.05710 0.1866 
DDR 
 Low passage only High passage only Both 
PCC -0.3697 -0.2053 -0.9017 
Pvalue <0.001 NS <0.0001 
R2 0.1367 0.04215 0.8130 
Cell cycle 
 Low passage only High passage only Both 
PCC -0.4425 -0.4499 -0.4503 
Pvalue <0.0001 <0.0001 0.0001 
R2 0.1958 0.2024 0.2028 
Transcription/ Translation 
 Low passage only High passage only Both 
PCC -0.4632 -0.2298 -0.8446 
Pvalue <0.0001 NS <0.0001 
R2 0.2146 0.0579 0.7133 
DNA replication 
 Low passage only High passage only Both 
PCC -0.4572 -0.5493 -0.2573 
Pvalue 0.0004 NS NS 
R2 0.2090 0.3018 0.06623 
Ubiquitination 
 Low passage only High passage only Both 
PCC -0.4397 0.8313 -0.3271 
Pvalue <0.0001 <0.0001 NS 
R2 0.1934 0.6910 0.1070 
 
Table 4.1 The table shows the Pearson’s Correlation Coefficient (PCC) for differentially expressed 
genes (DEGs) explored in figure 4.3. NS = not significant.   
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4.2.2 Functional enrichment analysis using REACTOME pathway analysis tool 
Upon FLCN knockdown, a lot of small transcriptional changes occur (figure 4.1-4.3). To 
better understand the biological impact of these transcriptional changes the REACTOME 
online resource was used to visualise and interpret the DEGs following FLCN knockdown 
(Fabregat et al. 2017; Fabregat et al. 2018). REACTOME is a curated database of pathways 
and reactions in biology (Fabregat et al. 2018). Cells function through a complex network of 
molecular interactions. Molecules are synthesised and degraded, undergo an array of 
temporary and permanent modifications, are transported from one location to another, and 
form complexes with other molecules. REACTOME represents these layers of complexity as 
reactions. These reactions can occur spontaneously or be facilitated by physical entities 
acting as catalysts, and their progress can be modulated by regulatory effects of other 
physical entities. Reactions are linked together by shared physical entities; a product from 
one reaction may be a substrate in another reaction, which in turn may catalyse a third. It is 
convenient to group such sets of interlinked reactions into pathways. To do this, the 
REACTOME tool cross-references over 100 different online bioinformatics resources, 
including NCBI Gene, Ensembl, UniProt and the PubMed literature database, and merges 
various pathway analysis-related tasks to a single portal (Nardini et al. 2015).  REACTOME 
was chosen over other software, such as Qiagen’s Ingenuity Pathway Analysis (IPA) as 
REACTOME is a freely available, open source database. All DEGs identified by RNA-seq 
following FLCN knockdown, regardless of cell age, were submitted to REACTOME for 
functional analysis to produce a genome-wide overview of pathways affected by FLCN 
knockdown (figure 4.4). REACTOME pathways are arranged in a hierarchy. The centre of 
each of the circular "bursts" is the top level pathway, for example "DNA Repair". Each step 
away from the centre represents the next level, lower in the pathway hierarchy; i.e., a 
specific repair pathway. The dark yellow lines indicate that at least one gene within that 
pathway is differential expressed as a result of FLCN Knockdown. This illustration shows a 
globalised dysregulation upon FLCN Knockdown.  
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Figure 4.4 An overview of pathways hit by differentially expressed genes following FLCN knockdown. The coloured segments indicate pathways that have 
at least 1 gene significantly differentially expressed upon FLCN loss, regardless of age status, as generated by REACTOME pathway analysis tool.  
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Next, REACTOME was used to perform a functional enrichment analysis of the DEGs. 
REACTOME’s pathway analysis tool uses an over-representation analysis. This is a statistical 
test that determines whether certain pathways are over-represented (or enriched) in the 
submitted data. It answers the question; does the list of genes contain more genes for 
pathway ‘X’ than would be expected by chance? REACTOME produces a probability score, 
which is corrected for false discovery rate using the Benjamani-Hochberg FDR method. 
Enrichment analysis was done on DEGs identified between age matched cell lines (LP-WT vs 
LP-KD and HP-WT vs HP-KD). When analysing all DEGs in low passage cells, no pathways 
were deemed statistically significant once corrected for multiple testing (figure 4.5A). In 
high passage cells, however, six pathways were noted as enriched, including Ub-specific 
processing of protease (FDR Pvalue 2.96E-04), post-translation protein modification (FDR 
Pvalue 0.009) and Neddylation (FDR Pvalue 0.009). The enrichment of neddylation is worth 
noting. Neddylation is a type of post-translation modification that involves the conjugation 
of the ubiquitin-like protein NEDD8 to a protein substrate. Levels of neddylation enzymes 
are elevated in many human cancers (Xie et al. 2014; Barbier-Torres et al. 2015; Brown and 
Jackson 2015; Hua et al. 2015; Chen et al. 2016b; Zhou et al. 2018). Moreover, 
overexpression of the neddylation modifying enzymes is associated with cancer progression 
and a worse overall patient survival (Li et al. 2014; Barbier-Torres et al. 2015; Chen et al. 
2016b). Neddylation has been linked to cell cycle regulation and DDR. NEDD8 has been 
shown to localise to sites of DSBs (Ma et al. 2013). Moreover, neddylation of H2AX 
negatively regulates ubiquitylation of H2AX and blocks the recruitment of the damage 
response proteins, such as BRCA1 (Li et al. 2014).  Neddylation also seems to be an inhibitor 
of DNA-end resection and HR (Jimeno et al. 2015).  In addition, neddylation has been linked 
to cell cycle regulation (Rizzardi and Cook 2012). An increase in NEDD8 conjugation in 
human oral carcinoma cells led to an abnormal increase in cell proliferation (Chairatvit and 
Ngamkitidechakul 2007). Conversely, inhibition of NEDD8 has been shown to lead to cell 
cycle arrest. Interestingly, the induction of cell cycle arrest, via chemical inhibition of 
neddylation, can occur in different phase of the cell cycle in a cell line dependent manner. 
For example, the S phase arrest was observed in GCB lymphoma cells, whereas in ABC 
lymphoma cells the arrest occurs in G1 phase (Milhollen et al. 2010; Zhou et al. 2018).  At 
this stage, the impact of FLCN knockdown on neddylation is unclear. Neddylation is a 
complex modulator of multiple cellular signalling pathways. Given its links to the topic of 
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this thesis, namely DDR and cell cycle control, NEDD8 and associated neddylation pathways 
linked to DDR and cell cycle control may be worth following up at a later date. Equally, it’s 
worth stating that over-representation analysis assumes pathways are independent from 
each other, which is contrary to the acknowledgment that many pathway overlap (Barabasi 
and Oltvai, 2004). Therefore, due to its function in numerous cellular processes, the 
enrichment of neddylation within this gene list could also be an artefact of over-
representation analysis.  
Surprising, a lot of DEGs have been linked to immunity, with the most significantly 
enriched processes being antigen processing: ubiquitination and proteasome deregulation 
(FDR Pvalue 2.31E-09), Class I MHC mediated antigen processing and presenting (FDR Pvalue 
2.40E-07), and adaptive immune system (FDR Pvalue 6.14E-04). In addition, the Immune 
system just outside significance (FDR Pvalue 0.06). Interestingly, almost all RCCs are 
associated with immune dysfunction (Florek et al. 2005; Alikhan et al. 2017). RCCs are rich in 
immune infiltrates consisting of T cells, natural killer cells, and macrophages (Santoni et al. 
2014; Murphy et al. 2015). While the functions of some of these cells are still elusive, others 
have well-defined roles in tumour progression. For example, tumour-associated 
macrophages (TAMs) are known for their immunosuppressive action, which is associated 
with the secretion of inhibitory cytokines, the generation of reactive oxygen species, and 
the induction of angiogenesis (Daurkin et al. 2011; Santoni et al. 2014; Ricketts et al. 2018). 
Very recently, FLCN has been linked to immune regulation, where loss of FLCN was shown to 
promote AMPK induction of TFEB/TFE3-dependent pro-inflammatory cytokine expression 
(El-Houjeiri et al. 2019). While interesting, this activity was considered out of scope for this 
thesis, and therefore wasn’t pursued further.  
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Figure 4.5 REACTOME function enrichment analysis of significantly differentially expressed genes 
(DEGs) following FLCN knockdown. A list of all DEG names were analysed for functional enrichment 
using REACTOME online resource. A) Graph shows top 20 pathways that are enriched in low passage 
HK2 cells following FLCN knockdown (LP-WT vs LP-KD) B) Graph shows top 25 pathways that are 
enriched in high passage HK2 cells following FLCN knockdown (HP-WT vs HP-KD). Blue bars = 
log10(Pvalue) as determined by REACTOME hypergeometric distribution test; Red bars = -log10(FDR), 
represent pathway enrichment Pvalue corrected for multiple testing using the Benjamani-Hochberg 
method. 
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One of the biggest limitations of over-representation analysis is that it only uses the 
number of genes and ignores how strongly those genes are associated with whatever is 
being studied. Furthermore, you must arbitrarily decide what is classed as significant. If an 
FDR Pvalue threshold of 0.05 and fold change cut-off of 2 is used, genes with a fold change 
of 1.95 or FDR Pvalue 0.051, which are arguably as important as the genes within the 
arbitrary cut-off, will not be counted. Pathway analysis methods that are classified as 
‘Functional Class Scoring’ (such as gene set enrichment analysis (GSEA) or Qiagen’s IPA) use 
the fold change in gene expression, in addition to the number of genes present within a list, 
to compute an enrichment score (Subramanian et al. 2005). Furthermore, it is well 
appreciated that large changes in individual genes can have significant effects on pathways; 
however, weaker but co-ordinated changes in a set of functionally related genes can also 
have significant biological effects (Subramanian et al. 2005; Kukurba and Montgomery 
2015). Functional Class Scoring analysis allows a better understanding of the weaker effects 
of gene dysregulation (Subramanian et al. 2005). Nevertheless, resources to do such analysis 
are hidden behind paywalls, or require additional skill sets and/or time. As such, this type of 
analysis was not performed.  
Subsequently, an altered and slightly biased approach was taken. The analysis used a 
list of genes known to function within the DNA-damage response (GO 0006974) or cell cycle 
(GO 0007049) that are differently expressed upon FLCN knockdown. This changed the 
question from ‘Are there any functional pathways over-represented in the list of genes?’ to 
‘Within this list of genes is a particular aspect of a known functional process over-
represented?’ It is important to stress that neither DDR and the cell cycle groups where 
enriched in the unbiased analysis and that Pvalue significance sited in this section may be 
artificially inflated. Instead, the Pvalues are used to compare ‘sub-categories’ between cell 
lines. To do this the four previously mentioned pairwise comparisons were used; LP-WT vs 
LP-KD, HP-WT vs HP-KD, LP-WT vs HP-WT, and LP-KD vs HP-KD. 
When looking at DEGs with a DDR role following FLCN knockdown (figure 4.6) 
nucleotide excision repair (NER) was the most enriched repair pathway (FDR Pvalue 3.57x10-
5) in low passage FLCN knockdown cells. NER is a versatile repair pathway. It is known to 
eliminate the broadest range of structurally unrelated DNA lesions, including: 
cyclobutane–pyrimidine dimers and pyrimidine–pyrimidone photoproducts, which are 
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the caused by UV radiation; numerous bulky chemical adducts; intra-strand crosslinks; 
and ROS-generated cyclopurines. Defects in NER commonly lead to cancer, particularly 
skin cancer due to UV induced pyrimidine–pyrimidone photoproducts. Interestingly, 
studies have shown reduced expression of NER genes are associated with increased risk in 
cancer (Cheng et al. 2000; Cheng et al. 2002; Latimer et al. 2010). The increased 
susceptibility to internal tumours is presumably due to the accumulation of endogenously 
induced DNA lesions (for example, cyclopurines that are caused by ROS) (Marteijn et al. 
2014).  
In aged cells (HP-WT vs HP-KD), FLCN knockdown resulted in a marked increase in 
the enrichment of genes involved specifically in the repair of DSB (DSBR) (FDR Pvalue 
1.55x10-14). Furthermore, in cells aged following FLCN knockdown (LP-KD vs HP-KD), DSBR 
genes are further enriched (FDR Pvalue 9.44x10-15). This is interesting as the previous 
chapter validated DNA-PKcs to interact with FLCN. DNA-PKcs is the apical protein in NHEJ 
repair of DSBs. Over-representation analysis, however, is non-directional and does not take 
into account upregulation or downregulation of gene expression. Therefore, the potential 
transformative effects this has on the cells are unclear. For example, Does DSBR gene 
expression increased following FLCN knockdown, indicating that these cells are responding 
to an increase in DNA damage? Or are these genes downregulated in response to FLCN 
knockdown, which would suggest FLCN plays a role to ensure transcription of repair genes in 
order to prevent genomic instability?  
 87 
 
  
Figure 4.6. Diagram showing REACTOME pathway enrichment analysis of genes that are significantly 
differentially expressed following FLCN loss and that have a role in DNA-damage response (DDR). Gene 
list identified by GO0006974. LP = low passage cells, HP = high passage cells; WT = wild type FLCN control, 
KD = FLCN knockdown  
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Therefore, a heatmap was generated from the top 23 genes identified to function in 
DSBR by REACTOME (figure 4.7). In low passage cells (LP-WT vs LP-KD) while expression 
changes are minimal (less than 1 log2 fold change), they are universally downregulated 
(figure 4.7). Confoundingly, in aged cells many of these genes become upregulated. These 
cells display a decrease in DSBR gene expression as a part of normal cell ageing (LP-WT vs 
HP-WT). Perhaps the increase in these genes are an artefact of comparing HP-WT to HP-KD 
where in both cell lines a decrease gene expression is observed due to ageing, however such 
age-related expression changes are smaller in aged FLCN knockdown cells when compared 
to aged wild type cells. Equally this may be a result of compensatory mechanisms where 
more DNA damage is present in FLCN knockdown cells.  
Of special note is the gene, APBB1. APBB1 encodes Amyloid Beta Precursor Protein 
Binding Family B Member 1. It is a nuclear adaptor protein most known for interacting with 
the amyloid precursor protein responsible for Alzheimer's disease. APBB1 thought to 
specifically recognise and bind to histone H2AX phosphorylated on Tyrosine 142 at DSB.  
APBB1 is also required for histone H4 acetylation at double-strand breaks (DSBs) permitting 
a more open chromatin structure and allowing repair molecules access to DSB (Dhar et al. 
2017). This gene becomes highly upregulated upon continued growth without FLCN (figure 
4.7). However, it’s also highly downregulated when compared to the aged matched control, 
suggesting cells may be trying to respond to an increase in DSB but the response is still 
suboptimal.  Collectively, this evidence could support FLCN being a positive regulator of 
DSBR, however, how FLCN may regulate DSBR is unclear.   
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Figure 4.7 Heatmaps of the top 23 DSBR response genes that are differentially expressed following 
FLCN knockdown. Scale is based on log2 fold change, red = over-expressed genes, blue = under-
expressed genes.  
 
 
Next DEGs involved in the cell cycle (identified by GO 0007049) were explored in 
REACTOME to see if any phase of the cell cycle is enriched upon FLCN knockdown (figure 
4.8). Transcriptional changes can be seen at all stages at the cell cycle upon FLCN 
knockdown, however, G1-G1/S phase has by far the largest amount of gene enrichment 
(figure 4.8). This suggests FLCN may be involved in cell cycle progression or checkpointing at 
the G1/S phase boundary. FLCN has previously been linked to the cell cycle. In fact, FLCN has 
been linked to nearly all aspects of the cell cycle. In vitro studies have suggested that wild 
type FLCN delays cell cycle progression through late S and G2/M phase (Laviolette et al. 
2013). FLCN has also been shown to bind to γ-tubulin at centrosomes at the basal body of 
cilia and mitotic spindle (Luijten et al. 2013), important for planar cell polarity, microtubule 
function, and chromosome segregation in anaphase, and therefore could play a role in 
mitosis. Finally, FLCN has been linked to G1/S phase where it was shown to inhibit cyclin D1 
expression (Baba et al. 2008; Kawai et al. 2013). In zebra fish embryos upon re-introduction 
of wild type FLCN the number of cells in G1 increased (Kenyon et al. 2016). Furthermore, 
FLCN has been found to regulate RhoA signalling, which is also involved in the G1 to S phase 
transition of the cell cycle and regulates cyclin D1 activity (Mammoto et al. 2004; Watts et 
al. 2006). 
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Figure 4.8. Diagram showing REACTOME pathway enrichment analysis of genes that are 
significantly differentially expressed (DEGs) following FLCN loss and that have a role in the cell 
cycle. Gene list identified by GO0007049. LP = low passage cells, HP = high passage cells; WT = wild 
type FLCN control, KD = FLCN knockdown. 
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To explore this further, genes involved in G1/S phase transition were segregated into 
positive and negative regulators of cell cycle as indicated by gene ontology lists GO 1902807 
and GO 2000134 respectively (figure 4.9). The most dysregulated genes (largest log2 fold 
change) are highlighted. These include genes known to contribute to cancer progression or 
aggressiveness. For example, GPNMB is a transmembrane glycoprotein that regulates a 
variety of physiologic processes in a cell-type dependent manner. In immune cells, for 
example, GPNMB was shown to block entry into the S phase of the cell cycle in T-cells 
(Chung et al. 2009). While GPNMB overexpression in macrophages led to an increased Cyclin 
A expression and a shortened S phase (Guo et al. 2019). GPNMB is overexpressed in 
numerous cancers including RCC (Kuan et al. 2006; Taya and Hammes 2018; Trail et al. 
2018), and its expression often correlates with increased proliferation, migration, invasion, 
and decreased tumour cell apoptosis. Indeed, its overexpression is a prognostic indicator for 
RCC (Qin et al. 2014; Taya and Hammes 2018) . In addition, it has been demonstrated that 
upon FLCN inactivation, GPNMB gene expression is upregulated in renal cancer cells, mouse 
embryonic fibroblast cells, and human renal cell carcinomas (Hong et al. 2010a). In 
accordance with this, both low (2.93 log2FC, Pvalue 1.3x10-31) and high (0.98 log2FC, Pvalue 
0.0004) passage FLCN knockdown HK2 cells displayed elevated expression of GPNMB (figure 
4.9).  Another interesting gene is FHL1, which has an inhibitory effect on cell growth. FHL1’s 
activity was associated with both G1 and the G2/M cell cycle arrest. This was indicated by a 
marked inhibition of cyclin A, cyclin B1 and cyclin D as well as the induction of the cyclin 
dependent kinase inhibitors p21 (WAF1/CIP1) and p27 (Kip1) (Niu et al. 2012). Its gene 
expression has been shown to be downregulated several cancers, including breast, 
kidney, prostate, and lung (Asada et al. 2013). Similarly, both low (-0.76 log2FC, Pvalue 
2.9x10-09) and high (-0.92 log2FC, Pvalue 2.8x10-14) passage FLCN knockdown HK2 cells 
displayed decreases in FHL1 gene expression (figure 4.9).  
TERT forms the catalytic component of the telomerase holoenzyme complex 
essential for countering telomere attrition (Wang et al. 2014; Hosen et al. 2015). Like most 
cancers, RCCs exhibit widespread telomerase re-activation, and a close correlation 
between TERT expression and telomerase activity is well documented (Kanaya et al. 1998; 
Wang et al. 2014; Hosen et al. 2015). An increase in TERT expression is associated with more 
advanced forms of malignant diseases (Heidenreich et al. 2014; Liu et al. 2014; Wang et al. 
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2014; Hosen et al. 2015; Simon et al. 2015). However, studies looking specifically into RCC 
overexpression of TERT show underwhelming results. One study looked at 188 tumours 
from patients with clear cell RCC and found only twelve tumours (6.4%) carried a mutation 
that could result in TERT overexpression (Hosen et al. 2015). Another study explored 109 
patients with RCC (96 clear cell RCC, and 8 chromophobe RCC tumours) with only 9/96 
(9.3%) clear cell RCC tumours and 1/8 (13%) chromophobe RCC tumours contained 
overexpressed TERT (Wang et al. 2014). Both studies, however, linked TERT overexpression 
to poor patient outcome, and increased tumour aggression. TERT is overexpressed in both 
low and high passage FLCN knockdown cells, log2FC 1.34 and 1.24 respectively, however 
neither are statistically significant (figure 4.9). 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Comparison of genes that are significantly differentially expressed in aged-matched 
FLCN knockdown HK2 cells (LP-WT vs LP-KD and HP-WT vs HP-KD).  Orange = negative G1/S 
transition regulators (GO 1902807); green = positive G1/S transition regulators (GO 1902808).  
 
 
 
Cytochrome P450 1A1 (CYP1A1) is part of the cytochrome P450 superfamily of 
enzymes that play major roles in the detoxification, activation and metabolism of several 
endogenous and exogenous substances. CYP1A1 catalyses the oxidation of pro-carcinogens 
to carcinogenic reactive intermediates (Badal and Delgoda 2014; Go et al. 2015). As a result, 
the expression of CYP1A1 is an important contributor to carcinogenesis. Indeed, CYP1A1 is 
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overexpressed in many human tumours (Androutsopoulos et al. 2013; Li et al. 2018).  More 
importantly CYP1A1 was shown to regulate breast cancer cell proliferation and survival via 
suppression of AMPK signalling. Additionally, CYP1A1 has been shown to be involved in β-
catenin signalling contributing to cancer metastasis (Braeuning et al. 2011; Kasai et al. 
2013). As a result, constitutive expression of CYP1A1 in tumours may not only directly 
influence cancer progression via activation of carcinogenic compounds, but also via 
biological pathways are linked to the functional role of this enzyme. However, in both low 
and high passage FLCN knockdown cells, CYP1A1 expression is downregulated (-0.21 log2FC, 
low passage; -2.6 high passage (figure 4.9). Furthermore, differential expression is only 
significant for high passage cells (Pvalue 0.005).  
Additionally, Phospholipase C, β1 (PLCB1) is a G-protein coupled receptor that plays 
critical roles in intracellular transduction important to tumorigenesis. Deregulation of signal 
transduction pathways frequently elicits survival advantages to tumours. Once activated, 
PLCB1 triggers a series of events culminating in an increase in intracellular calcium and the 
activation of cell proliferation (Ngoh et al. 2014). In addition, PLCB1 can positively target 
cyclin D3, and PKC α-mediated cell proliferation pathways to regulate the cell cycle 
(Bavelloni et al. 2015). Overexpression of PLCB1 is found to be sufficient to drive Swiss 3T3 
cell into the S phase of the cell cycle (Martelli et al. 1992; Manzoli et al. 1997). In addition, 
PLCB1 could reduce cell damage under oxidative stress (Guo and Scarlata 2013). As such, 
PLCB1 is upregulated in several cancer cells, and their increased expression is associated 
with with poor overall survival and metastatic relapse (Tan et al. 2015; Li et al. 2016; Zhang 
et al. 2019). Curiously, in low passage FLCN knockdown cells PLCB1 expression is 
upregulated (0.83 FC; FDR Pvalue, 0.019), while in high passage cells it is down regulated (-
0.92 FC; FDR Pvalue 0.005).  
Perhaps the most striking DEG is CCND1. This gene belongs to the highly conserved 
cyclin family, whose members are categorised by a periodicity in protein abundance 
throughout the cell cycle. Cyclins function as regulators of cyclin-dependent kinases 
(CDKs). Cyclin D1 forms a complex with CDK4 or CDK6 and is required for the G1/S transition 
in the cell cycle. Cyclin D1 overexpression correlates with early cancer onset and tumour 
progression (Diehl 2002). RNA-seq analysis suggests that cyclin D1 is overexpressed in low 
passage cells (0.58 log2FC, Pvalue 4.64x10-06), however, becomes markedly down regulated 
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in high passage cells (figure 4.9; -5.23 log2FC, Pvalue 3.01x10-272). This was validated by 
qPCR (figure 4.10). Nevertheless, it’s unclear at this stage why a dramatic change in CCND1 
expression is seen upon ageing with FLCN knockdown. The previous study looking at CCND1 
expression following FLCN loss did so in transiently knocked-down Hela cells (Kawai et al. 
2013). Cyclin D1 is explored in detail in chapter 6. 
The overall trend in expression of positive and negative regulators of G1/S transition 
suggests that upon FLCN knockdown, the negative regulators (orange) show a moderately 
weak positive correlation with gene expression upon ageing (PCC 0.4325, Pvalue 0.01, R2 
0.1871). Negative regulators of G1/S transition are generally upregulated in both low and 
high passage cells. However, most genes only reach a significant level of differential 
expression in high passage cells suggesting age contributes to the up-regulation G1/S 
negative regulators, and not exclusively FLCN. Interestingly, positive regulators (green) of 
G1/S transition also follow a similar but extremely weak pattern, but this is not significant 
(PCC 0.07527, Pvalue NS, R2 0.005665). Based on this data it should be concluded that upon 
FLCN knockdown in both low and high passage cells there is a globalised dysregulation of 
expression for genes involved in G1-G1/S cell transition.  
 
4.2.3 Validating RNA sequencing data 
To validate the results of RNA-seq, quantitative real-time PCR (qPCR) was performed on 8 
genes; FLCN, CCND1, TP53, FOXN3, PGC1A, TGFA, JUN, and RPA1 (figure 4.10). These genes 
were selected has they are the more highly dysregulated genes, and each plays a role in 
DDR and/or G1/S transition. qPCR validation was performed by Mr Jesse Champion (FLCN, 
CCND1, TP53, and FOXN3) and Dr Elaine Dunlop (FLCN, PGC1A, TGFA, JUN, and RPA1). Each 
gene was validated by 3-5 independent qPCR assays. A high PCC between RNA-seq and qPCR 
expression data revealed a strong correlation (PCC 0.82, Pvalue<0.0001, R2 0.6655; figure 
4.10A) indicating the reliability of the RNA-seq analysis. The slight difference in expression 
levels between RNA-seq and qPCR data is most likely due to the different methods of 
normalisation for each technique. In qPCR a reference gene is used for gene expression 
normalisation. The expression for the reference gene is assumed to be constant for all 
samples, and the expression of the experimental gene is relative to the expression of the 
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reference gene. In RNA-seq data, however, we assume each sample has the same total 
expressed mRNA. Expression is read as read count per million mapped reads or transcripts 
per million and represents an absolute count. qPCR validation of FLCN knockdown was of 
limited use as FLCN was always detected in the negative control. This may explain the 
restricted amount of FLCN knockdown in high passage cells (figure 4.10B). Prior to RNA-seq, 
however, FLCN knockdown was confirmed by western blot (data not shown, Dr Elaine 
Dunlop). 
In addition to CCND1 (discussed previously), it is worth mentioning PPARGC1A. This 
gene encodes the transcription cofactor PGC-1α and is considered the master regulator of 
mitochondrial biogenesis (Mastropasqua et al. 2018). It’s well documented that upon FLCN 
knockdown PGC-1α expression is elevated (Klomp et al. 2010; Wada et al. 2016; Yan et al. 
2016a). This observation was also shown in the RNA-seq data and validated by qPCR (figure 
4.10E). Additionally, FOXN3 is the only gene to have conflicting results between RNA-seq 
and qPCR. FOXN3 is a member of the forkhead/winged helix transcription factor family and 
promotes DNA damage-inducible cell cycle arrest at G1 and G2 (Huot et al. 2014). This gene 
was highlighted as a gene of interest by undergraduate student Mr Jesse Champion due to 
FOXN3 being downregulated in a number of human cancers (Basso et al. 2005; Chang et al. 
2005; Markowski et al. 2009). Upon validation, FOXN3 expression was not statistically valid 
in low passage cells, due to inconsistences between replicates. Furthermore, RNA-seq 
suggests this gene is down regulated in low passage cells, while qPCR failed to validate this, 
and suggests that FOXN3 expression is instead marginally upregulated (figure 4.10F). 
However, upon ageing it is statistically downregulated, agreed by both RNA-seq and qPCR. 
The effects of CCND1 and PGC-1α that are observed upon FLCN knockdown in the RNA-seq 
data are mirrored in FLCN literature (Klomp et al. 2010; Kawai et al. 2013; Wada et al. 2016; 
Yan et al. 2016a). This supports the use of the HK2 knockdown cells, suggesting they are 
representative of FLCN loss. 
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Figure 4.10 Validation of RNA sequencing (RNA-seq) by quantitative real-time PCR (RT-qPCR). A) 
Correlation between RNAseq and quantitative real-time PCR (RT-qPCR). Pearson’s correlation 
Coefficient (PCC) was calculated to show the reliability of the gene expression analysis from the RNA-
seq. PCC 0.82, Pvalue<0.0001, R2 0.6655. Dashed line indicates the 95% prediction band, this is the 
area in which it is expected 95% of all data points will fall. B-I) Comparison of log2 fold change of 8 
genes obtained by RNA-seq and RT-qPCR. Real-time PCR was performed using the amplified cDNA 
from each RNA-seq sample for 3 independent qPCR assays. An additional 2 biological repeats were 
used so qPCR log2FC are calculated from a total of 5 independent repeats. All samples are compared 
to low passage wild type cells (LP-WT).  Statistics and graphs were produced in GraphPad Prism4. 
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4.3 Conclusion  
 
Collectively, these data show a transcriptional dysregulation following FLCN knockdown. It 
would be interesting to see how this global dysregulation translated at the protein level. 
mRNAs levels do not always represent an over- or under- abundance of protein 
(Schwanhausser et al. 2013). For example, most housekeeping genes including those coding 
for ribosomal, glycolytic and TCA cycle proteins mostly have stable mRNAs and are 
translated faithfully into stable proteins. On the other hand, transcription factors, signalling 
genes, chromatin modifying genes, and genes with cell cycle specific functions usually have 
unstable mRNA and unstable protein. Therefore, it’s likely the most important and 
interesting regulators of DDR and/or cellular division have a poor correlation between 
mRNA and protein levels. In many cases mRNA translation is regulated by microRNAs 
(Catalanotto et al. 2016). In addition, cells have a multitude of post-translational 
mechanisms for controlling protein turnover and abundance that have been well described 
(Karve and Cheema 2011; Cajee et al. 2012; Stintzing and Lenz 2014; Brown and Jackson 
2015; Santos and Lindner 2017). As such mRNA levels cannot be used as surrogates for 
corresponding protein levels without verification. Therefore, it’s hard to conclude the true 
biological implications of the gene dysregulation observed in these HK2 cells in response to 
FLCN knockdown (McCarthy and Smyth 2009; Schwanhausser et al. 2013). In an attempt to 
understand the functional impact of this transcriptional dysregulation, DDR and cell cycle 
control was explored in more detail. Both were found to be perturbed. Thus, from this, the 
effects of FLCN knockdown on DDR in HK2 cells was explored further in chapter 5 of this 
thesis, while G1/S checkpoint regulation was explored in chapter 6. 
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Chapter 5: Exploring the role of FLCN in the DNA-damage response 
 
5.1 Introduction  
 
The accumulation of mutations and the resulting genomic instability lie at the origin of 
cancer (Jackson and Bartek 2009). To maintain genomic integrity, cells have developed a 
multifaceted network of mechanisms in order to respond to and repair DNA damage (DDR) 
(Bartkova et al. 2005; Branzei and Foiani 2008; Shrivastav et al. 2008; Jackson and Bartek 
2009). Once DNA lesions are identified, cellular pathways can promote a number of 
outcomes depending on the severity of the damage in order to limit the deleterious 
consequences of the lesions. Damage to DNA can result in mismatched base pairs, insertion 
or deletion of nucleotides (indels), the addition of bulky adducts, inter- and intra-strand 
links, single-strand DNA breaks (SSBs), and double-strand DNA breaks (DSBs) (Jackson and 
Bartek 2009). DSBs are considered the most harmful lesions and can lead to cell death if not 
repaired (Mills et al. 2003; Scott and Pandita 2006).  If mis-repaired they can cause large 
deletions, translocations, and fusions in the DNA. These consequences are collectively 
referred to as genomic rearrangements, and are hallmarks of human cancers (Negrini et al. 
2010). DSBs can result from exogenous agents such as ionizing radiation (IR) and 
chemotherapeutic drugs, or endogenous processes, such as the production of reactive 
oxygen species (ROS) or the collapse of stalled DNA replication forks (Jackson and Bartek 
2009).  
In chapter 3, it was demonstrated that FLCN interacts with the catalytic subunit of 
the serine/threonine kinase, DNA-PKcs. Following DNA damage, DSBs are rapidly bound by 
the Ku heterodimer (Ku70 and Ku80) which, in turn, loads and activates DNA-PKcs to the site 
of damage (Mahaney et al. 2009). This holoenzyme is responsible for initiating NHEJ repair 
of DSB by stabilising break ends in order to prevent exonucleolytic degradation. Binding to 
DNA promotes the activation of DNA-PKcs kinase activity, although the exact mechanism 
underlying this event remains poorly understood. Once activated, DNA-PKcs phosphorylates 
and alters the activity of proteins that mediate NHEJ, which include Ku70, Ku80, Artemis, 
the X-ray cross complementing protein 4 (XRCC4), XRCC4-like factor (XLF), and DNA ligase IV 
(LigIV) (Mahaney et al. 2009; Ciccia and Elledge 2010; Roberts et al. 2010). Activated DNA-
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PKcs also phosphorylates Ser139 on histone variant H2AX (γH2AX) both directly, and 
indirectly through AKT/GSK3β signalling (An et al. 2010). γH2AX is a well-established marker 
of DSBs (Sak and Stuschke 2010). It aids in the recruitment of repair factors to break site 
(Paull et al. 2000) and coordinates the signalling cascades required for efficient repair (Lukas 
et al. 2004). This chapter will attempt to understand the role of FLCN in DDR and explore the 
implications of FLCN deficiency on DDR pathways.  
 
5.2 Results and discussion  
 
5.2.1 DNA-PK in vitro kinase assay 
As a well-established serine/threonine kinase, DNA-PKcs has 47 characterised substrates, 
covering a range of functions from DDR to metabolism (Chung 2018). Therefore, to explore 
the biological relevance of the FLCN/DNA-PKcs interaction, an in vitro kinase assay was 
performed in the first instance (figure 5.1). It’s worth noting, FLCN has a potential DNA-PKcs 
phosphorylation site; serine 302 (Ser302, figure 5.1A), and the kinase responsible for the 
phosphorylation of this residue is unknown. DNA-PKcs preferentially catalyses the transfer 
of a phosphate group to the oxygen atom of serine when followed by a glutamine (S/G). The 
Ser302 on FLCN is serine followed by glutamate (S/E). DNA-PKcs has, however, previously 
been demonstrated to phosphorylate S/E residues both in vitro and in vivo (figure 5.1A) 
(Wong et al. 2009; Wang et al. 2013). Furthermore, the p-FLCN Ser302 is maximally 
phosphorylated during the G1 phase of the cell cycle, where NHEJ is the repair mechanism 
of choice for DSBs (Dephoure et al. 2008). 
GST-FLCN or GST-p53 was overexpressed in HEK293 cells and a GST-pull down assay 
was performed to purify the protein substrates of interest. p53 is a well characterised 
substrate of DNA-PK (Leesmiller et al. 1992) and was used as a positive control. 
Incorporation of radiolabelled phosphate [32P] was determined in the presence of short 
dsDNA to mimic DSBs. The kinase assay suggests FLCN is not a bona fide substrate of DNA-
PKcs in response to DSBs (figure 5.1B and 5.1C). The kinase activity of DNA-PK is 5-10 fold 
higher in the presence of dsDNA (Jette and Lees-Miller 2015), which was observed in the 
GST-p53 control. FLCN may be phosphorylated independently of DSBs, as incorporation of 
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radiolabelled phosphate [32P] is consistently observed; however, the experiment lacks a 
non-DNA-PKcs peptide substrate control for reference. Therefore, based on these results, 
FLCN is not considered a substrate of DNA-PKcs.   
 
Protein Site Sequence   
p53 S9-p EEPQsDPsVEPPLsQ 
Confirmed DNA-PKcs  
phosphorylation sites  
p53 S15-p PsVEPPLsQEtFsDL 
p53 T18-p EPPLsQEtFsDLWkL 
p53 S20-p PLsQEtFsDLWkLLP 
p53 S37-p NVLsPLPsQAMDDLM 
p53 S46-p AMDDLMLsPDDIEQW 
USF1 S262-p RQSNHRLsEELQGLD 
    
FLCN S302-p ESEsWDNsEAEEEEK 
Potential DNA-PKcs 
phosphorylation site  
 
 
 
 
 
 
 
 
 
Figure 5.1 In vitro DNA-PK kinase assay. A) Table showing confirmed DNA-PKcs phosphorylation 
sites on p53 and USF1, and the potential DNA-PKcs phosphorylation site on FLCN. Phosphorylation 
sites were identified using PhosphositePlus® online resource. B) GST-FLCN or GST-p53 was 
overexpressed in HEK293 cells and GST-pull down was performed to purify the proteins of interest. 
Incorporation of radiolabelled phosphate [32P] was determined in the presence of short double-
strand DNA (dsDNA) to mimic dsDNA breaks. GST-p53 used as a positive control. The blot shown is 
representative of at least 3 independent experiments, with the exception of GST-FLCN with no 
dsDNA which had two independent values. C) Densitometry of DNA-PKcs in vitro kinase assay. For 
each tagged protein pixel intensity was normalised against no substrate control. Error bars indicate 
standard error of mean, SEM.  * = Pvalue <0.05.  
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5.2.2 Exploring the effect of FLCN knockdown on DNA-damage signalling  
Given that FLCN is unlikely to be a DNA-PK substrate, and that the FLCN interactome 
described in chapter 3 indicates a number of proteins which function within the DDR, the 
effect of FLCN loss on DNA damage signalling pathways was explored next. To begin with, 
etoposide was used to induce DSBs (figure 5.2). Etoposide is a topoisomerase II inhibitor 
that prevents the re-ligation of DNA strands after helix unwinding. During DNA replication 
this leads to DSBs (Montecucco et al. 2015). Preliminary results suggested phosphorylation 
of DNA-PKcs at serine 2056 (Ser2056) was down in aged knockdown cells (HP-KD cells), 
while phosphorylation of Chk1 and H2AX were up in aged cells (figure 5.2A), with γH2AX 
being up in basal as well as damage-induced FLCN knockdown cells (figure 5.2A and 5.2B). 
During this initial analysis, however, western blots demonstrated large inconsistences, 
where biological replicates were vastly different (data not shown). Etoposide requires a 
round of replication to introduce DSBs; given that FLCN is suspected to have a role in the cell 
cycle (Chapter 3 figure 3.5, chapter 6, (Kawai et al. 2013; Laviolette et al. 2013; Kenyon et al. 
2016) the method of DSB induction was changed to ionising radiation (IR). IR directly affects 
DNA structure to induce DSBs (Scott and Pandita 2006). It does not require cells to be 
replicating and damage occurs throughout all phases of the cell cycle. Therefore, IR presents 
a more reliable and consistent DNA damage induction method. 
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Figure 5.2 Initial analysis of the DNA damage response in FLCN knockdown.  A) HK2 cells were 
treated with 100mM etoposide for 24 hours and immunoblotted for a response to DDR. Image is 
compiled of up to 4 independent experiments. Each replicate varied, and consensus with repeats 
could not be achieved. It is worth noting not all proteins where probed for in each experiment. 
*probed in 2 experiments, **probed in 4 experiments.  B) Phosphorylation of histone variant H2AX 
(γH2AX), a marker of dsDNA breaks was assessed under basal condition in HK2 cells, blot is 
representative of 3 independent experiments and carried out by Dr Elaine Dunlop. 
 
 
To ensure appropriate experimental conditions, increasing doses of IR (1-10Gy) were 
tested for different lengths of time in the low passage wild type HK2 cell line (LP-WT). H2AX 
is a key molecule in the repair of damaged DNA and its phosphorylation at serine 139 
(γH2AX) is commonly used as a marker of DSBs (Kuo and Yang 2008). After the induction of 
DNA damage, H2AX at the site of DSBs is rapidly phosphorylated allowing the DNA damage 
signal to spread along the chromatin surrounding each DSB lesion (Kinner et al. 2008). It 
functions to provide a platform for the recruitment of proteins that participate in DDR. 
γH2AX form within seconds after strand breakage, but since they are initially quite small 
and difficult to visualise, they are more reliably examined starting 15–30 min after damage 
(Lobrich et al. 2010). Other DNA repair-enabling proteins, such as 53BP1, Nbs1, Rad50, 
Rad51, and BRCA1 that are thought to be more technically challenging to detect because 
of their limiting sensitivity or more regulated occurrence (Polo and Jackson 2011). For 
A) B) 
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example, while γH2AX can be detected in all phases of the cell cycle, other proteins, such 
as Rad51, are restricted to S- and G2-phases, being specific for homologous recombination 
repair of DSBs. Within the LP-WT control cells used, γH2AX was not observed following 1 Gy 
or 2 Gy dose. It was, however, observed after 5 Gy and 10 Gy. The signal was seen from 30 
min to up to 48 h after IR, with the signal generally weakening over time, as excepted. 
Breaks induced by the higher dose took longer to repair as indicated by higher levels of 
γH2AX at the later time points, again as expected (figure 5.3A). Given that the objective is to 
see how FLCN knockdown cells respond to DNA damage, the lower dose was chosen to 
better mimic a more realistic damage risk found in FLCN-deficient patients. For this reason, 
an IR dose of 5 Gy with samples lysed at 1 h after IR was chosen (figure 5.3A). This enabled 
somewhat more consistent results with exploring DDR in FLCN knockdown cells, however, 
there were still inconsistencies between replicates (data not shown). Therefore, the lysis 
buffer was adapted next (figure 5.3B). 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Troubleshooting western blot analysis of DNA damage response. A) Optimising the use 
of ionising radiation (IR) treatment to induce DNA damage. Phosphorylation of H2AX (γH2AX) was 
used as a marker of double-strand DNA breaks. The blot is representative of 2 independent 
experiments. B) Optimising cellular lysis buffer. ‘BHD lysis buffer’ contains triton-X (0.1 % [v/v]) and 
protease inhibitors, while for the ‘sample lysis buffer’ cells were lysed directly in 1x LDS sample 
buffer in the presence of high SDS (0.1 % [w/v]) and DTT (50mM). For both lysis buffers, samples 
were washed once with cold PBS prior to the addition of lysis buffer and left for 30 minutes on ice. 
All samples were subjected to two 30 s rounds of sonication.  
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The lysis buffer (referred to as BHD lysis buffer) initially used contained the 
detergent Triton X-100, to break down cellular membranes. Triton X-100 is a non-ionic 
detergent, and is considered a milder, less denaturing detergent. The cell membrane 
encloses the cytoplasm and the cell organelles; it consists of a lipid bilayer. The nuclear 
membrane, on the other hand, encloses the nucleus and is made up of double lipid bilayer 
(Capell and Collins 2006). The DDR proteins being explored are primarily active and located 
within the nucleus. One idea for the inconsistencies is that Triton X-100 is not stringent 
enough to reliably break down the double lipid bilayer of the nuclear envelope. Therefore, 
‘sample lysis buffer’ was used as an alternative method of lysis. In the sample lysis buffer, 
cells were lysed directly in 1x LDS sample buffer (NuPage, Invitrogen) in the presence of high 
SDS and DTT concentrations (as previously used within the lab (Dodd et al. 2015). The high 
SDS concentration ensures efficient dissolution of cellular and nuclear membranes. While 
the high DTT concentrations were used to ensure reduction of proteins to diminish 
interaction with nuclear membrane, trafficking skeletons, and DNA, to limit proteins of 
interest being sequestered out of solution in the debris pellet (to exclude this becoming a 
source of inconsistency). For both buffers, cells were washed once with PBS prior to the 
addition of lysis buffer. Plates were kept on ice for 5 min before contents were scraped and 
transferred to ice-cold Eppendorf tubes. Samples were kept on ice for a further 30 min and 
subjected to two 30 s pulses of sonication at full power. Cells were centrifuged at 10,000 
rpm for 8 min at 4°C to pellet the non-soluble parts of the cell. Samples were stored at -20 
°C until needed. Proteins to test were selected based on size, ensuring maximum amount of 
membrane coverage from a single gel, to minimise time and resources used for 
troubleshooting. Sample lysis buffer showed proteins were more readily detectable in this 
solution (figure 5.3B). From this point on, all cells where lysed in ‘Sample lysis buffer’. 
As previously mentioned, γH2AX promotes the repair of DSBs, through the 
recruitment of DDR proteins to the site of damage and is considered a molecular marker for 
DSBs. Within weeks of FLCN knockdown (low passage knockdown cells), γH2AX levels were 
enhanced (Figure 5.4A). The degree of phosphorylation was elevated further upon long-
term FLCN knockdown (high passage cells). Both the basal and IR-induced level of γH2AX 
was higher in the FLCN-deficient HK2 cells (Figure 5.4A), suggesting that loss of FLCN results 
in an increase in DSBs.  
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Figure 5.4 FLCN knockdown cells show elevated levels of DNA damaging signalling following 
ionising radiation (IR).  Western blot analysis of wild type and FLCN knockdown HK2 cells 1 h 
following 5 Gy IR. A) Showing control blots (FLCN and −actin), and surrogate marker of dsDNA 
breaks (pH2AX). B) Showing the response of DNA-PKcs and a downstream substrate, p53, to IR. C) 
Exploring cellular response to DNA damage through ‘classical’ DNA damage signalling molecules.  
Blots are representative of 3 independent experiments. 
 
 
To determine whether FLCN influences DNA damage signalling pathways, FLCN 
knockdown cells where subjected to 5 Gy IR and lysed after 1 h and immunoblotted for a 
panel of DNA damage signalling molecules (figure 5.4B and 5.4C). Given that FLCN has been 
shown to interact with DNA-PKcs (see chapter 3), DNA-PK’s ability to autophosphorylate 
was explored in the first instance (Figure 5.4B). DNA-PKcs autophosphorylation is essential 
for the appropriate regulation of DNA strand end processing, enzyme inactivation, and 
complex dissociation from DNA (Chan et al. 2002). The best characterised 
autophosphorylation sites of DNA-PK occur at Ser2056 (PQR cluster) and Thr2609 (ABCDE 
cluster) (Meek et al. 2008). It is generally considered that phosphorylation of the Ser2056 
B) 
A) 
C) 
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blocks access to DNA ends, representing DNA-PK bound to DNA ends, tethering them 
together (Meek et al. 2007), while phosphorylation at Thr2609 leads to DNA-PK complex 
dissociation and allows repair molecules access to DNA ends (Meek et al. 2008). Both 
Ser2056 and Thr2609 were explored in FLCN knockdown cells. No change was observed at 
the Ser2056 site (figure 5.4B), and the Thr2609 site was difficult to blot, containing a high 
level of background (data not shown). As no convincing difference was observed with 
Ser2056, the Thr2609 site was not explored further. These post-translational modifications 
in DNA-PK are well understood, more than 40 phosphorylation sites have been identified for 
DNA-PK in vitro (Wang and Lees-Miller 2013), and the impact of each on DNA-PKcs function 
seems to be complex. It is unclear which sites are critical for tumour-associated activities. 
Pharmacologic inhibition of DNA-PK kinase activity results in inefficient repair and 
hypersensitivity to double-strand break–inducing agents (Zhao et al. 2006), therefore it is 
clear DNA-PKcs is required for direct ligation of broken DNA ends, rendering it a critical 
factor in NHEJ. However, the order of recruitment and function of both processing and 
ligation factors involved in NHEJ after binding of Ku remain poorly defined, and the process 
is likely dynamic. The results presented in figure 5.4B suggest FLCN is unlikely to impact on 
DNA-PK’s ability to autophosphorylate, and by extension function. The impact this has 
further downstream in the NHEJ process, however, may still be interesting to study, 
especially as γH2AX indicates an increase in DBS (Goodwin and Knudsen 2014).  
 
As previously mentioned p53 is a well characterised substrate of DNA-PK (Leesmiller 
et al. 1992). It is also the most frequently mutated gene presented in human cancers 
(Zigeuner et al. 2004; Brosh and Rotter 2009; Noon et al. 2010). Therefore, p53 
phosphorylation upon FLCN knockdown was explored next. Under normal conditions p53 is 
continuously expressed but is maintained at low levels by Mdm2-mediated ubiquitination 
and proteasomal degradation. Under stress conditions p53 undergoes phosphorylation at 
numerous sites which stabilise the protein. Serine 15 phosphorylation of p53 is a major focal 
point in the activation of p53. Serine 15 is the primary target on the p53 protein in response 
to DNA damage and is phosphorylated by DNA-PK, ATM and ATR protein kinases under 
genomic stress. Interestingly, it can also be activated by AMPK in response to metabolic 
stress/glucose starvation (Jones et al. 2005). As expected, phosphorylation of p53 at Ser15 
was induced under IR within the HK2 cells, however no differences were observed when 
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comparing FLCN knockdown with wild type cells (figure 5.4B). Furthermore, the aging of 
cells didn’t affect the phosphorylation of p53. Transcriptional analysis shows TP53 mRNA is 
significantly downregulated in high passage FLCN knockdown cells (chapter 4, figure 4.10). 
Interestingly FLCN loss did not affect basal levels of p53, nor did DNA damage change the 
total level of p53 within HK2 cells, regardless of FLCN status. The disconnect between mRNA 
and protein levels in FLCN deficient cells is likely to not impact on cellular response, neither 
total protein level nor phosphorylation at Ser15 of p53 was altered upon FLCN loss (figure 
5.4B). Stress responding proteins, transcription factors, signalling genes, chromatin 
modifying genes, and genes with cell-cycle specific functions tend to have unstable mRNA 
and unstable protein. The most important regulators of the cellular stress response are 
expected to have a poor correlation between mRNA and protein, as is the well documented 
case with p53 (Lavin and Gueven 2006). Indeed, a lot of evidence suggests mRNA levels 
cannot be used as surrogates for corresponding protein levels without verification 
(Schwanhausser et al. 2011,2013) 
 
To get a broad overview of DNA damage signalling after IR, a panel of DNA damage 
response molecules were assessed (Figure 5.4C). Across 3 independent experiments the 
phosphorylation ataxia-telangiectasia mutated (ATM) and ATM and RAD3-related (ATR) 
phosphorylation did not seem to be affected by FLCN loss (Figure 5.4C). As such FLCN loss 
isn’t likely to affect the activity of these kinases. Along with DNA-PKcs, ATM and ATR, are 
members of the PI3K-like protein kinase (PIKK) family which are involved in the cellular 
response to genotoxic stress.  ATM, ATR and DNA-PK have similar substrate specificities in 
vitro (SQ/TQ), and partially overlapping substrate specificities in vivo. Recent studies have 
identified several hundred proteins containing the PIKK phosphorylation motif, the 
phosphorylation of which is induced in response to ionising radiation (IR) (Matsuoka et al. 
2007; Bennetzen et al. 2010). However, it is difficult to estimate the contribution of 
individual PIKKs, as IR induces various types of DNA lesion and also damages other cell 
components, leading to the activation of numerous signalling kinases (Bensimon et al. 
2010). Interestingly, DNA-PKcs can also be phosphorylated by ATM during the DNA damage 
response (Meek et al. 2008; Davis et al. 2014). Furthermore, the Thr2609 cluster on DNA-
PKcs is primarily phosphorylated by ATM or ATR under different cellular stresses (Chen et al. 
2007; Meek et al. 2008). As the Thr2609 site is responsible for complex dissociation from 
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the DNA, it’s likely ATM functions as a regulatory component, ensuring DNA-PK dissociates 
not only when appropriate, but when DNA-PKcs fails to release, allowing strands to be 
ligated even if DNA-PK is compromised.  
 
ATM is best known for its role as an apical activator of the DNA damage response 
in the face of DSBs. ATM controls a complex signalling network by phosphorylating a 
multitude of substrates in numerous network branches including p53, BRCA1, FANCD2, 
Chk2, and Nbs1 to induce late-S phase and G2 checkpoints. ATM primarily stimulates the 
repair of DSBs through homologous recombination (HR). DSB resection is induced in the S 
and G2 phases of the cell cycle, when sister chromatids can be used for template driven HR 
(Guleria and Chandna 2016). Upon DNA damage, ATM autophosphorylates on residue 
serine 1981 resulting in an active ATM molecule (Kozlov et al. 2011; Cremona and Behrens 
2014; Ahmed et al. 2016).  ATR, on the other hand, responds to single strand breaks that are 
typically generated at the sites of stalled replication forks.  ATR is unable to interact with 
DNA directly, and depends on nucleofilaments that are formed between the replication 
protein A heterotrimer (RPA) and ssDNA for DNA binding (Zou and Elledge 2003). The 
phosphorylation site serine 428 is required to induce enzymatic activity of the kinase. While 
the apical responders to DDR (DNA-PK, ATM, ATR) activity was not altered by loss of FLCN, 
downstream responders were.  An increase in Breast cancer type 1 susceptibility protein 
(BRCA1), Checkpoint kinase 1 (Chk1) and Checkpoint kinase 2 (Chk2) phosphorylation was 
seen in FLCN-deficient cells and, similar to γH2AX, this effect was more pronounced in high 
passage cells (Figure 5.4C). However, in the case of Chk1 and Chk2, variation was seen in 
this data. Further work is required to validate if there is an increase in phosphorylation of 
Chk1 and Chk2 following FLCN knockdown.  
 
BRCA1 relocates to DNA damage sites and promotes HR to repair DSBs (Livingston et 
al. 1997; Scully et al. 1997). BRCA1 has two key roles; facilitating end processing of messy 
DNA ends, and inhibiting NHEJ (Wong et al. 1998; Zhong et al. 1999; Sartori et al. 2007; Kass 
and Jasin 2010). Numerous DNA damage-induced phosphorylation sites on BRCA1 have 
been identified, including Serine 988, 1189, 1387, 1423, 1457, 1524, and 1542. The site 
explored in this experiment is Ser1524. It has been demonstrated that IR induces BRCA1 
Ser1524 phosphorylation in S phase (Okada and Ouchi 2003) and that this phosphorylation 
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is required for the formation of the IR-induced G2/M checkpoint (Xu et al. 2001; Xu et al. 
2002a). BRCA1 Ser1524 phosphorylation has also been linked to with the regulation of cell 
growth after IR; HCC1937 cells re-expressing wild type BRCA1 can grow after IR damage, 
whereas cells expressing a phosphorylation-deficient mutant of Ser1524 residue showed 
growth retardation under the same condition (Cortez et al. 1999; Okada and Ouchi 2003). As 
FLCN knockdown HK2 celled showed elevated P-Ser1524 after DNA damage (Fig 5.4C), they 
may have a proliferative advantage after IR. Interestingly, claspin was found to control 
BRCA1 phosphorylation at Ser1524. Furthermore, BRCA1 and claspin then function to 
activate the tumour suppressor Chk1. Unexpectedly, claspin was found to have a second, 
positive role in control of the cell cycle as claspin overexpression increased cell proliferation. 
This is noteworthy as FLCN loss was previously cited to increase the expression of claspin 
(Seabra   et al. 2010). It would be interesting to test the effect of FLCN knockdown on other 
phosphorylation sites of BRCA1. For example, P-Ser1423 is responsible for the G2/M 
checkpointing (Xu et al. 2001; Ouchi 2006), P-Ser1387 is required for the S phase checkpoint 
but not the G2/M checkpoint, and P-Ser308 is responsible for mitotic entry (Xu et al. 2002b).  
Chk1 and Chk2 are both serine/threonine kinases that play a pivotal role in 
maintaining DNA integrity. Mechanistically, Chk1 becomes activated by ATR through 
phosphorylation of serine 317 and serine 345 (Petermann and Caldecott 2006). As a 
substrate of ATR, Chk1 activation is an important response to single-strand DNA break 
sensing (Zhao and Piwnica-Worms 2001; Gupta et al. 2018). Chk1 can also be 
phosphorylated by many other proteins, such as ATM, BRCA1, MCPH1 and p300/CBP 
(Yarden et al. 2002; Yoo et al. 2006). Chk1 activation results in the initiation of cell cycle 
checkpoints; late S phase and G2/M cell cycle arrest (Zhao et al. 2002; Brown and Baltimore 
2003; Petermann and Caldecott 2006). In the FLCN knockdown cells, ATR activation was 
unchanged, while Chk1 may be hyperphosphorylated (figure 5.4C). As it stands, evidence 
suggests DNA damage is not likely to be caused by replication stress and/or faulty 
replication forks; but the increase in Chk1 phosphorylation may represent an increase in 
DNA-damage burden in the FLCN knockdown cells. Chk2, on the other hand, is primarily 
activated by ATM through phosphorylation at residue threonine 68 which induces Chk2 
dimerisation and autophosphorylation of the kinase domain (Zannini et al. 2014). As a 
downstream kinase of ATM, Chk2 participates in the early steps of DSB repair 
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phosphorylating both BRCA1 (Lee et al. 2000) and BRCA2 (Bahassi et al. 2008),  and 
promoting HR over error prone-NHEJ during the G2/M checkpoint. Chk2 was 
hyperphosphorylated in high passage, but not low passage FLCN knockdown cells suggesting 
these cells may be accumulating damage upon aging (figure 5.4C). 
It’s important to state that despite best efforts to troubleshoot a reliable protocol, 
results still contained large inconsistences, making interpretation of results difficult. For this 
reason, confidence is only given to increased levels of γH2AX, and BRCA1, as these were the 
most consistent. Inconsistent results are not unusual when studying FLCN (Tee and Pause 
2013; Chen et al. 2015). For example, FLCN has been shown to both inhibit and promote 
mTOR signalling in multiple contexts. One idea is that FLCN functions in a lot of processes 
and as such inconsistencies may arise from stoichiometric pressure. This is particularly 
interesting with regards to the HK2 knockdown cells used in this thesis. Total FLCN knockout 
is not viable and, as such, work is done in cells that still express a small amount of FLCN. 
Therefore, inconsistencies may arise where a finite pool of FLCN can only do so much and 
random chance is involved in detecting a robust observation. 
 
Collectively, these results suggest FLCN-deficient cells have more DSBs, and elevated 
DDR signalling. Immunoblotting measures the total levels of γH2AX in whole cell lysates. 
While it is the easiest to perform, and relatively inexpensive; it is not the most informative 
method to explore the nature of DSBs. Immunostaining can be used to quantify the 
damage and to visualise co-localisation with DDR molecules.  It is also more sensitive than 
immunoblotting, as each γH2AX foci represents a single break (Kuo and Yang 2008). It also 
allows for the study of induction of breaks and repair kinetics. However, it is more 
laborious and costly. Flow cytometry, on the other hand, allows for accurate and fast 
analysis of γH2AX, and by extension, quantification of DSBs within individuals cells. 
Furthermore, γH2AX can be quantitated relative to DNA content, and as such by which 
phase of the cell cycle damage occurs. It would be interesting to compare how long it 
takes FLCN KD cells to repair from DSBs, if there is a stage of the cell cycle where damage 
occurs, or repair differs from wild type cells. Another idea would be to further explore 
BRCA1 phosphorylation. BRCA1 is strongly implicated in promoting HR over NHEJ. Perhaps 
the increase in BRCA1 is to drive HR as a compensation to insufficient NHEJ in G1. It would 
 111 
 
therefore be interesting to explore the efficacy and efficiency of both HR and NHEJ in FLCN 
deficient cells. 
5.2.3 Cell growth and proliferation following DNA damage 
One of the most notable observations with regards to the effect of FLCN loss on DDR 
signalling explored above is the elevation in γH2AX, indicating there is an increase in DSBs 
upon FLCN loss (figure 5.4A). DSBs are considered the most harmful lesions in genomic DNA 
(Mills et al. 2003; Scott and Pandita 2006). If not efficiently repaired, they can lead to 
chromosomal aberrations and apoptosis; in higher eukaryotes, even a single DSB in an 
essential gene can trigger the apoptotic signalling cascade (Rich et al. 2000; Lips and Kaina 
2001). Therefore, cellular proliferation and viability following FLCN loss was explored in low 
passage HK2 cells to see if FLCN had a role in cellular sensitivity to DNA damage.  
Low passage HK2 cells were subjected to 10 Gy IR, trypsininsed after 1 h, and DNA was 
stained with Solution 18™ (chemoetic), a mixture of Acridine Orange (a membrane 
permeable dye that stains both living and dead cells) and DAPI (which can’t penetrate the 
membrane and thus only stains dead cells). Cells where then quantified on NucleoCounter 
NC-3000™. 10 Gy IR was used, instead of 5 Gy previously used, to observed what affect 
FLCN knockdown would have under high levels cellular stress. 
The total cell count of samples was plotted as a quick and simple, but rough output 
for cell growth in the first instance (figure 5.5). Initial analysis suggests FLCN knockdown 
cells grow slower, having a lower total cell count at each time point (figure 5.5). However, 
variation between replicates was observed (figure 5.5). The error bars for figure 5.5 show 
the standard error of the mean (SEM) and is a measure of precision for an estimated 
population mean. The SEM error bars for both wild type and knockdown non-irradiated 
controls reveals the true mean of the cell lines could overlap. As such the differences 
between these non-irradiated control cell lines (No IR WT and No IR KD) are not statistically 
different, with the exception of the 96 hour time point (Table 5.1). From this data we cannot 
conclude a difference in cell number between the non-irradiated wild type and non-
irradiated knockdown. Once irradiated however, both wild type and FLCN knockdown cells 
fail to proliferate (figure 5.5). Interestingly, knockdown and wild type cell numbers remain 
similar until 96 h post irradiation. Here, knockdown cells start to increase their numbers but 
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are not statically different from irradiated wild type cells at any time point (figure 5.5, table 
5.1). Total cell number was obtained via staining (all living and dead) cells with Acridine 
Orange (AO). This is a very rudimentary output for cell proliferation. In addition, total cell 
number gives no information about the health of these cells, for example, while present in 
solution the cells may be dead, and as such won’t be a source of cellular transformation. 
The most reliable and accurate method of assessing cell proliferation is a measurement of 
DNA-synthesising cells. Using a thiamine analogue (such as BrdU or EdU) to label cells as 
they proliferate. Other methods measure the metabolic activity of cells via tetrazolium salts. 
These salts form a dye when present in a metabolically active environment. The resulting 
colour change of the media can be quantified in a spectrophotometer, and so indirectly give 
an indication of the extent of proliferation.  
 
Figure 5.5 Cell growth, as determined by total number of cells, after DNA damage.  Low passage 
wild type (WT) and FLCN knockdown (KD) HK2 cells were subjected to 10 Gy IR and left for up to 96 
hours. Graph showing total number of cells at each time point as determined by by staining with 
acridine orange and analysed via a NucleoCounter NC-3000. Performed over 3 independent 
experiments, with each experiment containing samples analysed in triplicate. Error bars = SEM. 
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WT No IR vs KD No IR 
Time (h) WT No IR (% viable) KD No IR (% viable) Pvalue 95% CI of diff. 
0 189500 183700 P > 0.05 -400500 to 388800 
24 240200 192700 P > 0.05 -369800 to 274700 
48 507700 371200 P > 0.05 -458700 to 185800 
72 761300 634300 P > 0.05 -449200 to 195200 
96 1160000 814000 P<0.01 -668500 to -23980 
WT No IR vs WT IR 
Time (h) WT No IR (% viable) WT IR (% viable) Pvalue 95% CI of diff. 
0 189500 159500 P > 0.05 -424600 to 364700 
24 240200 120700 P > 0.05 -441800 to 202700 
48 507700 145200 P<0.01 -684700 to -40180 
72 761300 145200 P<0.001 -938300 to -293800 
96 1160000 117100 P<0.001 -1365000 to -720900 
WT No IR vs KD IR 
Time (h) WT No IR (% viable) WT IR (% viable) Pvalue 95% CI of diff. 
0 189500 161500 P > 0.05 -422700 to 366700 
24 240200 124800 P > 0.05 -437600 to 206800 
48 507700 135000 P<0.01 -694900 to -50380 
72 761300 144500 P<0.001 -939100 to -294600 
96 1160000 176200 P<0.001 -1306000 to -661800 
WT IR vs KD No IR 
Time (h) WT No IR (% viable) WT IR (% viable) Pvalue 95% CI of diff. 
0 159500 183700 P > 0.05 -370500 to 418800 
24 120700 192700 P > 0.05 -250300 to 394200 
48 145200 371200 P > 0.05 -96260 to 548200 
72 145200 634300 P<0.001 166800 to 811300 
96 117100 814000 P<0.001 374700 to 1019000 
WT IR vs KD IR 
Time (h) WT No IR (% viable) WT IR (% viable) Pvalue 95% CI of diff. 
0 159500 161500 P > 0.05 -392700 to 396600 
24 120700 124800 P > 0.05 -318100 to 326400 
48 145200 135000 P > 0.05 -332400 to 312000 
72 145200 144500 P > 0.05 -323000 to 321500 
96 117100 176200 P > 0.05 -263100 to 381400 
KD No IR vs KD IR 
Time (h) WT No IR (% viable) WT IR (% viable) Pvalue 95% CI of diff. 
0 183700 161500 P > 0.05 -416800 to 372500 
24 192700 124800 P > 0.05 -390100 to 254400 
48 371200 135000 P > 0.05 -558400 to 86060 
72 634300 144500 P<0.001 -812100 to -167600 
96 814000 176200 P<0.001 -960000 to -315500 
 
Table 5.1 Statistical analysis of cell growth, as determined by total number of cells, after DNA 
damage. Two-way ANOVA was performed to assess the variation in the data. If Pvalue<0.05 
Bonferroni test was performed post-hoc. Statistical analysis was performed in GraphPad PRISM4. 
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Next, cell viability was explored to get a better idea of the cellular response to IR. 
Viability is a measure of the number of living cells in a population. No difference in viability 
between wild type and FLCN knockdown non-irradiated controls were observed, the 
viability of HK2 cells is not compromised by FLCN knockdown alone (figure 5.6, table 5.2). 
Following IR both wild type and FLCN knockdown cells showed a slight decrease in viability 
over time (figure 5.7). This became statistically different from wild type non-irradiated cells 
at 48 hours (Pvalue<0.01), with both cell lines showing a similar response to IR (figure 5.6). 
Interestingly, by 96 hours post-irradiation, FLCN knockdown cells were more viable than 
wild type cells (Pvalue <0.001, table 5.2), suggesting cell survival may be increased. 
Typically, cells that lack key DDR proteins (such as DNA-PKcs, ATM, or BRAC1) become more 
sensitive to ionising radiation due to their failure to initiate and co-ordinate repair 
mechanisms (Chistiakov et al. 2008) the opposite, however, is seen in these FLCN 
knockdown cells. Interestingly, the loss of FLCN has already been linked to increase in stress 
tolerance. Loss of the C.elegans FLCN homologue, flcn-1, led to a 21% increase in lifespan 
under heat stress (Gharbi et al. 2013). This increased longevity was attributed to an increase 
in HIF signalling (Gharbi et al. 2013) and the induction of autophagy (Schiavi et al. 2013; 
Possik et al. 2014). Indeed, flcn-1 deletion led to increased stress resistance through a 
constitutive activation of the C. elegans homologue of AMPK, aak2, which led to higher 
autophagic flux, higher levels of intracellular ATP, and inhibition of apoptosis (Possik et al. 
2014). These findings were replicated in mouse embryonic fibroblasts, suggesting that this 
pathway is evolutionarily conserved in mammals (Possik et al. 2014). Previous work has also 
suggested FLCN is pro-apoptotic; FLCN-null embryonic stem cells and loss of flcn-
1 in C.elegans have been shown to have increased resistance to apoptosis (Cash et al. 2011; 
Possik et al. 2014), and FLCN has been demonstrated to upregulate the expression of a 
number of pro-apoptotic genes (Verhagen et al. 2002; Martinez-Ruiz et al. 2008; Reiman et 
al. 2012).   
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Figure 5.6 Cell viability after DNA damage.  Low passage wild type (WT) and FLCN knockdown (KD) 
HK2 cells were subjected to 10 Gy IR and left for up to 96 hours. Graph showing percentage of viable 
cells as determined by staining with acridine orange/DAPI and analysed via a NucleoCounter NC-
3000. Performed over 3 independent experiments, with each experiment containing triplicate 
samples. Error bars = SEM. 
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WT No IR vs KD No IR 
Time (h) WT No IR (% viable) KD No IR (% viable) Pvalue 95% CI of diff. 
0 95.35 94.65 P > 0.05 -9.596 to 8.196 
24 96.93 95.71 P > 0.05 -10.11 to 7.683 
48 95.68 95.46 P > 0.05 -9.108 to 8.683 
72 96.56 93.40 P > 0.05 -12.06 to 5.733 
96 95.15 90.93 P > 0.05 -13.12 to 4.671 
WT No IR vs WT IR 
Time (h) WT No IR (% viable) WT IR (% viable) Pvalue 95% CI of diff. 
0 95.35 93.40 P > 0.05 -10.85 to 6.946 
24 96.93 93.25 P > 0.05 -12.57 to 5.221 
48 95.68 86.75 P<0.01 -17.82 to -0.02925 
72 96.56 74.08 P<0.001 -31.38 to -13.59 
96 95.15 44.13 P<0.001 -59.92 to -42.13 
WT No IR vs KD IR 
Time (h) WT No IR (% viable) WT IR (% viable) Pvalue 95% CI of diff. 
0 95.35 96.06 P > 0.05 -8.183 to 9.608 
24 96.93 92.26 P > 0.05 -13.56 to 4.233 
48 95.68 86.35 P<0.01 -18.22 to -0.4293 
72 96.56 73.18 P<0.001 -32.28 to -14.49 
96 95.15 71.76 P<0.001 -32.28 to -14.49 
WT IR vs KD No IR 
Time (h) WT No IR (% viable) WT IR (% viable) Pvalue 95% CI of diff. 
0 93.40 94.65 P > 0.05 -7.646 to 10.15 
24 93.25 95.71 P > 0.05 -6.433 to 11.36 
48 86.75 95.46 P < 0.05 -0.1832 to 17.61 
72 74.08 93.40 P<0.001 10.43 to 28.22 
96 44.13 90.93 P<0.001 37.90 to 55.70 
WT IR vs KD IR 
Time (h) WT No IR (% viable) WT IR (% viable) Pvalue 95% CI of diff. 
0 93.40 96.06 P > 0.05 -6.233 to 11.56 
24 93.25 92.26 P > 0.05 -9.883 to 7.908 
48 86.75 86.35 P > 0.05 -9.296 to 8.496 
72 74.08 73.18 P > 0.05 -9.796 to 7.996 
96 44.13 71.76 P<0.001 18.74 to 36.53 
KD No IR vs KD IR 
Time (h) WT No IR (% viable) WT IR (% viable) Pvalue 95% CI of diff. 
0 94.65 96.06 P > 0.05 -7.483 to 10.31 
24 95.71 92.26 P > 0.05 -12.35 to 5.446 
48 95.46 86.35 P<0.01 -18.01 to -0.2168 
72 93.40 73.18 P<0.001 -29.12 to -11.33 
96 90.93 71.76 P<0.001 -28.06 to -10.27 
 
Table 5.2 Statistical analysis of cell viability after DNA damage. Two-way ANOVA was performed to 
assess the variation in the data. If Pvalue <0.05 Bonferroni test was performed post-hoc. Statistical 
analysis was performed in GraphPad PRISM4. 
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5.2.4 Exploring the function of the FLCN/DNA-PKcs interaction  
Effort was next put into characterising the biological reason for the FLCN/DNA-PKcs 
interaction. As a DNA damage sensor and moderator of NHEJ, DNA‐PKcs is very abundant 
(Anderson 1996). In addition to the nuclear function, DNA‐PKcs is present in the cytoplasm, 
were emerging evidence suggest DNA-PKcs regulates aging and energy homeostasis, 
unrelated to DNA repair (Huston et al. 2008; Goodwin and Knudsen 2014; Chung 2018). 
Previously, FLCN has been shown to be important for the correct cytoplasmic-
nuclear shuttling of transcription factors TFEB and TFE3. Upon FLCN loss, TFEB and TFE3 
proteins accumulate within the nucleus, promoting the transcription of gene targets. The 
literature suggests the nuclear localisation of TFEB and TFE3 is controlled by mTORC1-
dependent phosphorylation and FLCNs involvement appears to be co-ordinated with its 
regulation of mTORC1. A novel idea suggests FLCN may be involved in nuclear-cytoplasmic 
shuttling of proteins directly, through a functional association with the nucleopore complex. 
Mass spectrometry analysis identified FLCN interacts with 11 components of the nucleopore 
complex (RANBP2, NUP205, NUP188, NUP54, NUP35 (NUP53), NUP155, NUP133, NUP160, 
NUP50, TPR, NUP153), and proteins that are important for nuclear export (XPO1, XPO5, 
EIF4) (figure 5.7A). FLCN has been demonstrated to interact with NUP155 (data 
unpublished, Dr Sara Seifan, and Mr Matt Lines), and limited evidence suggests it could be 
involved in establishing RAN:GTP gradients around the nucleopore required for nuclear 
export of proteins (unpublished data, M. Van Steensel, Maastricht University). Furthermore, 
FLCN was shown important for the nuclear export of TDP-43 (Xia et al. 2016). Therefore, the 
subcellular location of DNA-PKcs was explored following FLCN knockdown and DNA damage 
(data not shown). Low and high passage of HK2 cells were subjected to 5 Gy and then 10 Gy 
IR. No difference in DNA-PK localisation was observed upon FLCN loss, or under IR.  
Interestingly, however, FLCN may be chromatin bound (figure 5.7C). Subcellular 
localisation of total FLCN suggests it is primarily cytosolic. However, when phosphorylated at 
serine 62, FLCN is predominantly chromatin bound (figure 5.7C). FLCN has been shown to be 
chromatin bound by another group (unpublished data, M. Van Steensel, Maastricht 
University). Neither total nor phosphorylated FLCN’s localisation changed when cells were 
subjected to IR (figure 5.8C). Therefore, while the observation that FLCN is chromatin bound 
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is likely a true one, it may not play a direct role in organising repair molecules at the site of 
DNA lesions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Subcellular localisation of DNA-PK following FLCN loss. A) Interaction network visualising 
members of the nucleopore complex that were identified in the FLCN interactome via mass 
spectrometry. B) Diagram of the nucleopore complex, with members that are present in the FLCN 
interactome highlighted. C) Low passage wild type FLCN HK2 cells (LP-WT cells) were subjected to 5 
Gy IR and fractionated using the Thermo Scientific subcellular protein fractionation kit as directed by 
the manufacturer's protocol. CE = cytoplasmic extract, ME = membrane extract, NE = nuclear 
extract, and CB = chromatin bound. Blots are representative of 2 independent experiments. 
 
Another possible reason for the FLCN/DNA-PKcs interaction could be related to the 
regulation of heat shock protein 90 α (HSP90α). HSP90α is a molecular chaperone involved 
in maintaining the stability and activity of numerous signalling proteins under stress 
conditions. HSP90α plays a key role in DNA damage signalling, repair, and cell cycle control. 
Multiple components of the DNA double strand break repair machinery, including BRCA1, 
B) 
C) 
A) 
 
 119 
 
BRCA2, Chk1, DNA-PKcs, FANCA, and the MRE11/RAD50/NBN complex, have been described 
as client proteins of HSP90α. Additional HSP90α clients worth mentioning include cyclin 
dependent kinase 1 (CDK1), CDK2, CDK4, and CDK6 (and by association their cyclin 
counterparts cyclin B, cyclin D, and cyclin E). All of these proteins are important components 
at the G1/S boundary of the cell cycle (Burrows et al. 2004). Inhibition of HSP90α actions 
leads to the altered localisation and stabilisation of DDR proteins after DNA damage 
(Sreedhar et al. 2004; Pennisi et al. 2015).  
 
Recently, DNA-PKcs was shown to phosphorylate HSP90α at threonine 5 and 7 (t5,7) 
both in vitro and in vivo (Quanz et al. 2012; Park et al. 2017). This phosphorylation decreases 
HSP90α ability to interact with its clients, and is thought to inhibit HSP90α-directed folding 
of client proteins (Park et al. 2017). In rhesus monkey skeletal cells, it was demonstrated 
that age-related increases in DSBs can facilitate the suppression of mitochondrial 
biogenesis, by activating DNA-PKcs driven inhibition of HSP90α. This prevents the correct 
folding of AMPK and its upstream regulator LBK1 (Park et al. 2017). It is thought this 
mechanism is to limit further internal sources of DNA damage (i.e., to limit ROS production). 
In relation to FLCN, this becomes exciting. AMPK activity is upregulated upon FLCN loss, 
resulting in mitochondrial biogenesis and metabolic transformation in FLCN-deficient cells, 
primarily through an increase in PPARGC1A expression (Klomp et al. 2010; Hasumi et al. 
2012; Possik et al. 2014; Yan et al. 2016a). It is currently unclear what the mechanism is that 
leads to this AMPK upregulation. Furthermore, HPS90α was noted as an important network 
protein in the FLCN interactome (Chapter 3). FLCN itself, is thought to be a client of HSP90α 
(Woodford et al. 2016). Therefore, it was hypothesised that the FLCN/DNA-PKcs interaction 
observed in chapter 3, may act as a negative regulator for AMPK through HSP90α. 
 
In the FLCN knockdown HK2 cells, AMPK target genes are dysregulated upon FLCN 
loss (figure 5.8A and 5.8B), as previously shown by multiple studies (Klomp et al. 2010; 
Hasumi et al. 2012; Possik et al. 2014; Yan et al. 2016a). This includes PPARGC1A (figure 
5.8B), which encodes peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC1α). PGC1α is a transcriptional coactivator that regulates the genes involved  
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Figure 5.8 Exploring a biological role for the FLCN/DNA-PK interaction: The HSP90α hypothesis. LP-
WT = low passage-wild type cells; LP-KD = low passage-FLCN knockdown cells; HP-WT = high 
passage-wild type cells; HP-KD = high passage knockdown cells. A) Heatmap showing genes under 
control of AMPK and PGC1α in wild type and FLCN knockdown HK2 cells. B) Bar graph showing 
log2FC of PPARGC1A gene expression in low passage FLCN knockdown (LP-KD), high passage wild 
type (HP-WT), and high passage FLCN knockdown (HP-KD). For each, gene expression was compared 
to low passage wild type (LP-WT). Graph is taken from figure 4.10 C) Western blot analysis of 
HSP90α DNA-PK dependent phosphorylation in wild type and FLCN knockdown HK2 cells subjected 
to 5 Gy IR. D) Densitometry of HSP90α DNA-PK dependent phosphorylation. Error bars represent 
standard error of mean (SEM). 
 
 
in energy metabolism and is considered the master regulator of mitochondrial biogenesis 
(Mastropasqua et al. 2018). Collectively, this suggests cells are behaving in accordance with 
the literature. As a generalised stress responder, HSP90α expression is very low until 
induced by multiple causes of cellular stress, including DNA damage (Pennisi et al. 2015). To 
test if FLCN knockdown affected HPS90α phosphorylation, cells were subjected to 5 Gy IR 
A) 
C) 
D) 
B) 
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(figure 5.8C and 5.8D). As expected, in LP-WT control cells, HSP90α phosphorylation (p-
HSP90α) increased following IR (figure 5.8C and D). FLCN loss was hypothesised to lessen 
HSP90α phosphorylation, limiting its ability to regulate mitochondrial biogenesis through 
AMPK/PGC1α. Following FLCN knockdown in both LP- and HP-KD cells, less p-HSP90α was 
observed (figure 5.8C and 5.8D), however the findings were inconsistent (figure 5.8D). 
Therefore, FLCN is unlikely to regulate DNA-PKcs controlled phosphorylation of HSP90α. 
Furthermore, the initial paper citing DNA-PKcs regulation of p-HSP90α demonstrated, at 
least in monkey skeletal cells, that phosphorylation of HSP90α increased with age. However, 
in HK2 cells, it seems to do the opposite, decreasing with age. While it is not exactly clear 
why HK2 cells respond differently, it is documented that HSP90α has cell-type specific 
responses (Nollen and Morimoto 2002). 
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Conclusion  
 
Collectively, the enrichment of DDR proteins in the FLCN protein interactome, the validated 
interaction between FLCN and DNA-PKcs (both chapter 3), and the possible evidence of 
deregulated gene expression of damage responders in the transcriptome of FLCN deficient 
cells (Chapter 4) support the hypothesis that FLCN could be important for maintaining 
genomic stability. This chapter set out to explore FLCN’s role in DDR, and to try and 
understand the biological implications of FLCN interacting with DNA-PKcs.  
The most striking observation of this chapter is the increase in γH2AX (figure 5.4A), a 
surrogate marker of DSB, upon FLCN knockdown. DNA DSBs are harmful lesions and if left 
unrepaired can lead to cell death. If imperfectly repaired, they can cause deletions, 
translocations, and fusions in the DNA. γH2AX elevation is seen in low passage basal cells, 
suggesting loss of FLCN alone could be enough to promote genomic instability. Interestingly, 
FLCN knockdown may impart a survival advantage with a higher number of cells tolerating 
DNA damage (figure 5.6), although this needs further confirmation. An increase in BRCA1 
signalling was also observed. It’s currently unclear why BRCA1 signalling is up following FLCN 
loss. However, this could represent a compensatory mechanism, as BCRA1 is largely 
involved in promoting HR over the error prone NHEJ repair of DSBs (Davis et al. 2014; Isono 
et al. 2017). An unanticipated observation in the chapter was that FLCN may be chromatin 
bound. This observation was not affected by IR and is unlikely to represent FLCN having a 
direct involvement in DNA lesion repair. Nevertheless, it would be interesting to follow up 
on this. FLCN has no known DNA-binding domains, therefore it’s reasonable to assume 
chromatin localisation of FLCN could be due to protein interactions. For example, FLCN was 
shown to co-localise with the centrosome maker γ-tubulin, suggesting FLCN may be present 
at the kinetochore (a complex of proteins associated with the centromere of a chromosome 
during cell division) and, therefore, could function as a scaffold protein for chromosome 
alignment and/or correct segregation (Luijten et al. 2013).  The biological function of the 
FLCN/DNA-PK interaction is still unclear. However, cytosolic roles of DNA-PKcs have recently 
come to light, and novel findings are implicating DNA-PK in metabolism, autophagy, and 
hypoxia (Bouquet et al. 2011; Park et al. 2017; Chung 2018). Interestingly FLCN is largely 
implicated in metabolism and autophagy, and FLCN-deficient cells have an increase in HIF 
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signalling. It is plausible that DNA-PK may function with FLCN in one of these areas. This is 
discussed further in chapter 7.  
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Thesis chapter 6: The role of FLCN in cell cycle control 
 
6.1 Introduction  
 
The cell cycle is a tightly regulated and highly organised process that safeguards genetic 
material and cellular division. Proliferation depends on successful progression through 
four phases of the cell cycle: G0/G1, S, G2 and M. It is regulated by several  cyclin-
dependent kinases (CDKs) that act in complex with their cyclin partners. The activity of 
the CDKs are highly controlled; induced by mitogenic signals and the presence of their 
cyclins, but inhibited by the activation of cell cycle checkpoints in response to DNA 
damage (Malumbres and Barbacid 2009). 
In most tissues, the majority of cells are in an arrested growth state known as G0 
phase. This can be transient (quiescence) or permanent (senescence). Quiescent cells can 
re-enter the cell cycle once stimulated by mitogenic signals. These signals activate 
cascades of signalling networks that promote CDK4 and CDK6 (referred to CDK4/6 herein) 
to drive cell cycle progression from G0 to G1 and eventually into S phase, where DNA 
replication occurs. CDK4/6 are highly homologous serine/threonine kinases that 
phosphorylate a largely overlapping set of target proteins (Malumbres and Barbacid 
2009; Anders et al. 2011). The activity of CDK4/6 is controlled positively by association 
with D-type cyclins (cyclins D1–3) and negatively by CDK inhibitors of the INK4 family 
(Malumbres and Barbacid 2009). Cyclin D–CDK4/6 promote cell cycle progression by 
phosphorylating the tumour suppressor protein retinoblastoma (Rb). Phosphorylated Rb 
(p-Rb) then dissociates from the E2F family of transcription factors, enabling E2F to 
activate the transcription of S phase genes. Among the E2F transcriptional targets is 
cyclin E, which binds to and activates CDK2. Cyclin E–CDK2 complexes establish a positive 
feedback loop, further phosphorylating Rb and promotes the transition to S phase. Other  
E2F gene targets promote DNA replication, chromatin remodelling, chromosome 
segregation, and spindle assembly. During S phase, cyclin A levels gradually rise. Once DNA 
has been replicated, cyclin A-CDK1 promotes cell cycle progression into the G2 phase, 
preventing further replication of DNA and enabling the G2/M checkpoint. Cyclin B-CDK1 
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complex plays an important role for mitotic entry and during mitosis (Malumbres and 
Barbacid 2009). 
Cell cycle checkpoints are surveillance mechanisms that monitor the order, integrity, 
and fidelity of the cell cycle. This includes growth to the appropriate cell size, replication of 
genomic DNA and integrity of the chromosomes, and accurate chromosomal segregation at 
mitosis (Zhou and Elledge 2000; Foster et al. 2012). Proliferating cells can halt cell cycle 
progression, allowing repair of any DNA lesions, or, induce apoptosis if the defect is too 
great. This cell cycle stalling occurs between G1 and S phase before genomic replication 
(G1/S checkpoint), between S phase and G2 after genomic replication (S phase checkpoint), 
and between G2 and mitosis (G2/M checkpoint). The G1/S checkpoint is the crucial decision 
point for a proliferative cell. It is the point at which a cell commits to entering the cell cycle. 
In a healthy cell, transition into S phase only occurs when internal and external conditions 
are right for division. These conditions include receiving positive growth signals, sufficient 
supply of nutrients, energy and macromolecules, and that the integrity of DNA is not 
compromised. The S phase checkpoint is activated by genotoxic insults and mainly results in 
reversible inhibition of DNA replication. The G2/M checkpoint prevents cells from 
initiating mitosis when they have experienced unrepaired DNA damage that was 
previously inflicted during cell cycle progression through the G1 and S phases (Nyberg et 
al. 2002). The spindle checkpoint examines whether all the sister chromatids are correctly 
attached to the spindle microtubules. The separation of the sister chromatids during 
anaphase is an irreversible step; the cycle will not proceed until all the chromosomes are 
firmly attached to at least two spindle fibres from opposite poles of the cell. Cells with 
intact cell cycle checkpoint and DNA damage response (DDR) pathways frequently arrest 
or die in response to DNA damage, thus reducing the likelihood of cancer progression. 
Mutations in genes that regulate cell cycle checkpoint, DDR, and/or apoptosis can permit 
the survival or the continued growth of cells with genomic abnormalities, thereby 
enhancing the chance of malignant transformation (Zhou and Elledge 2000; Malumbres 
and Barbacid 2009; Foster et al. 2012).  
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6.2 Results and discussion  
6.2.1 Exploring the p21-cyclin D1-pRb-E2F axis control of G1/S transition in FLCN knockdown 
cells 
Proteomic analysis of the FLCN interactome highlighted a number of potential FLCN 
interactors that have known roles in the control of the cell cycle (chapter 3, figure 3.5). 
Interestingly, when these cell cycle associated proteins are plotted based on the phase of 
the cell cycle in which they are known to function, the G1 and G1/S phase transition are the 
most common phases associated with the FLCN-interacting proteins (figure 6.1). 
Complimenting this, transcriptional analysis of the RNA sequencing data showed that the 
most dysregulated phase of the cell cycle following loss of FLCN is likely the G1-G1/S phase 
transition (Chapter 4, figure 4.8). Furthermore, CCND1 (cyclin D1) gene expression appears 
to be highly dysregulated upon FLCN loss (Chapter 4, figure 4.10). Collectively, these data 
support a novel role for FLCN within the G1-G1/S phase transition of the cell cycle. This 
chapter will, therefore, explore these new potential links between FLCN function and cell 
cycle control further.  
 
 
 
 
 
 
 
Figure 6.1 Proteomics data suggests a role for FLCN in G1-G1/S cell cycle transition. Graph showing 
the number of cell cycle functioning proteins found in the FLCN interactome separated by the phase 
of the cell cycle in which they function. 
 
Given the importance of the G1/S phase of the cell cycle demonstrated in Figure 6.1 
and the key role played by CyclinD1-Rb-E2F in control of this checkpoint, this cyclin D1-pRb-
E2F signalling axis was explored in HK2 FLCN knockdown cells (figure 6.2). Low and high 
passage HK2 cells were subjected to 5 Gy IR to induce DNA damage and stall cell cycle 
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progression. Following DNA damage, cyclin D1 and p-Rb levels are expected to decrease as 
cells initiate checkpointing to halt their proliferation. This decreased in cyclin D1 and p-Rb 
was observed for wild type cells. However, the FLCN knockdown cells did not respond in 
such manner, as observed by retaining high levels of cyclin D1 protein expression and p-Rb 
hyperphosphorylation, particularly in low passage cells (figure 6.2). Interestingly, cyclin D1 
protein levels further increased in aged cells (at high passage). This was a surprising 
observation as CCND1 mRNA, shown by both RNAseq and qPCR validation, was substantially 
downregulated in aged FLCN-deficient HK2 cells (chapter 4, figure 4.10). Cyclin D1 protein 
levels were previously found to be increased upon FLCN loss. Increased cyclin D1 protein 
expression was observed by immunohistochemistry in FLCN-inactivated mice kidneys, along 
with Cyclin A1, Cyclin B1, CDK4 (Baba et al. 2008). Transient, FLCN knockdown in HeLa cells 
show both an increase in CCND1 mRNA and cyclin D1 protein, as seen in LP-KD HK2 cells 
used in this thesis (figure 6.2). Supporting this, re-introduction of FLCN in NR32 (FLCN-
deficient renal tumour cell line from the Nihon rat) lowered cyclin D1 protein levels (Kawai 
et al. 2013). It is worth pointing out that both HeLa and NR32 are derived from already 
established cancers, where cell cycle regulation may already abnormal. The finding that 
cyclin D1 is stable in the presence of IR when FLCN is deficient builds on previous published 
work and suggests that FLCN may be involved in the control of cyclin D1 during DNA 
damage. It is possible that FLCN loss is associated with an increase in cyclin D1 protein levels 
and could be a driving force behind RCC development.  
The increased levels of cyclin D1 protein in the FLCN-deficient cells may be as a result 
of reduced nuclear export of cyclin D1, enhanced protein translation or enhanced protein 
stability. Overexpression of cyclin D1 is observed in a variety of cancers (Hall and Peters 
1996; Alt et al. 2000) and suggests that cyclin D1 overexpression provides cells with a 
distinct growth advantage via enhanced proliferative drive. However, evidence suggests that 
overexpression of cyclin D1 alone is not sufficient to promote uncontrolled cell growth, but 
rather its nuclear retention promotes cell transformation. A constitutively nuclear cyclin D1 
mutant showed a more transformative phenotype than overexpressed wild type cyclin D1 
(Alt et al. 2000). During S phase, the nuclear exclusion of cyclin D1 complexes are critical for 
the regulation of normal cellular proliferation. GSK-3β phosphorylates Cyclin D1 at 
threonine 286, which promotes the nuclear-to-cytoplasmic shuttling of cyclin D1 (Resnitzky 
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et al. 1994; Diehl et al. 1998). Following GSK-3β-mediated phosphorylation, cyclin D1 
nuclear export is facilitated by the association of cyclin D1 with the nuclear XPO1 (a FLCN 
interactor identified by mass spectrometry, see chapter 3). In addition, the FLCN 
interactome, presented in chapter 3, also highlighted numerous nuclear pore complex 
proteins as previously discussed (chapter 5, figure 5.7). Interestingly, p21 can also promote 
the nuclear retention of cyclin D1 and is thought to protect cyclin D1 from cytoplasmic 
degradation (Alt et al. 2002). Therefore, similar to DNA-PK, the subcellular localisation of 
cyclin D1 in FLCN knockdown cells was explored under IR.  No evidence of dysregulated 
localisation was found when cells were subjected to 5 Gy IR (n=3, data not shown). 
However, a follow up study using 10 Gy IR indicates a modest increase in nuclear cyclin D1 
level, accompanied by a slight decrease to cytoplasmic levels in FLCN knockdown (n=2, data 
not shown, performed by Mr Matthew Lines). Due to time limitations, cyclin D1 was only 
tested in two independent experiments, the second of which does not contain a full 
complement of analysed controls. Therefore, for the purpose of this thesis, cyclin D1 
cytoplasmic-nuclear shuttling is considered to not be affected by FLCN knockdown. 
Although validation of these findings should be a priority for future work.  
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Western blot analysis of p21-CylcinD1-retinoblastoma regulation of G1/S transition 
following IR-induced DNA damage. Wild type and FLCN knockdown cells were subject to 5 Gy IR for 
1 h. Cyclin D1 and p21 total protein, and phosphorylated retinoblastoma (p-Rb) and phosphorylated 
histone marker H2AX (γH2AX) were analysed to see if the G1/S phase transition was activated. 
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On the other hand, in HeLa cells, it was demonstrated that FLCN negatively 
regulates cyclin D1 through elements on the CCND1 mRNA. The authors propose that the 
post-transcriptional regulation of CCND1 expression by FLCN may be associated with 
microRNA(s) or RNA binding protein(s) that bind to the 3' untranslated region (3’UTR).  
Interestingly, the mRNA cap-binding protein, eukaryotic initiation factor 4E (eIF4E) was 
identified in the FLCN interactome. eIF4E is a rate-limiting factor of cap-dependent 
translation initiation. eIF4E associates and promotes the nuclear export of CCND1 mRNA. 
The basis of this discriminatory interaction of FLCN with the CCND1 mRNA is an ∼100 
nucleotide sequence in the 3′UTR of CCND1 mRNA. It is possible that FLCN might be 
important for the export of CCND1 mRNA but functions as a negative repressor of its 
translation (Culjkovic et al. 2005).  
p21 is a member of the Cip/Kip family of CDK inhibitors and contributes to the 
regulation of multiple tumour suppressor pathways to promote several anti-proliferative 
activities (Deng et al. 1995; Abbas and Dutta 2009).  p21 inhibits the kinase activity of a 
broad range of cyclin-CDK complexes, preventing cyclin-dependent progression of the cell 
cycle. In recent years, the simplistic idea that p21 acts solely as a tumour suppressor has 
been complicated. For instance, p21 has been shown to exhibit oncogenic activities 
(Roninson 2002; Gartel 2006); it is often overexpressed in many human cancers, and 
upregulation of p21 positively correlates with tumour aggressiveness and poor survival 
(Abbas and Dutta 2009). p21 has been shown to promote the assembly of cyclin D-
CDK4/6 complexes, without inhibiting kinase activity (LaBaer et al. 1997; Gartel 2006; 
Abbas and Dutta 2009). Furthermore, it is thought cyclin D-CDK4/6 sequestration of p21 
could facilitate oncogenesis by freeing CDK2 from p21 inhibition (Liu et al. 2007; Abbas 
and Dutta 2009). In addition to halting cell cycle progression allowing time to repair DNA, 
p21 can compete for PCNA binding with several PCNA-reliant proteins that are directly 
involved in DNA synthesis. This interaction is thought to modulate repair processes 
(Mortusewicz et al. 2005; Walsh and Xu 2006; Abbas and Dutta 2009). For example, p21-
PCNA interaction is sufficient for p21 to inhibit mismatch repair (Umar et al. 1996) and 
PCNA-dependent base excision repair (Tom et al. 2001). The p21-PCNA interaction has 
also been shown to prevent ubiquitylation (Soria et al. 2006) of PCNA required for 
translesion DNA synthesis, limiting a cells ability to bypass stalled replication forks. 
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Nucleotide excision repair (NER) could also be modulated by p21, however the evidence 
is contradictory. In vitro, high p21:PCNA ratios have been shown to block DNA synthesis and 
NER (Floresrozas et al. 1994; Luo et al. 1995; Podust et al. 1995; Shivji et al. 1998; Soria et al. 
2006). In vivo, the majority of studies report little or no effect (Chen et al. 1995; Luo et al. 
1995; Nakanishi et al. 1995; Lin et al. 1996). One idea is that the p21:PCNA ratio is crucial to 
inhibit DNA synthesis and NER (Abbas and Dutta 2009). PCNA is an abundant protein, and 
even the highest physiological levels of p21 might be insufficient to titrate PCNA, as the 
p21:PCNA ratio likely never exceeds 1:1 in vivo (Luo et al. 1995; Gottifredi et al. 2004).  The 
inhibitory effect of the PCNA-interacting domain of p21 on DNA synthesis in vitro requires 
p21:PCNA ratios of 10:1 or higher (Shivji et al. 1998; Gottifredi et al. 2004). Furthermore, the 
amount of p21 available depends on other events, such as p21 sequestration by cyclin-CDKs 
and modifications to chromatin accessibility (Abbas and Dutta 2009). It’s likely any DNA 
synthesis or repair modulation activity of p21 derives from its tumour suppressive role, 
sequestering PCNA to limit DNA synthesis. Perhaps to nullify DNA repair to promote 
apoptosis. Given the significant role of various DNA repair processes in protecting against 
cancer, it would be useful to elucidate the extent to which p21 modulates DNA repair 
processes and whether this activity of p21 contributes to its tumour-suppressing or 
tumour-promoting activities within FLCN deficient RCC. Collectively, the western blot 
analysis of the cyclin D1-pRb-E2F axis, suggests that FLCN-deficient cells may be 
inappropriately transitioning through the G1/S checkpoint; and that the upregulation of pro-
proliferative components (cyclin D1 and pRb) occur shortly after FLCN loss (figure 6.2).  
 
6.2.2 Transcriptomic pressure of E2F regulated genes in FLCN knockdown cells 
The increase in cyclin D1 and p-Rb levels observed in the FLCN knockdown HK2 cells 
(figure 6.2) suggest a mechanism of proliferative drive. While the increase in p21 could 
indicate a compensatory mechanism for increased cyclin D1, or an oncogenic role within 
the cells. To better understand the proliferative pressure of this cyclin D1-p-Rb axis 
within the FLCN knockdown cells, the transcription of E2F target genes were explored 
(figure 6.3). 
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Transcriptional analysis of 110 E2F-regulated genes revealed 24 were differentially 
expressed (FDR Pvalue<0.05) as a direct consequence of FLCN loss (LP-KD vs LP-WT, Figure 
6.3A). This increased upon aging, with 40 genes significantly differentially regulated (HP-KD 
vs HP-WT, figure 6.3B), suggesting loss of FLCN allows for an acceleration in cell cycle 
progression. Of interest, pro-growth factors TGFA, PPARGC1A, c-JUN were most upregulated 
in low passage FLCN knockdown cells. TGFA encodes transforming growth factor α, and is a 
growth factor that activates cell proliferation. It has been shown to directly act as a specific 
growth-stimulatory factor for primary renal proximal tubule epithelial cells which are 
thought to give rise to RCC (Gomella et al. 1989; Humes et al. 1991; De Paulsen et al. 2001). 
It is commonly upregulated in many cancers, including RCC (Derynck et al. 1987; Mydlo et al. 
1989; Petrides et al. 1990; Walker et al. 1991). PPARGC1A, encoding PGC1-α, is the master 
regulator of mitochondrial biogenesis. It plays an essential role in the co-ordination of an 
array of genes involved in glucose and fatty acid metabolism, as well as metabolic 
reprogramming in response to nutrient availability (Mastropasqua et al. 2018). PGC1-α is 
well characterised to be up regulated upon FLCN loss (Klomp et al. 2010; Hasumi et al. 2012; 
Hasumi et al. 2014; Yan et al. 2014). Therefore, this result is supported by the literature on 
FLCN loss and adds to the reliability of the HK2 cells used and how they model this disease.  
Furthermore, the E2F target gene, PGC1-α, is commonly dysregulated in RCC (Mastropasqua 
et al. 2018) and has previously been shown to be upregulated in FLCN-null kidney cell lines 
(Yan et al. 2014). Additionally, in the aged cells, PGC1-α is consistently upregulated upon 
FLCN loss. This supports the idea of metabolic reprogramming commonly seen in RCC and 
FLCN-deficient in vitro and in vivo models (Klomp et al. 2010; Wada et al. 2016; Yan et al. 
2016a). An interesting observation when comparing changes in low passage cells to high 
passage cells is that several key cell cycle promotors (CCND1, CCND3, CCNA1, CCNE1, and 
E2F1) are upregulated in low passage cells (although only slightly) but become 
downregulated upon aging. This suggest the old cells still retain the ability to control cell 
growth, and perhaps represents the cells attempting to compensate for increased pressure 
to grow in the presents of DNA damage (Chapter 5, figure 5.4).  
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Figure 6.3 Analysis of E2F regulated genes. 110 E2F regulated genes were analysed comparing the 
effect of FLCN knockdown in low and high passage cells. A) Volcano plot showing differentially 
expressed E2F genes as a direct response to loss FLCN (LP-WT vs LP-KD). B) Volcano plot showing 
differentially expressed E2F genes in FLCN-deficient aged cells (HP-WT vs HP-KD). For both volcano 
plots black dots represent genes in which change in expression was not significant (NS), blue dots 
are down regulated genes (FDR Pvalue<0.05), and red dots are up regulated genes (FDR 
Pvalue<0.05). C) Differentially expressed E2F genes, directly comparing changes that occur upon 
aging in the absence of FLCN. Grey dots represent genes in which change in expression was NS, light 
blue dots represent significant changes (FDR Pvalue<0.05) in expression between low passage cells 
(LP-WT vs LP-KD) only, green dots represent significant changes (FDR Pvalue<0.05) in expression 
between high passage cells (HP-WT vs HP-KD) only; Black triangles represent significant change (FDR 
Pvalue<0.05) in expression in both low and high passage cells.  
 
Another E2F-target gene, c-Jun, is a proto-oncogene and functions as a key 
regulatory molecule for cell growth control.  c-Jun expression is associated with the 
recruitment of cells from G0 to G1 (Oya et al. 2005).  Altered c-Jun expression is thought to 
play a critical role in early carcinogenesis lung and oral squamous cancer, and RCC (Szabo et 
al. 1996; De Sousa et al. 2002). Interestingly, healthy proximal kidney tubules have little to 
no c-Jun expression, but it has been shown to be ectopically expressed in clear cell and 
papillary RCC originating from the proximal kidney tubules. c-Jun activation is commonly 
observed at an early stage of RCC; similarly, c-Jun expression increases were noted in LP-KD 
E2F-target DEGs 
 Low passage only High passage only Both 
PCC 0.3778 0.4362 -0.2548 
Pvalue NS 0.0160 NS 
R2 0.1427 0.1903 0.0006 
-5.0  -2.5   0.0   2.5    5.0 
-L
o
g 1
0(
FD
R
) 
Log2(Fold change) 
280 
270 
30 
20 
10 
0 
A) 
-5.0  -2.5   0.0    2.5   5.0 
Log2(Fold change) 
-L
o
g 1
0(
FD
R
) 
280 
270 
30 
20 
10 
0 
B) 
 
3 
2 
-2 
H
ig
h
 p
as
sa
ge
 c
el
ls
 L
o
g2
(F
o
ld
 
ch
an
ge
) 
C) 
CCND1 
4 
-6 
0 
NS 
Down regulated 
Up regulated 
-1 
-4 
-3 
-5 
Low passage cells Log2(Fold change) 
-2           -1               0             1              2 
1 
NS 
Low  
Both 
High 
TGFA 
PPARGC1A 
c-JUN 
CCNA1 
CCNE1 
CDKN1C 
CDKN2C 
 133 
 
cells (figure 6.3C). The negative regulators of cell proliferation, CDKN1C and CDKN2C, were 
also some of the most upregulated E2F controlled genes. CDKN1C strongly inhibits several 
cyclin-CDK complexes including cyclin E-CDK2, cyclin D2-CDK4, cyclin A-CDK2, and, to lesser 
extent, the mitotic cyclin B-CDK2 complex, to promote a non-proliferative state in cells. 
CDKN2C inhibits both CDK4 and CDK6; with a preference for the latter. Furthermore, the 
positive regulators of cell proliferation, CCNE2 (cyclin E2) and CCNA1 (cyclin A1), were down 
regulated. Cyclin E expression increases just before S phase initiation and represent cells 
committing to proliferation. Cyclin A expression increases in early S phase and is required 
for G2/M progression.  
In the high passage cells, on the other hand, the most aberrant observation is the 
upregulation of a selection of homeobox (HOX) genes (HOXA4, HOXA5, HOXA7, and HOXB9). 
HOX genes comprise a super-family of evolutionarily conserved genes that play essential 
roles in controlling body plan specification and cell fate determination (Haria and Naora 
2013). Overexpression or down-regulated expression of many homeobox genes have been 
observed in a wide variety of malignancies and have cell specific roles (Abate-Shen 2002; 
Samuel and Naora 2005; Shah and Sukumar 2010). For example, HOXA4 is reportedly 
overexpressed in colorectal cancer and epithelial ovarian cancer (Yamashita et al. 2006; 
Bhatlekar et al. 2014). HOXA4 expression was down-regulated in lung cancer tissues when 
compared with non-cancerous tissues. Furthermore, overexpression of HOXA4 in lung 
cancer cell lines decreased the protein expression levels of β-catenin, cyclin D1, and c-
Myc, supressing proliferation, migration, and invasion. The expression patterns and 
functional properties of HOX genes in solid tumours fall into two broad categories. HOX 
genes that are expressed in embryonic tissues and are ‘reactivated’ in tumours tend to have 
oncogenic properties. HOX genes whose expression is normally maintained in differentiated 
adult tissues but is down-regulated in tumours often exhibit tumour suppressive properties. 
Less commonly, homeobox genes can be expressed in tumours derived from a lineage in 
which these genes are not normally expressed during development; these often have 
tumour-promoting properties. Despite numerous reports of their aberrant expression, the 
mechanisms of many homeobox genes in tumours are poorly understood.   
The E2F transcription factor family consist of seven members (E2F1-7). E2F1-3 
function as transcriptional activators; acting as the classical E2F transcription factor enabling 
expression of S phase genes. E2F4 and E2F5 are repressors and are exported from the 
nucleus during early G1 (Di Stefano et al. 2003; Bracken et al. 2004).  E2F1-5 can bind to and 
be inhibited by Rb, while E2F6 and E2F7 are thought to act as a transcriptional repressors. 
E2F7 is induced during early S phase (Stott et al. 1998; Di Stefano et al. 2003), and is thought 
to repress only a subset of E2F target genes, such as CCNE1 and CDC6. It does not repress 
later-transcribed genes such as CCNA2 and CDC2 (Di Stefano et al. 2003). It is possible that 
E2F6 and E2F7 transcription factors function within feedback loops that allow orderly and 
finely tuned progression through the cell cycle. Very little is known about the function of 
E2F6. In the absence of ChIP data, it is unclear what E2F responsive genes E2F6 regulates, 
 134 
 
or whether this occurs throughout the cell cycle or is restricted to a specific phase 
(Trimarchi and Lees 2002). Transcriptome analysis of FLCN knockdown cells reveals a 
generalised dysregulation (figure 6.3C and 6.3D), there isn’t a trend in positive and negative 
regulators of G1/S phase transitioning genes being collectively up- or down-regulated in 
response to FLCN loss (figure 6.3C and 6.3D; chapter 4, figure 4.9). E2F luciferase assay may 
be able to provide a more direct idea of the proliferative drive FLCN-deficient cells are under 
as a result of FLCN knockdown. Unfortunately, time restrictions prevented the use of E2F 
luciferase assay. 
Collectively, E2F regulated gene expression upon FLCN loss is dysregulated. E2F 
regulation has a multitude of positive and negative feedback loops in addition proliferation 
driving genes. This allows highly controlled and finely tuned progression through the cell 
cycle. Examining E2F regulated genes as shown in figure 6.3, it can be concluded that FLCN 
loss leads to perturbed regulation, however, no obvious promotion or inhibition of G1/S 
transition can be concluded. Collectively, the results indicate that G1/S cell cycle checkpoint 
control through E2F is likely dysregulated as a direct consequence of FLCN loss, but further 
agitated during the ageing process in the continual absence of FLCN. 
 
6.2.3 Exploring cell cycle profile of FLCN knockdown cells  
Evidence so far suggests FLCN knockdown cells should be transitioning through the cell cycle 
irrespective of the presence of DNA damage, inappropriately skipping through the G1/S 
checkpoint of the cell cycle. DRAQ5 was used to quantify DNA content in order to profile the 
cell cycling properties of FLCN knockdown cells. DRAQ5 is a fluorescent dye that 
stoichiometrically stains DNA. As such, fluorescent intensity of a cell can be used to estimate 
the number of cells in G0/G1, S, and G2. As a cell progresses through the cell cycle, the 
quantity of DNA increases from 2N (G0/G1 phase) to 4N (G2 phase). Cells with DNA below 
2N are typically in apoptosis and are considered debris. While transcriptomic data suggested 
high passage cells may have a more dysregulated cell cycle, low passage cells were used 
with the aim of better understanding FLCN loss in establishing renal neoplasms. Low 
passage FLCN expressing HK2 cells were used to establish IR dose and timings before the 
effect of FLCN loss was explored (figure 6.4).  
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Figure 6.4. Analysis of HK2 cell line cell cycle profile. HK2 LP-WT cells were used to optimise 
protocol treatments. DRAQ5 was used to quantify DNA content. A-C) Establishing time points to 
analysis cell cycle profile.  Cells were treated with 10Gy IR and left for up to 72 h to establish a 
maximum treatment time. A) Isolating cells from debris. B) Isolating single cells to removed 
polyploidy or clumps of cells. C) Comparing the cell cycle profile of irradiated cells (red) versus their 
time match non-irradiated control (grey). Plots and graph are representative of 2 independent 
experiments. 
 
For the initial analysis of cells, forward scatter versus side scatter (FSC vs SSC) 
gating was used to identify cells of interest away from cellular debris. (figure 6.4A). In 
order to ensure only single cells are being analysed, cells were gated to removed doublets, 
or cell clumps, as well as polyploid cells (figure 6.4B). Cell cycle profiles were plotted as 
histograms of fluorescent intensity vs cell count (i.e., DRAQ5 incorporation vs the number of 
cells at a given intensity; figure 6.4C). In the first instance cells were subjected to 10 Gy IR 
and left for up to 72 h to establish a maximum time after IR to investigate (figure 6.4C). 
Although the experiment was only carried out once, it indicates the majority of cells will be 
in G2 by 24 h. Cells left longer will produce an increase in debris as cells choose to undergo 
apoptosis, which could impinge or complicate the interpretation of subsequent results. 
Next, an IR dose-course was performed to better establish a suitable radiation exposure. 
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The aim was to lightly damage cells, enough to encourage cellular stalling but not enough to 
induce apoptosis, in order to study the effect FLCN knockdown on cell cycle checkpointing. 
In the first instance, LP-WT HK2 cells were subjected to 1-10 Gy of IR and DNA content was 
examined after 24hrs. This dose test was only carried out once and initial analysis supported 
a 2 Gy IR dose would be an appropriate for experimental requirements. However, due to 
issues discussed later, 2 Gy IR was later found to not be a suitable dose. 
Nevertheless, DRAQ5 staining was used to ascertain cell cycle profiles following 2 Gy 
IR in LP-WT and LP-KD cells. Single cells were identified, and cell cycle profiles were plotted 
as described above (figure 6.5A and 6.5B). FlowJo V10 software was used to estimate 
G0/G1, S phase, and G2/M populations using DRAQ5 signal, to generate a cell profile model. 
Technically, cell ploidy is visualised rather than a cell’s true residence in interphase or 
mitosis. Therefore, it is more accurate to refer to the G0/G1 and G2/M populations as 2N 
and 4N respectively. The model assumes Gaussian distributions of the 2N and 4N 
populations, then a subtractive function is used to identify the S-phase population (figure 
6.5C).   
Non-irradiated LP-KD cells displayed fewer 2N cells (G0/G1) and more 4N (G2) cells 
than the wild type controls (figure 6.5D and 6.5E). DNA damage can stall cells at the G1/S 
and G2/M checkpoints. To see if FLCN knockdown cells have a more proliferative phenotype 
despite the presence of damage, cells were subjected to 2Gy IR and left for up to 24 h. 
Generally, LP-KD cells had fewer cells in G1 and more cells in G2 (figure 6.5F and 6.5G). This 
supports the idea the FLCN-deficient cells slip through G1/S phase. Interestingly, it’s been 
noted that FLCN reintroduction in zebra fish embryos caused a significant drop in S-M phase 
cells with a corresponding increase in G1 cells (Emma J. Kenyon et al 2016), agreeing with 
results observed in HK2 cells in figure 6.5. Nevertheless, there are consistently fewer cells at 
all time points (figure 6.5F and 6.5G). The results may just be from lower cell numbers and 
not be reflective of the biology. Therefore, the mitosis inhibitor colcemid (figure 6.7) and S 
phase marks, BrdU and EdU (figures 6.8 and 6.9) were used in an attempt validate findings.  
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Figure 6.5 Analysis the cell cycle profile in FLCN-deficient cells. Low passage wild type (LP-WT) and 
knockdown (LP-KD) cells were subjected to 2Gy IR.  A) Isolating cells from debris. B) Isolating single 
cells to removed polyploidy or clumps of cells. C) Histogram of DRAQ5 signal to produce cell cycle 
profile. D) Cell cycle profile comparison of wild type and FLCN knockdown. E) Percentage of cells at 
each stage of the cell cycle, as determined by DRAQ5 staining, under basal conditions. F) Percentage 
of cells in G0/G1 phase following 2 Gy IR G) Percentage of cells in G2/M phase following 2 Gy IR. 
Percentage of cells in each stage of the cell cycle was determined using FlowJo V10 cell cycle analysis 
function. Student’s T Test was used to determine statistical significance between wild type and 
knockdown cell lines, and was performed in Microsoft Excel 2013. Plots are representative of 3 
independent experiments. 
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Colcemid is a microtubule-depolymerising compound. Colcemid prevents cells from 
undergoing mitosis and, as such, stalls cells in G2 phase. Using a mitotic inhibitor would 
prevent cells re-entering the cell cycle, where these cells could otherwise confound results. 
In the LP-WT control cells, after the addition of 60ng/mL colcemid, cells accumulated 
overtime (figure 6.6A) with most of the cells in a 4N state (64%); a surrogate indication of G2 
(figure 6.6A and 6.6B), demonstrating the conditions of colcemid treatment are sufficient to 
stall cells in G2. It was expected that LP-KD cells would accumulate in G2 faster than WT 
cells, however, no difference could be observed between the cell lines (data not shown). 
FLCN has previously been thought of as a positive regulator of the G2/M phase transition 
(Lavoittle 2013) and required for mitosis (Kawai et al. 2013). Following IR, the cell lines still 
had a continuous and equal percentage difference in cells throughout the duration of the 
experiment, similar to what was previously observed under IR (figure 6.5G).  
 
 
 
 
 
 
 
 
 
 
Figure 6.6. Analysis the cell cycle profile in FLCN-deficient cells after treatment with G2/M phase 
blocker, colcemid. HK2 low passage wild type (LP-WT) and knockdown (LP-KD) cells were treated 
with colcemid (60 ng/µL) and analysed up to 24 h after treatment. A) Histogram of DRAQ5 signal in 
LP-WT cells to produce cell cycle profile. B) Percentage of LP-WT cells in each stage of the cell cycle 
was determined using FlowJo V10 cell cycle analysis function. Plots are representative of 3 
independent experiments.  
 
Next, in order to validate the G1/S slippage in FLCN KD cells, genomic DNA was 
labelled by exposing cells to the thymidine analogue, 5'-bromo-2'-deoxyuridine (BrdU). 
Interestingly, BrdU incorporation has been evaluated in FLCN-inactivated mouse kidney cells 
and was measured by immunostaining (Baba et al. 2008).  BrdU incorporation was 
statistically significantly greater in kidney cells from BHDf/d/KSP-Cre mice than BHDf/+/KSP-
Cre mice. The study did not quantify DNA content and so the information cannot be used to 
establish G1-G1/S slippage specifically, but that FLCN-deficient cells hyper-proliferate. 
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During DNA replication (in S phase), BrdU is incorporated into newly synthesised DNA. 
Incorporated BrdU is stained with anti-BrdU and fluorescent antibodies, in addition to the 
DNA dye (i.e., DRAQ5) This allows for a more accurate separation of G0/G1, S , and G2/M 
phase cells (Rothaeusler and Baumgarth 2007; Kim and Sederstrom 2015). For analysis, DNA 
was quantified as described above; cells were isolated from cellular debris and polyploidy 
(figure 6.7A and 6.7B) and plotted to show cell cycle profile (figure 6.7C). Once single cells 
were identified, and DNA content quantified, BrdU incorporation was analysed. Firstly, 
background fluorescence was established using an antibody free control (figure 6.7D; black). 
Then the sample with the largest expected signal (in this case cells exposed to BrdU for 24 h) 
was used to ensure BrdU incorporation could be detected (figure 6.7D; purple). To confirm 
the protocol was set up correctly, a secondary antibody only sample was used (figure 6.8E).  
When compared to the 24 h sample, the secondary antibody only control almost fully 
overlapped. This suggests wash steps were insufficient, and no conclusion of BrdU 
incorporation can be drawn. Furthermore, when analysing DRAQ5 staining following BrdU 
incorporation over time, cells with no exposure to BrdU display a normal cell cycle profile 
whereas those with BrdU did not (figure 6.7F).  
A disadvantage of BrdU incorporation method is that both membrane 
permeabilisation and harsh DNA denaturation processes are required for antibody 
penetration to the incorporated BrdU. As an alternative to BrdU, 5-ethynyl-2'-deoxyuridine 
(EdU) has been developed to overcome these limitations (Salic and Mitchison 2008; 
Cavanagh et al. 2011; Kim and Sederstrom 2015). After EdU treatment during cell 
proliferation, incorporation of EdU can be subsequently detected by a fluorescent azide 
molecule through a copper (I) catalysed reaction which results in a stable triazole ring 
formation between EdU and fluorescent dye (so called "Click-it” reaction). Since the small-
sized fluorescent dye readily penetrates the cell and it easily reacts with EdU even in intact 
DNA double strand, EdU method is more gentle, highly sensitive, and much faster than a 
classical BrdU incorporation assay (Salic and Mitchison 2008; Cavanagh et al. 2011; Kim and 
Sederstrom 2015). 
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Figure 6.7 Testing BrdU incorporation as a method of quantifying S phase cells. Low passage wild 
type (LP-WT) cells were treated with 8µM BrdU and left for up to 24 h A) Isolated cells from debris B) 
Isolating single cells to removed polyploidy or clumps of cells. C) Contour plot showing Brdu 
incorporation into cells after 24 h (purple), no anti-Brdu antibody (Ab) was used to establish a 
baseline to remove background florescence from the analysis (black). D) Contour plot showing 
antibody controls, secondary (2°) antibody only sample (black) shows almost total overlap with 24 h 
Brdu sample (purple) suggesting insufficient wash steps. E) Histogram of DRAQ5 signal to produce 
cell cycle profile. Plots are representative of 2 independent experiments.  
 
 
To test if EdU would be a more suitable S phase maker, low passage wild type cells 
were treated with 8 µM of EdU and left for either 8 or 24 h. In the absence of EdU, normal 
cell cycle profiles can be observed with DRAQ5 staining (figure 6.8A). However, similar to 
BrdU, the presence of EdU lead to abnormal cell cycle profile plots (figure 6.8B). To verify 
the cells were able to respond correctly, colcemid was used to stall cells at G2 (figure 6.8C). 
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nucleated cells. DRAQ5™ binds strongly to the A-T sites at the minor grove of DNA. One 
explanation could be that as BrdU and EdU are both thiamine analogues, therefore using a 
DNA binding dye that preference A-T sites has limited use. Furthermore, BrdU influences the 
fluorescence of many DNA dyes; it incompletely quenches DAPI, Hoechst, and acridine 
orange dyes; where, similar to DRAQ5, both DAPI and Hoechst are AT-specific (Kubbies and 
Rabinovitch 1983). BrdU has also been reported to enhance the fluorescence of 
mithramycin and 7-AAD (GC-specific DNA binding dyes) (Ormerod and Kubbies 1992). 
Specific information on EdU quenching or enhancing DRAQ5 was not found. Equally 
information on the effects of EdU with DRAQ5 could not be found. Many publications use 
propidium iodine (PI) to quantify DNA content alongside the use of thiamine analogues, 
where PI universally intercalates between base pairs (Sakimoto et al. 2006; Liu et al. 2013a).  
Based on data presented in figure 6.7 and 6.8, DRAQ5 is unlikely to be compatible with 
thiamine analogues use.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 Understanding the use of DRAQ5 with thiamine marker. A) Histogram of DRAQ5 signal in 
Low passage wild type (LP-WT) cells to produce cell cycle profile. Top row, cells treated with 20µM of 
DRAQ5 for up to 24 h; bottom row, cells treated with 20µM of DRAQ5 and 8µM Edu for up to 24 h. 
B) LP-WT cells were treated with 60ng/µL colcemid to check cells can respond appropriately. Grey, 
no treatment (NT) control; purple, cells treated with 60ng/µL colcemid for 24 h. Plots are 
representative of 3 independent experiments. 
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EdU incorporation without a DNA marker was explored in order to determine if a 
difference between the cell lines could be detected, and as such gauge its usefulness before 
optimising a new DNA binding dye (figure 6.9). Cells were isolated from debris, and a no 
antibody control was used to establish background florescence (figure 6.10A). EdU 
incorporation was assessed at 6 and 24 h (figure 6.9B). Over the course of 24 h EdU 
incorporation increased, with 65.1% (± 4.086 %) of cells staining positive for EdU at the end 
of 24 h (figure 6.9C). This shows that it is possible to track DNA synthesis within the HK2 
cells through incorporation of the thiamine analogue EdU. This was repeated in LP-KD cells 
after 2 Gy of IR, but no difference was observed between the cells lines (n=2, data not 
shown). However, when compared to non-irradiated controls, no evidence of cells stalling 
could be seen. This was further explored in the LP-WT control cell line (figure 6.9C). With 
increasing dose of IR, it is expected to see a smaller EdU signal at any given time point. This 
is because upon more DNA damage cells will stall DNA synthesis, although some 
incorporation of EdU will occur as part of DNA repair, this should be much lower than non-
irradiated controls. IR dose was increased incrementally to 50Gy, and EdU incorporation 
was detected up to 24 h after IR (figure 6.9C). Little difference can be observed, with minor 
decrease in percentage of cells with EdU incorporation at each time point. R2 of each of the 
timepoint trendlines suggest the data doesn’t fit the trendline very well (R2 = 0.37 for 6 
hours, and R2 = 0.58).  
Two-way ANOVA was performed to look at the effect of EdU incorporation over time 
and with increasing IR dose (table 6.1). The effect of IR dose was not significant, accounting 
for only 1% of variation observed in the data (p=0.6584). Time, however, contributed to 
61.83% of variation within the data (p<0.0001). This make sense, more EdU can be 
incorporated following longer time periods. Within this data, IR did not affect the 
incorporation of EdU, which implies that IR-induced DNA damage does not cause cell cycle 
arrest in these HK2 cells. It’s worth pointing out that doses 15-50 Gy had only 1 replicate, 
which limits confidence in the statistical analysis. It is possible that more repeats may 
support a contribution of the high IR dose to affect EdU incorporation, as suggested by the 
downward slope on the trendline. This analysis was not expanded upon to due time and 
resource constraints. Further troubleshooting could involve adapting the times of treatment 
in which cells are labelled with EdU. One limitation of the current protocol is that EdU is 
present throughout the whole duration of the experiment and, as such, could be 
incorporated as part of the DNA repair response. As the DNA content of the cells was not 
quantified in these experiments by flow, cells could indeed still be stalling (not replicating 
their DNA). Therefore, it cannot be ruled out that the increase in EdU signal observed in the 
LP-WT cells aren’t simply an artefact of cells repairing their DNA. Instead of adding EdU for 
the duration of the experiment, it might be better to add EdU for a limited amount of time 
(e.g. 1 h) prior to DNA damage induction by IR. This would allow for EdU incorporation into 
the genome but prevent continued increase of signal over time. This shorter 1 h pulse with 
EdU was briefly attempted n=1 (data not shown) but leads to a similar result to figure 6.9C. 
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It seems that thiamine analogue inclusion over time alone has limited usefulness, as to 
understand the cell cycle response to IR in these HK2 cell lines, thiamine analogue signal 
needs to be co-ordinated with DNA content. To continue this avenue, use of an alternative 
DNA marker (such as PI) would be required. 
Under normal conditions, the fraction of proliferating tubular epithelial cells in the 
kidney is below 1% (Moonen et al. 2018). This is to cover the casual loss of tubular epithelial 
cells due to physiological cell death or spontaneous release from the basal membrane into 
the urine (Moonen et al. 2018). The remaining 99% cells are quiescent, resting in the G0 
phase. For the proximal tubular epithelium, however, this is only partly true. Proximal 
tubule cells have particular high metabolic activity/demand of these cells; there is 
physiological hypoxia in the medullary region, and these cells experience a high exposure 
to intra-tubular toxins (Bonventre and Yang 2011). Studies show that stressing the kidney 
leads to an increase in cellular proliferation, yet, this stress also induces cell cycle inhibitors. 
It is thought that up to 40% of cells express cyclin D1, suggesting cells are in the mid-to-late 
G1 phase (Witzgall et al. 1994; Vogetseder et al. 2008; Moonen et al. 2018). Additionally, 
nearly all these cells were immunoreactive for p27, a cyclin dependent kinase inhibitor that 
blocks cell cycle progression and keeps cells in the G1 phase (Iwakura et al. 2014). 
Furthermore, studies looking into acute kidney injury suggest there is a rapid induction of 
p21, which is thought to contribute to arresting proximal tubule cells in the G1 phase (Price 
et al. 2009). It is assumed that proximal tubule cells have a physiological G1 arrest that, after 
toxic insult, ensures cells can initiate proliferation extremely rapidly. Proximal tubule cells 
in the kidney have a remarkably strong inherent ability to regenerate after injury 
(Moonen et al. 2018). Replacement of lost proximal tubule cells does not involve 
specialised progenitors, but the proliferation of proximal tubule cells themselves is the 
key of renal repair (Humphreys et al. 2011). Perhaps FLCN is important for the priming of 
these cells to respond to damage faster. In the absence of FLCN the intricate balance 
between pro- and anti-proliferative signals is tipped in favour of pro-proliferation at the 
G1/S boundary; reducing available time for DNA repair. The majority of cells proliferate 
out of damage, however, overtime in the absence of FLCN, the propagation of genetic 
defects leads to transformation of proximal tubule cells. Only a handful of cell cycle 
regulators (e.g., p53, p21) have been thoroughly studied during renal repair (Moonen et 
al. 2018). How and why proximal tubule cells decide to arrest their cell cycle and how this 
arrest can be overcome remains unanswered and are challenging questions to address.   
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Figure 6.9. Troubleshooting the use of Edu as an S phase marker in HK2 cells. LP-WT cells were 
treated with 8µM of Edu in the absence of DRAQ5 and left for up to 24 h, were stated cells were 
treated with IR. A) Cells were isolated from debris B) Antibody free control was used to establish 
background florescence. C) Graph showing the effect of increasing dose of IR on Edu incorporation in 
LP-WT cells over 24 h. Data displayed for No IR – 10 Gy IR dose are averages of 3 independent 
experiments, error bars represent standard deviation; data displayed for 15 – 50 Gy IR is from a 
single experiment. The trendline and R2 were calculated in Microsoft excel.  
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Table 6.1 Two-way ANOVA analysis of Edu incorporation in LP-WT cells subjected to increasing 
dose of IR (2-50 Gy) over time (0-24 h). Two-way ANOVA analysis was performed in GraphPad 
Prism4. 
 
 
 
 
Two-way ANOVA Summary 
Source of variation  % of total variation  Pvalue 
Interaction 0.85 0.9852 
IR dose 1.00 0.6584 
Time 61.83 P<0.0001 
No IR vs 2Gy 
Time (h) No IR (% cells Edu) 2Gy (% cells Edu) Pvalue 95% CI of diff. 
0 0.8783 0.2870 P > 0.05 -25.64 to 24.45 
6 27.30 32.60 P > 0.05 -19.75 to 30.35 
24 65.07 66.40 P > 0.05 -23.71 to 26.38 
No IR vs 5Gy 
Time (h) No IR (% cells Edu) 5Gy (% cells Edu) Pvalue 95% CI of diff. 
0 0.8783 0.3800 P > 0.05 -25.54 to 24.55 
6 27.30 39.17 P > 0.05 -13.18 to 36.91 
24 65.07 70.60 P > 0.05 -19.51 to 30.58 
No IR vs 10Gy 
Time (h) No IR (% cells Edu) 10Gy (% cells Edu) Pvalue 95% CI of diff. 
0 0.8783 1.173 P > 0.05 -23.13 to 23.72 
6 27.30 32.40 P > 0.05 -18.33 to 28.53 
24 65.07 65.03 P > 0.05 -23.47 to 23.39 
No IR vs 15Gy 
Time (h) No IR (% cells Edu) 15Gy (% cells Edu) Pvalue 95% CI of diff. 
0 0.8783 2.870 P > 0.05 -33.43 to 37.41 
6 27.30 26.00 P > 0.05 -36.72 to 34.12 
24 65.07 59.20 P > 0.05 -41.29 to 29.55 
No IR vs 20Gy 
Time (h) No IR (% cells Edu) 20Gy (% cells Edu) Pvalue 95% CI of diff. 
0 0.8783 1.120 P > 0.05 -35.18 to 35.66 
6 27.30 24.40 P > 0.05 -38.32 to 32.52 
24 65.07 61.90 P > 0.05 -38.59 to 32.25 
No IR vs 50Gy 
Time (h) No IR (% cells Edu) 50Gy (% cells Edu) Pvalue 95% CI of diff. 
0 0.8783 2.500 P > 0.05 -33.80 to 37.04 
6 27.30 21.40 P > 0.05 -41.32 to 29.52 
24 65.07 55.10 P > 0.05 -45.39 to 25.45 
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6.3 Conclusion 
 
As previously discussed, FLCN has been linked to the cell cycle. This chapter attempted to 
explore the G1/S phase transition control in more detail in HK2 cells. Similar to previous 
reports, FLCN knockdown lead to an increase in cyclin D1 levels. Results in this chapter show 
that the increase in cyclin D1 levels is a direct result of FLCN loss. This data supports 
previously proposed observations of heightened Cyclin D1 expression shown in HeLa cells 
and in vivo mouse tumour cells (Baba et al. 2008; Kawai et al. 2013), consolidating this as a 
genuine biological observation; not artefacts of already malignant cells. The cyclin D1 
pathway is disrupted in all human cancers leading to increased cell proliferation through 
shortening of the G1/S checkpoint control (Kim and Diehl 2009). In line with this, the 
increase in cyclin D1 levels observed in the LP-KD cells coincide with an increase in p-Rb 
under DNA damage. Furthermore, FLCN knockdown led to a decrease in the percentage of 
cells in the G1 phase and increased the percentage of cells in the G2 phase of the cell cycle 
(figure 6.5). These observations again agree with current literature, where it was shown that 
reintroduction of FLCN in zebrafish embryos lead to a significant decrease in cells in the S-
M phase of the cell cycle with a corresponding increase of cells in the G1 phase (Kenyon et 
al. 2016). In zebrafish, no increase in cyclin D1 levels were observed. However, it does 
suggest FLCN’s roles in G1/S transition is conserved between species and is not exclusive to 
mammalian models.   
Collectively, results indicate that loss of FLCN promotes modest G1/S phase 
checkpoint skipping, with cells inappropriately committing to cellular division. However, 
the exact nature of FLCN’s control on the cell cycle remains to be determined. It will be 
interesting to find out how FLCN’s role in cyclin D1 inhibition relates to its published role in 
G2/M phase promotion, and mitotic spindle association; do these studies show snapshots of 
different portions of a single, large, cell cycle regulatory pathway, or does FLCN function 
independently in multiple pathways in order to fine tune cell cycle regulation? Perhaps the 
specific development of kidney cancer in BHD patients is a reflection of the requirement of 
FLCN to help facilitate DNA damage repair during cell cycle progression in acute conditions 
of cellular stress that is present in the kidney. 
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Thesis chapter 7: Overall discussion  
 
The tumour suppressor FLCN has been implicated in a diverse range of cellular processes, 
including cellular trafficking, energy homeostasis and stress sensing. Collectively, the 
literature suggests a range of cell-type specific functions for FLCN. Within kidney cells, FLCN 
has been shown to regulate mTOR and AMPK signalling, mitochondrial biogenesis, cilium 
formation and cell polarity, and endocytic trafficking (Baba et al. 2008; Chen et al. 2008; 
Hasumi et al. 2009; Hasumi et al. 2012; Nahorski et al. 2012; Laviolette et al. 2017). FLCN 
loss is associated with RCC, were metabolic reprogramming is an integral part of cellular 
transformation (Zhang et al. 2014b). Uniquely, however, FLCN loss can lead to all 
histological subtypes of RCC, including hybrid tumours. It is currently unclear why such 
heterogeneity exists as a result of FLCN loss. Work within this thesis aimed to better 
understand the molecular role of FLCN loss in renal cell transformation. Preliminary work 
highlighted several potential FLCN interactors that have a role in DNA damage sensing or 
repair. DNA damage is a common occurrence for all cells and is a substantial risk to genetic 
stability. Indeed, genetic instability is an underlying driver of tumour development that is 
perpetuated by failures in the DNA repair processes (Mills et al. 2003; Negrini et al. 2010). 
As such, the focus of this thesis was to explore a novel role for FLCN within genomic 
maintenance. Given that FLCN loss exhibits intertumoral diversity it was hypothesised that 
FLCN plays an important housekeeping role to maintain genetic stability at the level of DNA 
damage repair. 
 
There are three key findings within this thesis; (1) a novel protein-protein interaction 
between FLCN and the DNA-damage responder DNA-PKcs was identified (2) FLCN 
knockdown lead to an increase in DSBs, as indicate by elevated γH2AX, and (3) FLCN 
knockdown lead to a perturbed G1/S phase transition control. The implications for these 
roles in the larger context of BHD and RCC, along with future research directions are 
discussed further within this chapter. A schematic illustration summarising FLCN’s currently 
known cellular roles and how the findings of this thesis might relate can be found in figure 
7.1.  
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Figure 7.1 A schematic illustration summarising FLCN’s currently known cellular roles. Proteins and actions coloured red hypothesise how 
findings within this thesis might fit within the current FLCN literature. This is discussed in detail within chapter 7.  
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7.1 A novel protein-protein interaction: FLCN/DNA-PKcs  
 
Perhaps the most exciting finding presented in this thesis is the interaction between FLCN 
and DNA-PKcs, a DSB sensor and mediator of NHEJ DNA repair. This implicates FLCN in the 
DDR. Indeed, FLCN knockdown lead to an increase in γH2AX, a marker of double strand 
breaks, in both basal and irradiated cells (figure 5.4). FLCN is unlikely to be a substrate of 
DNA-PKcs as incorporation of 32P did not increase upon DNA-PK activation with the addition 
of short dsDNA (figure 5.1). However, IR did weaken the protein-protein interaction in a 
dose dependent manner (figure 3.8C), revealing that this interaction is regulated upon IR 
treatment. FLCN knockdown did not apparently affect DNA-PKcs ability to become activated 
after DSB damage, as indicated by no change to Ser2056 phosphorylation of DNA-PKcs 
between wild type and knockdown cells (figure 5.4). Neither did FLCN loss contribute to mis-
localisation of DNA-PKcs under both basal and DNA damaged states (data not shown). 
DNA-PKcs is an extremely abundant protein. It is estimated that cells contain around 
100,000 copies of DNA‐PKcs (Anderson 1996). This is far in excess of what is needed for 
NHEJ, as only one DNA‐PKcs binds to each DSB (Sibanda et al. 2017). Furthermore, is has 
been published that DNA‐PKcs is not only present in the nucleus of a cell, but also in the 
cytoplasm (Huston et al. 2008). To date DNA-PKcs has been linked to various cytoplasmic 
pathways, including EGFR and NFκB signalling, mRNA metabolism, and the cytoskeleton 
(Panta et al. 2004; Dittmann et al. 2005; Szumiel 2006; Berglund and Clarke 2009). The most 
interesting emerging evidence, however, links DNA-PKcs to the regulation of energy 
homeostasis. While contradictory in the specifics, an overwhelming number of studies into 
FLCN’s cellular function is associated to energy homeostasis, including regulatory roles in 
metabolic signalling, autophagy, and hypoxia (Baba et al. 2006; Baba et al. 2008; Preston et 
al. 2011; Dunlop et al. 2014; Yan et al. 2014). Moreover, RCC is considered a metabolic 
disease, where undergoing metabolic reprogramming is an essential hallmark of 
carcinogenesis (Choyke et al. 2003; Zhang et al. 2014b; Wettersten et al. 2015; Li et al. 
2018). Another point worth mentioning is DNA-PKcs alone cannot bind DNA. Its interaction 
with the Ku complexes (Ku70/80) at DBS ends is essential for DNA-PKcs DNA binding 
(Leesmiller et al. 1992; Anderson 1996; Baumann and West 1998). This interaction is strong, 
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however, neither Ku70 nor Ku80 were identified in the FLCN protein interaction analysis 
(chapter 3). Collectively, this supports the idea that the FLCN/DNA-PKcs interaction might be 
independent of DNA damage sensing and/or direct repair.  
 
7.1.1 A role for FLCN/DNA-PKcs in mTOR signalling  
Multiple studies have linked DNA-PKcs activity to cellular metabolism. DNA-PKcs itself is 
regulated by the metabolic state of a cell, where it is active under fed conditions and 
inhibited during fasting (Wong et al. 2009). DNA-PKcs is thought to be a positive regulator of 
mTOR signalling, specifically mTORC2. DNA-PKcs has been shown to physically interact 
with two key components of mTORC2 activation; stress-activated protein kinase 
interacting protein 1 (SIN1) and rapamycin-insensitive companion of mTOR (Rictor) (Yang et 
al. 2006; Cameron et al. 2011; Zheng et al. 2016). In RCC, DNA-PKcs is commonly 
overexpressed and is thought to act as an oncogene by promoting cell proliferation (Zheng 
et al. 2016). Indeed, when in complex with SIN1, DNA-PKcs was shown to phosphorylate 
AKT at serine 473 (Zheng et al. 2016). In turn, phosphorylated AKT activates mTORC2 to 
promote proliferation. DNA-PKcs activity towards mTORC1, on the other hand, is less 
clear. Evidence suggests it does not interact with components required for mTORC1 
activation (raptor, LST8, PRAS40 and deptor) (Zheng et al. 2016), and DNA-PKcs depletion 
did not change mTORC1 activity under basal conditions or in response to etoposide 
(Puustinen 2018a). Several studies, however, have shown the usefulness of dual inhibitors 
that target both DNA-PKcs and mTOR. Targeting DDR and mTOR signalling has a potent 
anti-tumour activity against a large panel of hematopoietic and solid cancer cell lines 
resulting in a reliable induction of apoptosis in a subset of cancer lines (Shortt et al. 2013; 
Mortensen et al. 2015; Munster et al. 2016; Tsuji et al. 2017). The dual DNA-PKcs/mTOR 
inhibitors explored so far inhibit both mTORC1 and mTORC2, and it’s currently not clear if 
the potency comes from targeting two independent, synthetically lethally, pathways 
(DNA-PKcs/mTORC1) or synergistically targeting overlapping pathways (DNA-
PKcs/mTORC2).  
FLCN’s function in mTOR is complicated. Collectively, however, the data suggests 
that in kidney cells FLCN can inhibit both mTORC1 and mTORC2 (Baba et al. 2008; Chen et 
 151 
 
al. 2008; Hasumi et al. 2009; Petit et al. 2013; Tsun et al. 2013). However, the mechanism 
of how FLCN controls both mTORC1 and mTORC2 function is less clear. The most 
convincing evidence suggests FLCN regulation of mTOR occurs at the lysosome. FLCN was 
shown to interact with components of the ‘ragulator’ complex required for mTORC1 
activation. Specifically, FLCN was shown to interact with the GTPase domain of RagA when 
RagA is GDP bound (inactive form). The preferential binding to the GDP-bound form of a 
small GTPase is a property commonly seen in GEFs, suggesting it may function as a GEF 
towards RagA/B (Petit et al. 2013). Furthermore, FLCN was also shown to act as a GAP 
towards RagC/D (Tsun et al. 2013). In recent years, FLCN has also been demonstrated to act 
as a GAP towards RagA (Meng and Ferguson 2018). It is possible that FLCN binds to 
RagA/BGDP in a GEF-like manner that does not lead to nucleotide exchange. Rather it allows 
FLCN to be in close proximity to RagC/D and thus help facilitate GAP activity toward RagC/D 
(either directly as a GAP, or indirectly via an associated GAP protein). Such a pseudoGEF-
GAP function for FLCN toward RagA/B and RagC/D likely helps to tightly coordinate 
nucleotide status within Rag heterodimers. 
Regulation of mTOR activation at the lysosomes, specifically refers to mTORC1. 
mTORC1 is extremely dependent on cellular energy status, cell type, and FLCN being in 
complex with either FNIP1 or FNIP2. On the other hand, little is known about FLCNs 
involvement with mTORC2 activity. The mTORC2 target, AKT has been shown to be 
hyperphosphorylated at Ser473 in FLCN knockdown cells, and FLCN was demonstrated to 
physically interact with the mTORC2 regulator SIN (Mathieu et al. 2019). It has been 
suggested that the FLCN/SIN1 interaction may negatively regulate mTORC2 activity by 
preventing mTORC2/SIN1 interaction (Mathieu et al. 2019). However, this has yet to be 
biochemically proven. Given that DNA-PKcs promotes and FLCN likely inhibits mTORC2 by 
binding to SIN, perhaps the FLCN/DNA-PKcs interaction represents another layer of 
mTORC2 regulation?   
7.1.2 A role for FLCN/DNA-PKcs in autophagy  
Autophagy is a complex and highly regulated homeostatic process. Autophagy allows cells to 
efficiently remove defective organelles and molecules, and to recycle nutrients 
for survival under deprived conditions (Levine and Kroemer 2008; Mizushima et al. 2008; 
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Mizushima et al. 2011). Consequently, dysregulation in the normal rates of autophagy can 
result in a metabolic imbalance and disease (Levine and Kroemer 2008). Classic 
autophagy involves a process that uses a ubiquitin-like cascade of autophagy-related 
(ATG) proteins leading to the formation of double-membrane autophagosomes (Mizushima 
et al. 2011). Autophagosomes ultimately fuse with lysosomes targeting the cargo for 
proteolytic degradation (He and Klionsky 2009). An emerging body of evidence has 
associated autophagy with the DDR and suggest it is an integrated part of the genome 
surveillance network (Abedin et al. 2007; Katayama et al. 2007; Rieber and Rieber 2008). 
This overlap of processes likely co-ordinate the turnover of key DDR proteins, remove 
damage macromolecules, and to regulate the supply of ATP, NAD+, and dNTPs that are 
necessary to repair DNA (Rello-Varona et al. 2012; Eliopoulos et al. 2016).  
 
DNA-PKcs has been linked to autophagy (Paglin et al. 2001; Yao et al. 2003; Zhuang 
et al. 2011). DNA-PKcs knockdown or inhibition sensitises cells to IR-induces autophagy 
response and inhibition of autophagy can block DNA-PKcs dependent autophagic response, 
suggesting DNA-PKcs may negatively regulate autophagy (Zhuang et al. 2011). However, 
from these results it’s unclear if DNA-PKcs response in autophagy is a general phenomenon 
or specifically DNA damage induced, or if the DNA-PKcs kinase activity is required for the 
response. (Paglin et al. 2001; Yao et al. 2003; Daido et al. 2005). On the other hand, DNA-
PKcs has been demonstrated to be a positive regulator of autophagy through a direct 
regulation of AMPK (Amatya et al. 2012; Lu et al. 2016; Puustinen 2018b). DNA-PKcs was 
demonstrated to interact with the regulatory gamma subunit of AMPK (AMPKγ), where it 
has been shown to phosphorylated AMPKγ at Ser192 and Thr284. (Amatya et al. 2012; Lu et 
al. 2016; Puustinen 2018a). Alanine substitutions of these DNA-PKcs-dependent 
phosphorylation sites in AMPKγ inhibited the lysosomal localisation of AMPK and its 
starvation-dependent association with LKB1 (Puustinen 2018b). The lysosomal membrane 
has been recently recognised as an important site for the activation of AMPK (Zhang et al. 
2014a; Zhang et al. 2017). In the absence of glucose, LKB1 and scaffold protein AXIN 
translocate to the lysosomal membrane, where they form a large complex with AMPK, 
vacuolar H+-ATPase and the ragulator complexes (Zhang et al. 2014b). This super complex 
serves as the site for LKB1-mediated phosphorylation and activation of AMPK alpha subunit 
(AMPKα) (Zhang et al. 2014b). Mechanistically, it is thought that the DNA-PKcs-mediated 
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phosphorylation of AMPKγ primes AMPK for lysosomal activation. AMPK is a master 
regulator catabolic processes, including autophagy. AMPK promotes autophagy through 
Unc-51 like autophagy activating kinase (ULK1). AMPKγ subunit physically interacts with 
ULK1 and this interaction is required for the induction of autophagy (Lee et al. 2010). 
Multiple studies have identified numerous AMPK-dependent phosphorylation sites on ULK1 
(Egan et al. 2011; Kim et al. 2011; Shang et al. 2011). These studies often contradict each 
other as they identify AMPK-dependent phosphorylation sites unique to individual studies 
with very little consensus between them. Therefore, it’s unclear where AMPK 
phosphorylates ULK1 and mechanistically what the function of these phosphorylation sites 
maybe (Egan et al. 2011; Kim et al. 2011; Shang et al. 2011). Nevertheless, the evidence 
agrees that energy deprivation activates AMPK, which in turn activates ULK1 to initiate 
autophagy.  
FLCN’s role in autophagy is complicated. FLCN has been shown to inhibit the activity 
of autophagic transcription factors TFEB and TFE3 (Petit et al. 2013; Martina et al. 2014) and 
autophagy is increased in dBHD-null Drosophila (Liu et al. 2013b). Furthermore, FLCN has 
been shown to inhibit LC3B and stimulate LC3C autophagic activity (Bastola et al. 2013). 
LC3s are structural proteins of autophagosomal membranes that act as scaffolding proteins. 
The human LC3 family has three members, LC3A, LC3B and LC3C. LC3B is commonly 
upregulated in RCC and LC3B-mediated autophagy is often needed for tumour progression. 
LC3C, on the other hand, has tumour suppressor activity (Mikhaylova et al. 2012). It is 
currently unclear how LC3C acts as a tumour suppressor. LC3C could be a part of an 
unidentified autophagic pathway or could participate in a non-autophagic tumour-
suppressing pathway. FLCN may therefore inhibit the oncogenic LC3B and promotes the 
anti-tumour activity of LC3C. Collectively, these results suggest that FLCN usually inhibits 
autophagy, at least in vitro and in Drosophila. In contrast, however, autophagic flux was 
found to be reduced in mice primary cardiac cells, mouse embryonic fibroblasts, HK2 cell 
lines, and BHD-associated RCC (Dunlop et al. 2014; Hasumi et al. 2014). FLCN was 
demonstrated to enhance basal autophagic flux through its interaction with the autophagic 
proteins GABARAP and ULK1, acting as a positive regulator of autophagy in mammalian 
cells. 
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The functional relevance of autophagy in tumour formation and progression remains 
unclear. Autophagy seemingly has a paradoxical role in modulating cancer progression as it 
has been demonstrated to have both oncogenic and tumour suppressive roles. 
Collectively, it is thought that the effect autophagy has on tumour cell fate depends on 
the cancer type, stage, and genetic context (Eisenberg-Lerner and Kimchi 2009; Singh et 
al. 2018). Autophagy initially safeguards cells by preventing a build-up of toxic cellular 
waste products and preserve organelle function. However, as cancer progresses, the 
stress-mitigating properties of autophagy are hijacked by tumour cells to meet the 
heightened metabolic requirements necessary for tumour survival and rapid proliferation 
(White 2012; Singh et al. 2018). It would be interesting to see DNA-PKcs effects on AMPK-
dependent activation of autophagy, such as ULK1 activation, and if FLCN knockdown alters 
this. Furthermore, it is well established that AMPK is hyperactive upon FLCN loss. The 
mechanistic reason(s) for this are unknown to date and AMPK localisation to the lysosomes 
following FLCN loss has not yet been published, could FLCN be involved in the DNA-PKcs-
dependent localisation and activation of AMPK? 
7.1.3 A role for FLCN/DNA-PKcs in hypoxic signalling  
Another emerging aspect in which DNA-PKcs functions outside of DDR is hypoxia. Hypoxia is 
defined as the reduction or lack of oxygen in cells. The hypoxic response plays a critical role 
in cell biology and disease development; particularly in cancer, where solid tumours 
consume high amounts of oxygen despite inadequate vascularisation.  
Hypoxia-inducible factors (HIFs) are the central transcription factors regulating the 
cellular response to hypoxia. There are three known isoforms of HIF subunits; HIF1α, HIF2α, 
and HIF3α (Kondo et al. 2002; Yang et al. 2017). The functions of HIF1α and HIF2α are 
relatively well known, whereas little is known about the specific function of HIF3α due to its 
late discovery and low expression levels (Yang et al. 2017; Pezzuto and Carico 2018). Overall, 
HIFs play distinct and overlapping functions in various cell types (Yang et al. 2017). HIFs are 
commonly over-expressed in numerous cancers where they activate a number of hypoxia-
related genes required for adaptation to low oxygen levels (Wenger et al. 2005; Pezzuto and 
Carico 2018). Interestingly, DNA-PKcs is activated by hypoxia and was shown to positively 
regulate both HIF1α and HIF2α (Um et al. 2004; Wenger et al. 2005; Bouquet et al. 2011). 
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(Toschi et al. 2008). DNA-PKcs-dependent activation of HIFs was shown to be independent 
of DSBs (Zheng et al. 2016). Combined, these studies present the novel concept that co-
ordinated regulation between DNA-PKcs and the HIF family of transcription factors may 
influence cellular response to oxygen depletion. It would be interesting to see if FLCN 
knockdown alters these functions. FLCN is thought to negatively regulate HIF1α and HIF2α 
as FLCN loss correlates with increase in HIF gene expression (Lu et al. 2011; Preston et al. 
2011; Nishii et al. 2013). Indeed, increase in HIF2α is commonly observed in BHD-associated 
RCC (Lu et al. 2011; Preston et al. 2011). Moreover, HIF2α induces oncogenic CCND1 
expression in RCC cell lines, yet CCND1 expression is not hypoxia inducible in non-RCC 
cancer cell lines (Raval et al. 2005). This could represent a mechanism for cellular 
transformation unique to RCC.  
 
7.1.4 Conclusion  
The understanding of DNA-PKcs’ cellular function is moving beyond its classical role as a 
component of DDR. Recent findings illuminate a multi-faceted role for DNA-PKcs that affect 
numerous tumour-associated pathways. These effects can be both depend and independent 
of DNA damage. An interesting observation is that DNA-PKcs seems to promote both mTOR 
signalling and autophagy. Perhaps then the transformative process in BHD-associated RCC 
involves inappropriate cell growth via upregulated catabolic processes (mTOR) which are 
constantly fed via an upregulation of anabolic processes (AMPK, autophagy). Could FLCN act 
to regulate DNA-PKcs oncogenic tendencies? Given FLCN’s extensive links to energy 
homeostasis, it would be interesting to explore the activity of DNA-PK under nutrient and/or 
oxygen deprivation following FLCN loss. 
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7.2 FLCN knockdown results in an increase of DNA double-strand breaks (DSB) 
 
Daily, a wide range of insults damage cellular DNA and continuously challenging genome 
integrity. These can be physical or chemical insults that directly damage DNA bases, or 
errors incorporated during DNA replication (Hoeijmakers 2001). To prevent the harmful 
consequences of genotoxic stress, organisms have evolved a complex network of genome 
surveillance mechanisms. These are designed to maintain the genomic integrity, or to 
eliminate hazardous cells when DNA damage is beyond repair (Jackson and Bartek 2009; 
Ciccia and Elledge 2010). DSB are considered the most lethal DNA insult and can lead to 
large chromosomal rearrangements if not repaired. FLCN knockdown in HK2 cells lead to an 
increase in γH2AX, suggesting these cells have an increase in DSBs (figure 5.4). Additionally, 
FLCN knockdown did not make cells hypersensitive to IR. Suggesting cells can tolerate the 
increase in DSB observed. Indeed, initial analysis hints that FLCN knockdown cells may 
recover more readily to DNA insults than wild type cells (figure 5.6).  
7.2.1 Exploring the cause of the increase in DSB upon FLCN loss 
At present, it is unclear why cells accumulate DSB upon FLCN knockdown. It would be 
interesting to expand on the increase in γH2AX observed; are they the result of replication 
stress, increased metabolic burden, or are DSB repair mechanisms compromised as a result 
of FLCN loss? Below these questions are discussed in more detail.  
7.2.1.1 Replication stress as a cause for increase in DSBs 
 
Although replication stress is widely recognised as a significant problem for genome 
stability, there is currently no unifying description of this phenomenon. Nor is there a clear 
set of cellular markers which unambiguously characterise this state. The most widely 
accepted definition considers replication stress as the slowing or stalling of replication fork 
progression and/or DNA synthesis (Zeman and Cimprich 2014). Replication stress can be 
generated by a wide range of physical obstacles that usually results in stretches of single-
stranded DNA (ssDNA). The ssDNA frequently form when the replicative helicase continue to 
unwind the parental DNA after the polymerase has stalled (Pacek and Walter 2004). 
However, DSBs can occur as a result of collapsed replications forks when stalling is not 
overcome. Many markers that are used to detect replication stress reflect the activation of 
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the ATR repair pathway, including γH2AX. γH2AX can be generated by numerous kinases, 
which detect different types of DNA damage throughout the cell cycle. Therefore, it is not a 
useful marker to isolate replication stress. ATR-dependent phosphorylation of RPA or Chk1, 
or the direct detection of ssDNA, are more reliable indicators of replication stress (Marechal 
and Zou 2013; Zeman and Cimprich 2014). Within this thesis ATR activation was not affected 
by FLCN knockdown, and Chk1 phosphorylation, while possibly elevated in response to IR 
compared to wild type cells, had an inconsistent response (figure 5.4C). On the other hand, 
RPA gene expression is increased upon FLCN knockdown. It should be noted that the use of 
ATR substrates or ssDNA accumulation as markers of replication stress assumes that the 
stress is sufficient to activate ATR to a high enough level to induce widespread 
phosphorylation of its downstream targets, or that the stress generates large enough 
patches of ssDNA that they are readily detectable, neither of which is necessarily true 
(Koundrioukoff et al. 2013). For example, the cell may experience replication stress at one 
or a few stalled forks and respond locally, but not globally, to that stress (Koundrioukoff et 
al. 2013). There is also evidence that replication stress can be induced by protein-DNA 
complexes or inter-strand DNA crosslinks that do not accumulate ssDNA from helicase-
polymerase uncoupling (Marechal and Zou 2013). These structures may be resolved by 
other repair pathways without activating ATR (Zeman and Cimprich 2014). Therefore, it may 
be worth co-ordinating the induction of γH2AX with a phase of the cell cycle, in the first 
instance, to help establish the cause of the DSB observed in response to FLCN loss.   
 
7.2.2 Metabolic burden as a cause for increase in DSBs 
7.2.2.1 Reactive oxygen species (ROS) 
 
One of the most cited observations following FLCN loss is the upregulation of mitochondrial 
biogenesis (Klomp et al. 2010; Lindor et al. 2012; Pradella et al. 2013; Raymond et al. 2014; 
Wada et al. 2016; Yan et al. 2016a). This is accompanied by an increase in mitochondrial 
ROS. An increase in ROS has long been associated with cancer (Moloney and Cotter 2018). 
ROS are primarily oncogenic, causing oxidative damage to DNA, proteins, and lipids (Liou 
and Storz 2010; Roy et al. 2015; Moloney and Cotter 2018). Overtime, this damage 
accumulates and promotes cellular transformation. Indeed, high or sustained levels of ROS 
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contribute to the development of cancer (Martien and Abbadie 2007; Ralph et al. 2010; 
Verbon et al. 2012), as shown by the inhibitory effects of antioxidants on tumour formation 
(Zhang et al. 2002). Furthermore, ROS have been demonstrated to generate DSB. Chronic 
exposure to ROS resulted in oxidative clustered DNA lesions (OCDLs), closely spaced 
oxidative lesions (within 20bp) that result in the breakdown of double strand interactions. 
ROS is thought to be the largest cause of DSB during G1 phase of cell cycle. In addition, NHEJ 
is thought to be the primary repair pathway for oxidative DSBs. Cells become hypersensitive 
to ROS stress when components of NHEJ (e.g. DNA-PKcs, Ku 70/80, X-ray repair cross-
complementing protein 4 (XRCC4), and DNA ligase 4 (Lig IV)) are compromised. This 
hypersensitivity to ROS is above that observed when HR is prohibited (Karanjawala et al. 
1999; Karanjawala et al. 2002; Woodbine et al. 2011; Dolan et al. 2013; Sharma et al. 2016).  
A simple explanation, therefore, would be that FLCN loss results in an increase in 
mutagenic ROS through dysregulation of mitochondria. This promotes DSB via oxidative 
clustered DNA lesions. Surprisingly, however, it’s been reported that the increase in 
mitochondrial ROS production in FLCN knockdown cells did not increase oxidative DNA 
bases to a statistically significant level in mouse embryonic fibroblasts (Yan et al. 2014). 
Instead the authors showed ROS acted as a signalling molecule to enhance HIF 
transcriptional activity (Yan et al. 2014). OCDLs can have a combination of different DNA 
lesions including abasic sites, SSBs and oxidative damaged bases. However, the most reliable 
method for detecting OCDLs is pulse field gel electrophoresis (PFGE). Nevertheless, if the 
increase in ROS contributed to the aetiology of BHD-associated RCC by causing OCDLs-
induced DSB, a notable increase in oxidative DNA indicated by 8-hydroxydeoxyguanosine (8-
OHdG) ELISA, as used in the study, theoretically should have been detected. Therefore, 
current evidence doesn’t support the increase in DSBs upon FLCN loss to be caused by ROS.  
 
7.2.2.2 Hypoxia-associated γH2AX 
 
Under hypoxic conditions, several cancer cell lines have been noted to have HIF-dependent 
accumulation of γH2AX (Economopoulou et al. 2009; Wrann et al. 2013; Goodwin and 
Knudsen 2014). RNAi knockdown of either HIF-1α or HIF-2α reduced observable γH2AX, 
which can be further reduced by knockdown of both HIF-1α and HIF-2α. Interestingly, no 
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detectable levels of DSBs were observed following the HIF-dependent accumulation of 
γH2AX (Wrann et al. 2013). Suggesting this may be a damage independent mechanism. One 
idea is that increase in γH2AX allows for more relaxed chromatin and might increase a 
cancer cell's capacity to repair DNA damage or promote HIF target gene transcription 
providing cells with a selective advantage in conditions with reduced oxygen (Wrann et al. 
2013; Goodwin and Knudsen 2014).  
 
Furthermore, reduced oxygen levels may prohibit effective repair of DSB. Residual 
DSBs were observed 24 hours after IR under long term hypoxia. Previous studies that have 
investigated DNA repair during hypoxic irradiation conditions were followed by re-
oxygenation, and concluded that the mutation rate and DSB repair rate were not influenced 
by hypoxia (Olive and Banath 2004; Kumareswaran et al. 2012). However, DNA repair under 
continued hypoxia leads to decreased repair of G1-associated DSBs (Kumareswaran et al. 
2012). NHEJ is the predominant DSB repair pathway in the G1 phase of the cell cycle 
(Shrivastav et al. 2008). Due to the increase in G1-associated DSBs, it is thought that NHEJ 
may be compromised under hypoxia. This might, in part, explain the increased genetic 
instability observed in hypoxic cells that adapt to low oxygen conditions. There are 
conflicting data in the literature regarding the effect hypoxia has on NHEJ repair. NHEJ-
related genes have been shown downregulated at mRNA and protein levels in both normal 
and malignant hypoxic cells (Meng et al. 2005). By contrast, the apical protein of NHEJ, DNA-
PKcs has been demonstrated to have increased activity under hypoxic conditions (Um et al. 
2004). However, neither of these studies directly measured DSB repair in chronically hypoxic 
cells. The mechanism by which hypoxia may alter NHEJ is not known. More studies are 
required to test whether hypoxia leads to a defect in both DNA-PKcs-dependent and/or 
DNA-PKcs-independent NHEJ pathways throughout the cell cycle. As previously mentioned, 
FLCN is thought to inhibit HIF signalling (Preston et al. 2011). It would be tempting to 
speculate the increase in γH2AX could be HIF-driven. However, γH2AX was observed under 
normal oxygen conditions. While an upregulation of HIFs seems to promote γH2AX foci, its 
unclear whether HIFs upregulation alone is enough to drive γH2AX foci or if hypoxic 
conditions are essential for this. Nevertheless, it may be interesting to explore the increase 
in γH2AX observed in FLCN knockdown cells under the context of HIF signalling.  
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7.2.3 Defective repair mechanisms as a cause for increase in DSBs 
Leading on from the idea of a hypoxia induced comprise to NHEJ repair of DSBs, it would be 
interesting to explore if DSB repair kinetics are altered in FLCN knockdown cells. DNA-PKcs 
interaction with FLCN was weakened by IR (figure 3.8C), suggesting there is regulation over 
their interaction. However, activation of DNA-PKcs is not altered in FLCN knockdown cells 
(figure 5.4). Due to time constraints, downstream NHEJ components were not investigated. 
Co-localisation between key NHEJ factors (such as XRCC4 , Lig IV, and XRCC4‐like factor 
(XLF)) and DSB are often used as markers on NHEJ (Costantini et al. 2007; Yano et al. 2008; 
Chatterjee and Walker 2017). Another common marker for cells undergoing NHEJ repair is 
p53-binding protein 1 (53BP1). 53BP1 plays an important regulatory role by recruiting the 
NHEJ components to the DNA break site, and activating checkpoint signalling (Panier and 
Boulton 2014).  
Furthermore, NHEJ is error prone process. It can result in fusing mismatched DNA 
ends, fusing ends that contains damaged bases, loss of DNA sequence by haphazardly 
stitching DNA ends together, and even large chromosomal translocations or chromosome 
fusion (Shrivastav et al. 2008). HR on the other hand, uses an intact sister chromatid as a 
template. This process is normally accurate but is only available during late S phase and 
G2/M checkpoint, after DNA replication. The decision of which DSB repair pathway to use is 
a highly controlled process. Interestingly, one of the key regulators of this decision is BRCA1. 
Specifically, BRCA1 promotes 53BP1 dephosphorylation and RIF1 release, favouring repair 
by HR (Ciccia and Elledge 2010; Isono et al. 2017). BRCA1 was found hyperphosphorylated in 
FLCN knockdown cells in response to DNA damage. Could this represent a compensatory 
mechanism whereby HR in G2 is working to overcome unrepaired DSB from G1, or as a 
result of malfunctioning NHEJ? It would be interesting to compare the recruitment of NHEJ 
components upon FLCN knockdown to see if NHEJ repair is perturbed. In addition, it would 
be interesting to compare the efficiency of NHEJ and HR repair of DSBs following FLCN 
knockdown to investigate if FLCN plays a role in repair kinetics.  
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7.2.3.1 Compromised DNA repair through nuclear accumulation of the autophagic regulator 
Sequestosome 1 (SQSTM1/p62) 
 
Sequestosome 1 (SQSTM1/p62) is a regulator of autophagy and is often upregulated in RCC 
(Liu et al. 2015). Interestingly, SQSTM1/p62 is emerging as an important mediator of the 
effects of autophagy on DNA damage repair. Nuclear SQSTM1/p62 has been shown to bind 
RNF168, inhibiting its E3 ubiquitin ligase activity toward histone H2A. The accumulation of 
nuclear SQSTM1/p62, driven by a loss of autophagy, decreases chromatin ubiquitination. In 
turn, this hinders the recruitment of DNA repair proteins such as BRCA1, RAD51, and RAP80 
to sites of DSBs, and thus impacts on their ability to repair damaged DNA (Wang et al. 2016). 
RAD51 is further regulated by nuclear SQSTM1/p62 through filamin A, which physiologically 
responds to DNA damage by recruiting RAD51 to DSBs. Inhibition of autophagy increases the 
interaction of SQSTM1/p62 with filamin A, causing proteasomal degradation of both filamin 
A and RAD51 (Hewitt et al. 2016). Therefore, nuclear SQSTM1/p62 that accrues from 
defective autophagy compromises DNA damage repair and genomic integrity. Total 
SQSTM1/p62 was shown to be increased in FLCN knockdown cells and to become nuclear 
localised in renal tumours from BHD patients (Dunlop et al. 2014). Preliminary data suggests 
that SQSTM1/p62 is likely to be increase in the nucleus of FLCN knockdown HK2 cells (n=1, 
data not shown). It would be interesting to validate the increase in nuclear SQSTM1/p62, if 
RAD51 levels are altered, and/or if there is a reduction in H2AX ubiquitination upon FLCN 
loss. 
7.2.4 Conclusion  
There are many reasons why cells accumulate DSBs. Genetic instability is a hallmark of 
cancer. It would be useful to mechanistically explore how FLCN knockdown facilitates an 
increase in γH2AX formation and confirm if this γH2AX represents an increase in DSB. A 
simple set of experiments would be to examine γH2AX foci via immunofluorescence. Unlike 
radiation induced γH2AX foci, ROS-induced γH2AX foci (specifically hydrogen peroxide) does 
not induce the formation of distinct foci but rather a whole nucleus staining pattern with 
only few separate countable foci (Sharma et al. 2016). In addition, matching the induction of 
γH2AX foci to a phase of the cell cycle would provide a preliminary indication for which DSB 
mechanism would be worth investigating.  γH2AX foci accumulating in G1 would suggest a 
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fault in NHEJ, while G2 would represent HR. Equally, accumulation of γH2AX during S phase 
would advocate replication stress as a cause for DSB following FLCN knockdown.  
 
7.3 FLCN knockdown results in dysregulated G1-G1/S phase transition 
 
There is a growing body of evidence to suggest the cell cycle may be perturbed following 
FLCN Knockdown (Kawai et al. 2013; Luijten et al. 2013; Kenyon et al. 2016). Indeed, within 
this thesis numerous proteins involved in G1-G1/S phase transition were identified in the 
FLCN interactome (figure 3.5) and FLCN knockdown led to an enrichment of differentially 
expressed genes within in G1-G1/S phase transition (figure 4.8). Elevated levels of cyclin D1 
are observed in both low and high passage HK2 cells following FLCN knockdown. 
Furthermore, cyclin D1 protein level did not change when cells were subjected to IR, unlike 
wild type control cells whose level of cyclin D1 decreased slightly (figure 6.2). FLCN 
knockdown also led to a decrease in the percentage of cells in G1 phase, with a 
corresponding increase in the percentage of cells in G2 phase as indicated by DRAQ5 
incorporation (figure 6.6E-G). Similarly, in zebra fish embryos, reintroduction of wild type 
FLCN led to an increase in G1 cells and a decrease in G2 cells (Kenyon et al. 2016). 
Collectively, the results implicate FLCN in the G1/S control of the cell cycle, specifically FLCN 
may have a role in G1/S checkpoint to halt proliferation. However, it is not clear exactly 
what FLCN may be doing at this checkpoint, or how it contributes to checkpointing. For 
example, why dose FLCN loss result in the increase in cyclin D1? A previous study reported 
that FLCN negatively regulates cyclin D1 through elements on the CCND1 mRNA (Kawai et 
al. 2013). It’s worth noting that nearly a third of the FLCN interactome has been linked to 
transcription and/or translation (figure 3.5). Although it has not been previously explored, 
protein interactions between FLCN and molecules involved in protein transcription and/or 
translation were considered out of the confines of this thesis. Given FLCNs association with 
mTOR signalling, which is heavily implicated in protein synthesis, FLCN may function to 
restrict cyclin D1 protein translation. This idea is discussed in detail later (see section 7.5.1, 
future research directions).  
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7.3.1 An increase in ROS promotes G1/S skipping  
Increased levels of ROS are considered tumorigenic (Liou and Storz 2010; Moloney and 
Cotter 2018). They result in the activation of pro-survival signalling pathways, loss of tumour 
suppressor gene-function, increased glucose metabolism, adaptations to hypoxia and the 
generation of oncogenic mutations (Heiden et al. 2009; Sabharwal and Schumacker 
2014). As previously mentioned, FLCN loss is documented to increase in mitochondrial ROS 
which functioned as a signalling molecule to promoted HIF signalling (Preston et al. 2011; 
Yan et al. 2014). Indeed, ROS has been demonstrated to act as a signalling molecule in many 
cancers, contributing to abnormal cell growth, metastasis, resistance to apoptosis, 
and angiogenesis (Sabharwal and Schumacker 2014; Moloney et al. 2017).  
Interestingly, a growing body of evidence suggest ROS may have central role in 
controlling cell proliferation. The amount of ROS present seems to determine the effect of 
ROS on cell proliferation: low amounts result in correct cell cycle progression whereas high 
amounts have been associated to uncontrolled cell proliferation (Deshpande and Irani 2002; 
Boonstra and Post 2004; Stockl et al. 2006; Qin et al. 2011). ROS has also been shown to 
influence proliferation in the form of secondary messengers in many pathways regulating 
cell proliferation, such as those involving p21, MAPK, or EGFR (Boonstra and Post 2004). In 
the example of EGFR, ROS is able to inhibit EGFR internalisation in addition to directly 
activating EGFR (De Wit et al. 2000; Papaiahgari et al. 2006; Leon-Buitimea et al. 2012). 
Furthermore, ROS were shown to be important modulators of enzymes that ubiquitinate or 
phosphorylate cell cycle proteins (Boonstra and Post 2004). In fact accumulating evidence 
suggests modulating ubiquitination of cell cycle components may be the central mechanism 
of ROS-mediated cell cycle progression (Havens et al. 2006; Yamaura et al. 2009). 
Appropriate ubiquitination and subsequent degradation of the cyclin protein family is an 
integral mechanism controlling the regulation of the cell cycle progression (Boonstra and 
Post 2004). Furthermore, ubiquitination is essential for the regulation of the expression of 
cyclin kinase inhibitors, such as p21  (Lu and Hunter 2010; Starostina and Kipreos 2012). ROS 
can influence ubiquitination by inhibiting Ubiquitin-activating E1 and ubiquitin conjugating 
E2 enzyme activities. In addition, ROS can also directly inhibit the proteasome, to further 
decrease ubiquitin-mediated degradation (Boonstra and Post 2004). ROS has also been 
shown to indirectly influence the ubiquitination of pro-proliferation factors. For example, in 
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human fibroblasts an accumulation of cyclin A at the end of G1 is necessary for progression 
into the S phase. Treatment with antioxidants prevents cyclin A accumulation resulting in G1 
phase arrest. ROS was demonstrated to promote the inactivation of anaphase promoting 
complex (APC) via APC phosphorylation (Havens et al. 2006). As such, APC cannot 
ubiquitinate cyclin A and thus cyclin A is not degraded. Since ubiquitination regulates cell 
cycle progression, ROS influences ubiquitination, and ROS has already been demonstrated 
to act as a secondary messenger under the context of FLCN loss, it seems reasonable to 
suggest that the perturbed cell cycle phenotype observed following FLCN knockdown may 
be mediated by an increase in ROS. Specifically, the increase in ROS contributes to cell cycle 
progression in FLCN loss cells by inhibiting the ubiquitination, and thus preventing 
proteasomal degradation, of pro-proliferative factors. Indeed, hydrogen peroxide has been 
shown to cause a reversible inhibition of the ubiquitin-proteasome dependent degradation 
of cyclin D1 in HER14 fibroblasts (Munoz et al. 2001). This may explain the increase in cyclin 
D1 protein levels shown in this thesis. Especially as in high passage FLCN knockdown cells, 
elevated cyclin D1 protein is observed alongside a marked down-regulation in CCND1 gene 
expression, and published work suggest FLCNs negative regulation of cyclin D1 may not be 
directly at the level of gene transcription (Kawai et al. 2013).  
Nevertheless, while the main body of evidence suggest ROS can promote cell cycle 
progression, ROS has also been noted to cause cell cycle arrest. For example, sublethal 
doses of hydrogen peroxide caused a transient arrest in NIH 3T3 fibroblasts, while nitric 
oxide caused a G1 phase arrest in human pancreatic carcinoma cell lines (Gansauge et al. 
1998; Barnouin et al. 2002; Boonstra and Post 2004). Ultimately, the effect of ROS on 
cellular processes is complex. While more work needs to be carried out to understand the 
specifics, the influence ROS has on cell cycle regulation seems to be dependent upon cell 
type, location of ROS production, and even the type of ROS produced. (Yamaura et al. 2009). 
Still, it would be exciting to test the effects of ROS-mediated inhibition of cyclin D1 in the 
context of FLCN knockdown. 
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7.4 Potential therapeutic targets based on observation presented within this 
thesis  
 
Understanding the function of FLCN and the cellular pathways in which it interacts with will 
inform the development of targeted therapies to treat BHD-associated RCC. For example, 
recent research indicates that FLCN plays an important role in the EGFR signalling pathway  
and treatment with the tyrosine kinase inhibitor Afatinib has been shown to inhibit BHD-
associated renal tumour growth in a mouse model (Laviolette et al. 2017). Tyrosine kinase 
inhibitors are usually used within sporadic RCC to combat a metastatic disease, but no 
tyrosine kinase inhibitor to date has been cleared to specifically treat BHD-associated 
tumours (Rudresha et al. 2017; Wei et al. 2018). Similarly, despite showing promise in Flcn-
deficient mouse models, no mTOR inhibitor has passed clinical trials for use with BHD-
associated RCC (Baba et al. 2008; Chen et al. 2008; Wu et al. 2015). 
Work within this thesis may provide justification for exploring other therapeutic avenues. 
Defects in the DDR give rise to genomic instability in cells, aiding in cancer initiation and 
progression by allowing mutations to accumulate. However, this also offers targetable 
vulnerabilities that are specific to cancer cells which can be exploited for clinical benefit 
with the use of DDR inhibitors. The identification of the protein-protein interaction 
between FLCN and DNA-PKcs is exciting. Inhibition of DNA-PKcs, through pharmacological 
inhibitors or RNAi knockdown, have been shown to significantly reduced RCC cell 
proliferation in vitro and in vivo (Zheng et al. 2016). Therefore, DNA-PKcs might be a 
valuable target for BHD-associated RCC intervention. Three DNA-PK inhibitors are 
currently being investigated in phase I/II clinical trials: CC-115, M9831 (VX-984), and 
Nedisertib (M3814; MSC2490484A). Of these, CC-115 is a small-molecule inhibitor of 
both DNA-PK and mTOR (Mortensen et al. 2015). CC-115 monotherapy has been 
evaluated in a phase I clinical study (NCT01353625) with an initial 44 patients treated 
across 10 dose-escalation cohorts (Munster et al. 2016). Preliminary anti-tumour activity 
was reported, although it is unclear if these responses are attributable to activity against 
DNA-PK or mTOR; especially considering that CC-115 led to hyperglycaemia, which is 
consistent with mTOR inhibition, and that associated pharmacodynamic studies provided 
evidence in favour of mTORC1 and mTORC2 inhibition (Munster et al. 2016). However, 
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more work is needed to understand the biological impact of the interaction between FLCN 
and DNA-PKcs before therapeutic exploitation is seriously considered. 
 
Another interesting therapeutic option worth discussion is the use of CDK4/6 
inhibitors. FLCN knockdown lead to an increase in cyclin D1 gene expression and protein 
abundance (chapter 4 and chapter 6). Furthermore, FLCN knockdown cells cycle through 
G1/S more readily than wild type controls (Kenyon et al. 2016), figure 6.6).  CDK4/6-
selective inhibitors, such as Palbociclib, Ribociclib and Abemaciclib, have shown 
significant benefits in clinical studies (Hamilton and Infante 2016; Eggersmann et al. 
2019; Petrelli et al. 2019; Poratti and Marzaro 2019). Global genetic ablation of individual 
cyclins or inhibition of CDK activity in tumour-bearing mice selectively blocked the 
progression of cancers driven by oncogenic insults, whilst having limited effects on 
normal tissues (Deng et al. 1995; Liu et al. 2007). Collectively, studies suggest tumour 
cells become dependent on specific CDKs depending on the genetic lesions they carry, 
and hence, CDK inhibition may selectively target cancer cells while sparing normal tissues 
(Poratti and Marzaro 2019). In some instances, inhibition of CDK activity in mouse cancer 
models not only led to cell cycle arrest but also triggered tumour cell senescence or 
apoptosis (Puyol et al. 2010; Otto and Sicinski 2017).  
Alternatively, inhibition of cell cycle proteins that are crucial for checkpoint 
function, such as Chk1 and WEE1, in cancer cells prevents cell cycle arrest during S or G2 
phase and enables cell proliferation despite accumulation of DNA damage. This promotes 
cell death during mitosis by mitotic catastrophe (Castedo et al. 2004). This strategy is 
particularly useful to cancer cells with compromised G1-checkpoint, as these cells 
critically depend on the G2-checkpoint, especially in the presence of DNA damage-
inducing drugs. FLCN knockdown was shown to result in elevated γH2AX suggesting an 
increase in DBS. Therefore, combining compounds to inhibit G2 checkpointing with a DNA 
damaging agent may promote tumour cell death in cancers with FLCN loss. Nevertheless, 
while it is fun to speculate potential therapeutic options, more research is needed to 
better understand the mechanistic actions of FLCN with DNA-PKcs, and within G1/S cell 
cycle regulation.  
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7.5 Future research directions 
 
Future research directions directly based observations presented within the thesis have 
already been discussed. Namely, future work should focus on characterising the kinetics of 
γH2AX; aiming to establish when in the cell cycle they occur, or if repair facilitating binding 
partners are effected by FLCN knockdown. Co-ordinating γH2AX with the cell cycle will 
better inform future directions to take the research. For example, an accumulation of γH2AX 
foci during S phase strongly suggests DSB damage arise as a result of replication stress 
following FLCN loss. Moreover, exploring the cellular function of the FLCN/DNA-PKcs 
interaction would be highly informative. DNA-PKcs loss of function has huge consequences 
for the stability of cellular genomes, while unregulated DNA-PKcs activity has been 
implicated in multiple oncogenic pathways. Furthermore, DNA-PKcs is an attractive 
therapeutic target.  
Discussed below are additional research directions that either complement or build 
on results shown within this thesis, and that have not previously been discussed within this 
chapter. 
7.5.1 Eukaryotic translation initiation factor 4E (eIF4E); implicating FLCN in protein 
translation and/or nuclear export 
The eukaryotic translation initiation factor 4E (eIF4E) is an important modulator of cellular 
growth and is often upregulated in many cancers (Ramaswamy et al. 2003; Pelletier et al. 
2015).  eIF4E has functions in both the cytoplasm and nucleus. In the cytoplasm, eIF4E is 
required for cap-dependent translation (Sonenberg and Gingras 1998). Here, eIF4E binds the 
methyl 7-guanosine (m7G) cap moiety present on the 5′ end of mRNAs and subsequently 
recruits the mRNA to the ribosome (Sonenberg and Gingras 1998). In the nucleus, eIF4E 
functions to promote the nuclear export of mRNAs (Culjkovic-Kraljacic et al. 2016). It should 
be noted that not all translation targets of eIF4E are nuclear export targets. For example, 
vascular endothelial growth factor (VEGF) mRNA is a translation target of eIF4E, but it’s 
nuclear export does not involve eIF4E (Sonenberg and Gingras 1998). eIF4E was identified in 
the FLCN interactome (chapter 3). This protein narrowly missed out on being a hub protein 
as defined by being 2 standard deviation (SD) above mean degree within the whole 
interactome (eIF4E had a degree of 89, while the 2 SD upon the mean is 92.4) but it was a 
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bottleneck protein as defined by being 2 SD above mean betweenness centrality (BC) within 
the whole interactome (eIF4E had a BC of 0.015, 2 SD is 0.012). This suggests it may have an 
important role with regards to information flow within the interactome.  Within the 
literature, as eIF4E is cited as the least abundant initiation factor and, therefore, is 
considered the rate-limiting factor for translation (Duncan and Hershey 1983; Galicia-
Vazquez et al. 2012; Pelletier et al. 2015).  
7.5.1.1 A role for FLCN in protein translation  
 
Translation initiation in eukaryotes commences with the binding of the eukaryotic 
translation initiation factor 4F (eIF4F) complex to the 5′-cap of mRNAs (Topisirovic et al. 
2011). eIF4F consists of the cap-binding subunit, eIF4E, the RNA helicase eIF4A, and the 
scaffolding protein eIF4G (Sonenberg and Hinnebusch 2009; Jackson et al. 2010). It is 
thought that eIF4A unwinds the secondary structure present in the 5′-UTR of the mRNA to 
promote the binding of the ribosome (Sonenberg and Hinnebusch 2009; Jackson et al. 
2010). eIF4G interacts directly with eIF4E, eIF4A, eIF3 and the poly (A)-binding protein 
(PABP) (Sonenberg and Hinnebusch 2009; Jackson et al. 2010). The interaction of eIF4G with 
the multi-component initiation factor eIF3 is required in mammals for the recruitment of 
the 43S pre-initiation complex (which consists of the 40S ribosomal subunit and associated 
initiation factors), via the direct binding of eIF3 to the 40S subunit (Sonenberg and 
Hinnebusch 2009; Jackson et al. 2010). Following assembly at the cap structure, the 43S pre-
initiation complex traverses the mRNA 5′UTR in a 5′ to 3′ direction, until it encounters the 
initiation codon where it stops and the 60S large ribosomal subunit joins to form the 80S 
ribosomal complex (Hinnebusch 2014). This is followed by the translation elongation step 
(Hinnebusch 2014). Although eIF4E is necessary for cap-dependent translation, its 
requirement varies dramatically among mRNAs (Bhat et al. 2015). It preferentially 
stimulates the translation of a subset of mRNAs (Bhat et al. 2015). These mostly encode 
proliferation and survival-promoting proteins such as cyclin D1, c-Myc, MDM2, VEGF, 
Survivin and Bcl-2 (Gehrke et al. 1983). In general, mRNAs containing long G/C-rich 5′-UTRs, 
with the potential of forming stable secondary structures are feebly translated (Gehrke et al. 
1983).  mRNAs with extensive secondary-structure in their 5′-UTRs are exceedingly 
dependent on eIF4E and eIF4A activity (Koromilas et al. 1992; Svitkin et al. 2001). 
Mechanistically the eIF4E-binding region within eIF4G can inhibit eIF4A helicase activity 
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when not bound to eIF4E. This inhibition is alleviated upon eIF4E binding to eIF4G 
(Feoktistova et al. 2013). In addition to eIF4E, both the eIF4G scaffolding proteins that 
bridge the mRNA and the ribosome (eIF4G1 and eIF4G2), and the hypoxia-induced eIF4E 
homologue, eIF4E2 where identified as potential FLCN interactors (appendix 1). Several lines 
of evidence suggest that human eIF4E2 has a distinct cytoplasmic role in the stress 
response, (Okumura et al. 2007; Feoktistova et al. 2013; Kubacka et al. 2013). Under 
genotoxic stress, the ubiquitin-like molecule ISG15 is covalently added to eIF4E2 to increase 
its cap-binding affinity (Okumura et al. 2007). Additionally, eIF4E2 was identified as an 
activator of translation initiation during periods of hypoxia (Feoktistova et al. 2013). The 
eIF4E2 interacts with eIF4A and eIF4G3 to form a hypoxic eIF4F complex that increases 
translation efficiency independent of mRNA abundance (Ho et al. 2016). Interestingly, the 
protein levels of eIF4E2, eIF4G3, and eIF4A do not change in hypoxia relative to normoxia 
(Feoktistova et al. 2013; Ho et al. 2016), suggesting that post-translational modifications or 
compartmentalisation may play a role in modifying their activities (Melanson et al. 2017).  
A number of components of the eukaryotic translation initiation factor 3 (eIF3) were 
also identified in the FLCN interactome (EIF3A, EIF3E, EIF3G, and EIF3I). The eIF3 complex 
specifically targets and initiates translation of a subset of mRNAs involved in cell 
proliferation, including cell cycling, differentiation and apoptosis. eIF3 is the largest and 
most complex of all eukaryotic initiation factors (eIFs) comprised of five core subunits and 
seven non-essential subunits. It is though that that non-essential subunits may have 
regulatory functions (Zhou et al. 2005; Kim et al. 2007; Grzmil et al. 2010; Choudhuri et al. 
2013). For example, eIF3A is the largest subunit. It is not required for the general function of 
eIF3, instead eIF3A regulates the translation of a subset of mRNAs that modulate the cell 
cycle. Specifically, eIF3A may be the translational regulator for proteins important for 
entrance into S phase (Saletta et al. 2010). Moreover, the eIF3A mRNA is found elevated in 
several cancers. Similarly, eIF3E knockdown had no major effect on global translation but 
numerous genes involved in cell cycle related processes were negatively regulated by 
eIF3E at the level of translation and inhibition of eIF3E expression has been shown to 
delay mitotic progression in human cells (Morris and Jalinot 2005). One final noteworthy 
protein identified in the FLCN interactome worthy of discussion is eukaryotic translation 
elongation factor 1 alpha 1 (eEF1A1). eEF1A1 was identified as a hub-bottleneck protein 
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suggesting it plays a significant role with regards to the integrity and function of the FLCN 
interactome. eEF1A1 has a well-defined role in protein synthesis, it delivers amino-acylated 
tRNAs to the A site of ribosome during translation elongation in a GTP-dependent manner 
(Mateyak and Kinzy, 2010; Li et al., 2013). Additionally, eEF1A1 can enter the nucleus to 
mediate the export of mature tRNAs and proteins. Indeed, eEF1A1 has been shown to 
function as a component of the nuclear export machinery in mammalian cells and is 
involved in the nuclear export of specific proteins such as the VHL tumour suppressor and 
poly(A)-binding protein (PABP1) (Khacho et al. 2008). Furthermore, reduced expression of 
EEF1A1 is seen in many cancers (breast, lung, gastric, kidney, head and neck) (Khacho et al. 
2008). Collectively, FLCN seems to interact with several cell proliferative specific translation 
factors. It would therefore be interestingly to see if FLCN modulates protein translation in 
anyway.  
7.5.1.2 A role for FLCN in nuclear export 
 
Alternately, through eIF4E, FLCN may have a role in nuclear export. eIF4E export activity has 
been categorised as independent of ongoing protein synthesis (Culjkovic et al. 2006). At 
least three reported mRNAs have been characterised for the eIF4E-mediate nuclear export; 
CCND1 (cyclin D1), MCL1 (Induced myeloid leukemia cell differentiation protein Mcl-1), and 
ODC (ornithine decarboxylase) (Rousseau et al. 1996; Culjkovic et al. 2005,2006). 
Interestingly, evidence has linked the mRNA export function of eIF4E to its oncogenic 
activity. A mutant form of eIF4E (W73A), which results in enhanced eIF4E-dependent cyclin 
D1 mRNA export was shown to transform cells in vitro (Cohen et al. 2001; Topisirovic et al. 
2003). Moreover,  the W73A eIF4E cannot bind eIF4G and thus cannot act in translation, 
suggesting cellular transformation was due to mRNA export (Sonenberg and Gingras 1998). 
eIF4E has been demonstrated to promote nuclear export of cyclin D1 mRNAs via an element 
in the 3′UTR. This is interesting as previous study on the relationship between cyclin D1 and 
FLCN suggests FLCN regulates cyclin D1 expression post-transcriptionally by an unknown 
mechanism, and that the central portion of cyclin D1’s 3’UTR is necessary for this regulation. 
Therefore, could FLCN modulate this eIF4E-mediated nuclear export of cyclin D1? How FLCN 
would do this, however, is currently unclear. 
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Alternately, FLCN may be involved in nuclear-cytoplasmic shuttling independent of 
eIF4E. Mass spectrometry analysis identified FLCN interacts with 11 components of the 
nucleopore (RANBP2, NUP205, NUP188, NUP54, NUP35 (NUP53), NUP155, NUP133, 
NUP160, NUP50, TPR, NUP153), and proteins that are essential for nuclear export (XPO1, 
XPO5, EIF4) (figure 5.7A). FLCN has been demonstrated to interact with NUP155 (Dr Sara 
Seifan, and Mr Matt Lines, data unpublished), where this interaction was strengthened 
under IR. There is also limited evidence to suggest it could be involved in establishing 
RAN:GTP gradients around nucleopore required for nuclear export of proteins (unpublished 
data, Prof. M Van Steensel). Furthermore, FLCN was shown important for cytoplasmic 
shuttling of TDP-43 (Xia et al. 2016). Two candidate proteins where briefly explored within 
this thesis; DNA-PKcs and cyclin D1. Neither produced evidence to convincingly say FLCN 
knockdown alters protein translocation both under basal and IR conditions. However, cyclin 
D1 required further testing. 
7.5.2 Single-cell RNA sequencing (scRNA-seq) of FLCN knockdown cells 
To date, there are 7 genes linked to hereditary forms RCC; Von Hippel-Lindau (VHL), 
tyrosine-protein kinase Met (MET), Fumarate Hydratase (FA), Succinate Dehydrogenase 
(SD), Tuberous Sclerosis Complex 1 (TSC1), Tuberous Sclerosis Complex 2 (TSC2), and FLCN. 
Apart from FLCN, each of these genes have relatively well described molecular and 
aetiological roles with regards to RCC. Furthermore, mutations within these genes typically 
promote a defined RCC subtype. For example, VHL mutations lead to upregulation of 
hypoxia inducible factors HIF1α and HIF2α. This facilitates metabolic reprogramming that 
results in the cytoplasmic accumulation of glycogen and lipids, and an increase in 
vascularisation to produce a network of small, thin walled blood vessels that are definitive 
of clear cell RCC (Linehan 2012; Haas and Nathanson 2014). Uniquely, however, FLCN 
mutations are associated with all RCC histological subtypes. The observed heterogeneity in 
RCC following FLCN loss could be caused by dysregulated cell cycle checkpoint and increase 
in DNA damage, coupled with metabolic changes previously observed that collectively push 
unregulated cell proliferation. This would promote an element of randomness to cellular 
transformation, thus giving rise to the heterogenous tumour phenotypes represented in 
BHD. However, it would be informative to investigate if it is possible to predict a cancer 
subtype that may arise, i.e., what are gene signatures that define a cell’s transition into a 
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particular RCC subtype? Until recently, most genomic profiling studies have analysed cell 
populations. Although, cells of the same ‘type’ can exhibit substantial heterogeneity, 
reflecting finer sub-types, regulated functional variation, or inherent stochasticity 
(Altschuler and Wu 2010; Grun et al. 2015; Zeisel et al. 2015). In addition, colonialism is well 
documented in cancer (Altschuler and Wu 2010). Rapid technological advances in recent 
years have enabled genome-wide profiling of RNA, DNA, protein, epigenetic modifications, 
chromatin accessibility, and other molecular events in single cells (Tang et al. 2009; Navin et 
al. 2011; Bodenmiller et al. 2012; Farlik et al. 2015; Wagner et al. 2016). The scale and 
precision of such studies have continued to increase (Macosko et al. 2015). By exploring the 
identity of an individual cells, large-scale single-cell data allows specific molecular 
exploration of features without relying on prior definitions, hypotheses, or markers (Wagner 
et al. 2016). Single-cell RNA sequencing (scRNA-seq) can reveal complex and rare cell 
populations, uncover regulatory relationships between genes, and even track the 
trajectories of distinct cell lineages in development (Tang et al. 2009; Zeisel et al. 2015; 
McGranahan and Swanton 2017; Hwang et al. 2018). Transcriptional profiling of a single 
cell is a powerful approach to categorise heterogeneous cell states. This would be 
particularly useful to account for biological variation such as stochastic transcription. For 
example, over the last two decades, knowledge regarding the transcriptional landscape in 
RCC has come largely from whole tumour profiling using either microarray or RNA-seq data 
(Wu and Humphreys 2017). These studies have been highly informative, but they are 
fundamentally limited to describing a transcriptional average across a cell population. This 
may hide or skew signals of interest. The use of scRNA-seq within cancer has been used to 
explored intratumor heterogeneity for which it can reliably detect small sub-populations of 
tumour cells. These may have previously been masked when analysed alongside other low 
and high RNA expressing cells within a bulk tumour sample or monolayer of cultured cells 
(McGranahan and Swanton 2017). Within sporadic RCC, scRNA-seq has been used to 
identify molecular patterns found within RCC subtypes (Eckel-Passow et al. 2015; Chen et al. 
2016a).  For example, gene expression signatures have been used to predict tumour 
aggressiveness and progression within clear cell RCC (Kosari et al. 2005; Chen et al. 2014).  
Given the heterogeneity found in FLCN associated RCC and the large array of biological 
processes FLCN has been demonstrated to function in, scRNA-seq may provide a way to 
study gene expression dynamics that contribute to cellular transformation and inform 
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aetiological parameters of tumorigenesis upon FLCN loss. Exploring the transcriptomic 
landscape of individual cells over a period of time following FLCN loss (from low passage 
FLCN knockdown, to high passage or even ultra-high passage knockdown of ~2 years in 
culture) may even identify molecular signatures that promote the devolvement of one 
tumour subtype over another. Understanding the molecular and genetic features that 
characterise the RCC subtypes will provide the foundation for the development of better 
clinical management of RCC. scRNA-Seq could provide a wealth of knowledge for not just 
FLCN loss associated RCC, but also sporadic tumorigenesis.   
7.5.3 FLCN-interacting proteins 1 and 2 (FNIP1 and FNIP2) 
One final thought would be to explore the effect of the FLCN-interacting proteins (FNIP1 and 
FNIP2) have on the observations presented within this thesis. Both FNIP1 and FNIP2 have 
been noted to co-ordinate functions with FLCN in a tissue dependent manner.  Binding of 
FLCN to both FNIP1 and FNIP2 is mediated through the C-terminal region of FLCN (Baba et 
al. 2006; Hasumi et al. 2008; Takagi et al. 2008). In BHD syndrome, the majority of mutations 
are predicted to result in a protein truncation (Schmidt et al. 2005). This results in the loss of 
the C-terminus of FLCN and therefore abolishes FLCN’s ability to interact with FNIP1/FNIP2. 
It is generally considered that FNIP1 and FNIP2 are largely functionally redundant, however 
there maybe cell-type specific FNIP functions (Baba et al. 2012; Park et al. 2012; Reyes et al. 
2015). Within the kidneys, FNIP1 and FNIP2 have somewhat interchangeable roles alongside 
FLCN in tumour suppression. FNIP1 and FNIP2 were found to be functionally redundant, 
with either able to interact with FLCN and inhibit tumorigenic growth in mouse kidneys 
(Hasumi et al. 2015). Only a complete loss of both FNIP1 and FNIP2 lead to the development 
of tumours and aberrant mTOR signalling as seen by FLCN loss (Hasumi et al. 2015). 
Mechanistically, FNIP1 and/or FNIP2 are required for FLCN’s localisation to lysosomes during 
amino acid starvation, where FLCN interacts with the Rag proteins in order to regulate 
mTOR signalling (Petit et al. 2013; Tsun et al. 2013). Furthermore, both FNIP1 and FNIP2 
have been found in complex with AMPK. Here they function alongside FLCN to inhibit AMPK 
activity (Preston et al. 2011; Siggs et al. 2016). Interestingly, no detectable phenotype in was 
observed in Fnip2 only knockout mice, whereas Fnip1-deficiency produced phenotypes 
similar to those seen in Flcn-deficient mice in multiple organs, but not in kidneys. One study 
showed that absolute Fnip2 mRNA copy number was low relative to Fnip1 in mice organs 
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that showed phenotypes under Fnip1 deficiency. However, Fnip2 was comparable 
to Fnip1 mRNA copy number in mouse kidney (Hasumi et al. 2015). Collectively this 
suggests, at least in kidney cells, both FNIPs function equally, and that it is FLCN that 
dictates biological effects. 
Of particular interest, however, would be FNIP2. FNIP2 was shown to be important 
for O6 methylguanine induction of apoptosis (Komori et al. 2009; Lim et al. 2012). 
O6 methylguanine is an alkylated base that can mis-pair with thymine and cytosine during 
DNA replication to introduce DNA base mutations (Komori et al. 2009; Lim et al. 2012). This 
suggest FNIP2 may play a role in mis-match repair. Just as FLCN knockdown did not sensitise 
cells to IR-induced apoptosis, FNIP2 knockdown did not dramatically affect cells sensitivity 
to alkylating agents, etoposide, or UV irradiation. Equally, FNIP2 knockdown also lead to 
an increase in γH2AX (Komori et al. 2009). Therefore, it would be interesting to see if 
FNIP2 complexes with FLCN to bring about observed results presented within this thesis. 
For example, like the FLCN/FNIP2/AMPK protein complex, does FNIP2 complex with 
FLCN/DNA-PKcs. 
 
7.6 Final summary 
 
The molecular role of FLCN is complex. Having cell type, and context dependent functions 
that may be modulated by numerous protein interactions. As such, FLCN should be 
considered a generic regulator of cellular homeostasis rather than having a distinct cellular 
purpose. Nevertheless, this thesis highlights a novel aspect of FLCN’s highly convoluted 
cellular role; implicating FLCN in genomic maintenance. FLCN cited functions can all be 
linked back to energy homeostasis. Interestingly, the surveillance and repair of DNA, the 
control of the cell cycle, and energy homeostasis are ever increasing being demonstrated to 
be highly interlinked processes. Cell division requires the co-ordinated generation of energy 
for multiple processes, including the synthesis of the machinery required for DNA 
replication and mitosis. The relationship between energy and the cell cycle is bidirectional, 
and several cell-cycle checkpoints can sense energy deficits in the cell, thus leading to cell-
cycle arrest or exit (Salazar-Roa and Malumbres 2017; Laphanuwat et al. 2018). Thus, it 
seems sensible for a key cell cycle machinery component such as cyclin D1, to be involved in 
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energy control during the cell cycle (Laphanuwat et al. 2018). Equally, DNA-repair pathways 
can be influenced by cellular metabolic status and nutrient availability. DNA repair often 
requires chromatin remodelling  through different histone post-translational 
modifications—including acetylation, methylation, phosphorylation, and ubiquitination; 
these are energy extensive processes (Turgeon et al. 2018). Furthermore, cell metabolism 
can regulate DNA-repair through the regulation of the pool of nucleotides required for 
repair (Turgeon et al. 2018) Indeed, many different metabolic pathways are involved in de 
novo nucleotide synthesis (Patra and Hay 2014; Turgeon et al. 2018). Again, having a direct 
impact on energy homeostasis would be beneficial to DDR components such as DNA-PKcs. 
Nevertheless, FLCN precise role in genomic maintenance is undefined. Further research to 
should focus on understanding this role from a mechanistic point of view and begin to 
explore how FLCN’s DDR and cell cycle roles integrate with that of energy balance and 
cellular trafficking. Given that FLCN loss predisposes individuals to all RCC subtypes, 
understanding the molecular mechanisms of FLCN as a tumour suppressor could reveal new 
cancer promoting pathways linked to RCC progression. Indeed, while rare themselves, 
inherited genetic conditions that promote the development of tumours can provide 
valuable insight into the molecular mechanisms behind tumorigenesis within the general 
population. 
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Supplementary figure 1: FLCN knockdown impacts telomeres 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1 FLCN knockdown impacts telomeres. A) Telomere components found in the FLCN 
interactome. B) Single telomere length analysis (STELA) shows increase in telomere length following 
FLCN loss over time. Red line indicates mean length in the gel (left) and graph (right). ** p < 0.01, 
*** p < 0.001. C) Telomere fusion events were observed in low passage FLCN knockdown cells. 
Single telomere length analysis (STELA) and telomere fusion analysis was performed by Dr Rhiannon 
Jones, Cardiff University as described in (Baird et al. 2003; Capper et al. 2007). Figures B and C were 
taken from the PhD grant application submitted to Tenovus cancer care by Dr Andrew Tee. D) GST-
tagged FLCN was overexpressed in HEK293 cells and used as bait to validate interaction between 
FLCN and endogenously expressed TPP1. Due to time constraints, and a lack of validation of FLCN 
interacting with telomere components TPP1 and RIF1 (shown in figure 3.6C), telomere dynamics 
upon FLCN knockdown was not explored further. 
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Appendix 1: Full list of potential FLCN interactors identified by mass 
spectrometry 
 
Protein Name Degree BC Protein Name Degree BC 
AASDHPPT 8 1.57E-04 BAG5 5 2.39E-04 
ABI1 11 3.66E-04 BAT1 Not mapped in STRING 
ACACA 91 0.01349732 BAT2 Not mapped in STRING 
ACLY 117 0.02286661 BAT2L Not mapped in STRING 
ACOT8 Not mapped in STRING BAX 27 6.39E-04 
ACTA2 84 0.01179367 BCCIP 10 2.64E-04 
ACTB 116 0.0217231 BCOR 3 6.63E-05 
ACTBL2 67 0.00469542 BIRC6 4 1.11E-05 
ADSS 18 4.23E-04 BRE 12 5.70E-04 
AHCY 19 4.09E-04 BTAF1 8 1.06E-04 
AIP 3 3.60E-07 BUB1B 68 0.002048 
ALB 74 0.01747427 BUB3 75 0.00324558 
ALDH1B1 19 5.63E-04 BZW2 6 1.89E-04 
ALDOA 21 0.00145022 C11orf58 2 8.41E-06 
ANAPC1 46 0.00159967 C12orf5 17 2.00E-04 
ANKHD1 7 9.09E-05 C14orf166 17 4.66E-04 
ANKRD17 5 6.66E-06 C1orf174 Not mapped in STRING 
ANXA2 16 0.00171845 C1QBP 32 0.00154119 
ANXA2P2 Not mapped in STRING C20orf117 Not mapped in STRING 
AP1GBP1 Not mapped in STRING C22orf28 10 9.35E-04 
APIP 4 2.61E-05 C22orf9 Not mapped in STRING 
APOOL 4 0.00327557 C3orf75 Not mapped in STRING 
ARCN1 12 3.57E-04 C5orf33 Not mapped in STRING 
ARD1A Not mapped in STRING C5orf51 1 0 
ARFGAP1 9 4.68E-05 CA2 13 0.00268692 
ARFIP2 4 1.18E-05 CACYBP 10 3.57E-04 
ARHGAP5 1 0 CAD 132 0.02412087 
ASCC3 26 8.08E-04 CALM1 67 0.00530828 
ASNS 23 4.65E-04 CALM2 Not mapped in STRING 
ATG2A 7 0.00339191 CALM3 Not mapped in STRING 
ATM 59 0.00447422 CAMSAP1L1 Not mapped in STRING 
ATP5A1 61 0.00442671 CAND1 11 2.95E-04 
ATP5B 72 0.00500404 CAP1 16 0.00116887 
ATP5C1 36 0.00194902 CAPZA1 16 6.89E-04 
ATP6V1B2 21 8.26E-04 CAPZB 17 4.72E-04 
ATP6V1D 8 1.47E-05 CARM1 13 1.27E-04 
ATP6V1E1 11 4.32E-04 CBR1 7 6.16E-05 
ATP6V1H 9 1.02E-04 CBR3 7 6.16E-05 
ATR 46 0.00468388 CBS 27 0.00143392 
ATXN10 5 1.06E-04 CBWD2 1 0 
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ATXN2 16 8.30E-04 CCS 10 0.00328105 
ATXN2L 7 7.32E-05 CCT2 112 0.00899685 
ATXN3 15 0.00189512 CCT3 94 0.00734996 
AURKA 83 0.0095123 CCT4 Not mapped in STRING 
BAG4 7 3.07E-05 CCT5 106 0.00786906 
CCT6A 72 0.00484691 DHX30 5 2.93E-05 
CCT7 107 0.00932019 DHX36 9 1.91E-05 
CCT8 41 8.06E-04 DHX9 57 0.00381552 
CCT8 Not mapped in STRING DIAPH1 13 3.38E-04 
CDC2 Not mapped in STRING DIAPH3 11 1.74E-04 
CDC20 88 0.00556448 DICER1 55 0.00788685 
CDC37 12 2.23E-04 DKC1 52 0.00292496 
CDK1 145 0.02768301 DNAJA1 41 0.00622249 
CDK3 50 0.00162173 DNAJA2 27 1.62E-04 
CDK4 65 0.00313211 DNAJA3 27 2.53E-04 
CDKN2A 46 0.0035106 DNAJB11 24 0.00414955 
CEP170 Not mapped in STRING DNAJC7 24 5.46E-04 
CEP55 23 6.76E-04 DNMT1 28 0.00462831 
CFL1 40 0.00398562 DOCK6 1 0 
CHD4 20 3.69E-04 DOCK7 2 0.00326797 
CKAP5 52 0.00202422 DOCK9 Not mapped in STRING 
CKB 11 1.22E-04 DPH2 5 6.60E-05 
CLASP2 33 2.85E-04 DPM1 13 4.14E-04 
CLIC1 8 1.57E-04 DRG1 7 6.71E-04 
CLNS1A 12 3.89E-04 DSG1 4 0.0012007 
CLTC 40 0.00743698 DSP 3 4.32E-04 
CLTCL1 31 0.00555338 DUT 42 0.00208268 
CMAS 7 3.20E-04 DYNC1H1 45 0.008754 
CNN3 1 0 DYNC1LI2 19 4.99E-04 
CNOT1 20 8.88E-04 EDC3 7 4.26E-05 
COPA 16 0.00422151 EEF1A1 112 0.01379316 
COPZ1 13 4.44E-04 EEF1A2 66 0.00141771 
CORO1C 20 5.03E-04 EEF1B2 51 5.12E-04 
CPNE1 2 0 EEF1D 50 8.44E-04 
CPNE7 1 0 EEF1E1 35 0.00115753 
CRKL 7 3.80E-04 EEF1G 95 0.00757227 
CROP Not mapped in STRING EGLN1 6 0.00332568 
CSTB 12 3.09E-04 EIF2S3 60 0.00325508 
CTBP2 14 1.67E-04 EIF3A 70 0.00475799 
CXorf26 1 0 EIF3E 60 0.0018886 
CXorf56 3 2.96E-05 EIF3G 48 7.28E-04 
CYFIP1 12 0.00121175 EIF3I 52 0.00409215 
DARS 20 9.71E-05 EIF3L 44 9.36E-05 
DBNL 22 0.00135874 EIF4E 89 0.0146893 
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DCAF7 9 1.49E-04 EIF4E2 9 1.49E-04 
DCD Not mapped in STRING EIF4G1 79 0.0079174 
DDB1 36 0.00288404 EIF4G3 15 4.48E-04 
DDX49 31 0.00127448 EIF5A2 47 9.22E-04 
DDX6 23 0.00510881 ELAVL1 62 0.0048738 
DENND4A Not mapped in STRING ELP3 16 0.00129349 
DGCR14 4 3.11E-05 ELP6 5 2.54E-05 
ENO1 88 0.00852909 GSTM4 5 5.57E-06 
ENO2 67 0.00366656 GSTP1 14 0.00176789 
EPPK1 4 9.72E-06 GTF2I 11 1.01E-04 
EPRS 118 0.01377429 GTF3C1 8 1.66E-04 
EPX 3 1.02E-04 GTF3C5 4 2.29E-05 
ERO1L 4 5.40E-07 HAT1 29 0.00831237 
ESYT1 2 9.84E-06 HDAC1 66 0.01252736 
EXOSC2 32 0.00130986 HDAC2 54 0.00468868 
EXOSC6 26 4.98E-04 HDGF 2 3.37E-06 
FAM120B 1 0 HDLBP 11 3.12E-04 
FAM62A Not mapped in STRING HEATR1 33 6.91E-04 
FAM98A 4 1.53E-05 HEATR5A 2 1.08E-06 
FANCD2 21 3.00E-04 HECTD1 17 1.60E-04 
FANCI 24 3.74E-04 HIST1H1C 5 2.44E-05 
FARSA 25 2.88E-04 HIST2H2BE 52 0.00588673 
FASN 20 0.00180367 HNRNPA1 91 0.01065132 
FKBP4 10 3.65E-05 HNRNPA2B1 57 0.00310668 
FLAD1 15 6.18E-05 HNRNPA3 51 0.00180908 
FLCN 7 0.00184071 HNRNPAB 34 8.39E-04 
FLII 15 2.89E-04 HNRNPCL1 19 2.34E-04 
FLNA 31 0.00158237 HNRNPD 58 0.005184 
FLNB 18 6.57E-04 HNRNPF 35 5.23E-04 
FLNC 20 5.68E-04 HNRNPH1 49 0.00973122 
FNIP1 5 9.36E-05 HNRNPK 56 0.00406562 
FNIP2 4 8.08E-05 HNRNPL 37 9.75E-04 
FNTA 4 0.00327541 HRNR Not mapped in STRING 
FNTB 1 0 HSD17B10 26 0.00343227 
FSCN1 12 2.24E-04 HSD17B12 7 4.01E-05 
FTO 1 0 HSP90AA1 153 0.0400851 
FTSJ1 22 0.003461 HSP90AA2 Not mapped in STRING 
G6PD 23 3.04E-04 HSP90AB1 105 0.0104931 
GAPDH 142 0.02650159 HSPA1A 88 0.00837303 
GAPVD1 6 4.50E-05 HSPA1B Not mapped in STRING 
GART 87 0.00691245 HSPA1L 69 0.00435919 
GCLM 8 2.72E-05 HSPA7 Not mapped in STRING 
GCN1L1 23 0.0022618 HSPA8 161 0.03225994 
GIGYF2 5 7.16E-05 HSPBP1 11 1.01E-04 
 180 
 
GLRX3 11 2.50E-04 HSPC152 Not mapped in STRING 
GNB2L1 82 0.00636729 HSPD1 102 0.01432717 
GOPC 5 1.27E-04 HTT 21 7.51E-04 
GPKOW 31 1.56E-04 HUWE1 33 0.00302487 
GPN1 6 9.33E-06 IARS 46 0.00223831 
GRWD1 22 0.00130636 IFIT5 7 1.65E-05 
GSR 43 0.00749891 IKBKAP 17 0.00180799 
GSTM2 5 5.57E-06 ILF2 35 0.0012066 
GSTM3 6 8.74E-05 ILK-2 Not mapped in STRING 
IMPDH2 114 0.01697763 MAP4 9 1.87E-04 
INPP5K 3 2.19E-05 MAT2A 27 9.25E-04 
IPO5 28 0.0011855 MAT2B 6 1.20E-04 
IPO7 16 1.45E-04 MAZ 2 0 
IRS2 10 1.22E-04 MCCC2 11 1.52E-04 
ISCA2 4 3.29E-05 MDN1 13 0.00141634 
ISYNA1 11 3.85E-04 METTL1 10 2.92E-04 
KATNA1 3 0 MLLT4 6 9.84E-05 
KCTD12 Not mapped in STRING MNT 2 0 
KDM3B Not mapped in STRING MPP2 8 8.17E-06 
KDM5C 10 1.93E-04 MPP6 13 3.88E-04 
KHDRBS1 24 0.00139968 MSH6 37 0.00313329 
KIAA0368 42 0.00239671 MTHFD2 14 2.05E-04 
KIAA0391 4 1.35E-04 MTMR14 5 6.52E-05 
KIAA0664 11 3.00E-04 MTOR 75 0.01252427 
KIAA0930 3 0 MYH10 18 0.00148921 
KIAA1429 1 0 MYH9 31 0.00115329 
KIAA1486 Not mapped in STRING MYL6 20 5.30E-04 
KIF1B 10 2.68E-04 MYO10 15 3.12E-04 
KLF4 12 3.70E-05 NAA10 6 2.22E-04 
KLHL15 Not mapped in STRING NACA 37 3.65E-04 
KNTC1 49 0.0026243 NADKD1 1 0 
KPNA1 27 6.58E-04 NAE1 17 3.69E-04 
KPNA2 57 0.00401336 NAMPT 4 4.24E-05 
KPNA3 19 2.28E-04 NAP1L1 22 0.00295745 
KPNA4 26 5.99E-04 NAP1L4 8 3.81E-05 
L2HGDH 2 1.22E-05 NASP 12 2.11E-04 
LANCL1 Not mapped in STRING NCAPD2 23 4.94E-04 
LANCL2 Not mapped in STRING NCAPD3 14 4.84E-04 
LARP1 14 1.56E-04 NCAPG 28 4.70E-04 
LARS 32 7.62E-04 NDUFAF3 1 0 
LCN1 1 0 NEFM 1 0 
LDHA 52 0.00187997 NF1 33 6.60E-04 
LDHB 55 0.00229064 NIPBL 10 4.85E-05 
LGALS7 3 0 NME1 65 0.00349539 
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LGALS7B Not mapped in STRING NONO 13 3.34E-04 
LOC389842 Not mapped in STRING NOP58 64 0.00504362 
LPCAT1 Not mapped in STRING NPM1 62 0.0043789 
LRPPRC 8 9.72E-05 NT5DC2 Not mapped in STRING 
LRRC59 Not mapped in STRING NUBP2 10 9.48E-04 
LTN1 14 5.60E-05 NUDC 29 8.87E-04 
LUC7L2 22 1.94E-04 NUP133 50 0.00227649 
LUC7L3 17 4.08E-04 NUP153 41 0.00152142 
LYZ 12 0.00335078 NUP155 39 0.00139126 
MAP1B 14 0.00215369 NUP160 45 0.00128665 
MAP3K7IP1 Not mapped in STRING NUP188 25 1.23E-04 
NUP205 32 7.41E-04 POLR1C 60 0.00510066 
NUP35 29 0.00256602 POLR2B 113 0.02123163 
NUP50 42 0.00364193 PPA1 38 0.00241027 
NUP54 29 5.36E-04 PPAT 18 1.63E-04 
ORC5 14 8.10E-05 PPIA 44 0.00296498 
ORC5L Not mapped in STRING PPM1B 21 8.64E-04 
OTUB1 8 0.00330249 PPP1CB 23 4.74E-04 
PAICS 86 0.01099495 PPP1CC 52 0.00745493 
PAIP1 14 5.94E-04 PPP2CA 125 0.01820768 
PBK 38 0.0021062 PPP2R1A 110 0.01305476 
PCBP1 46 0.00292856 PPP2R1B 56 0.00159694 
PCBP2 39 0.0013708 PPP2R2A 62 0.00194811 
PCNA 105 0.01447422 PPP2R2B 34 0.00153929 
PCYT1A 3 4.27E-06 PPP2R5C 52 6.94E-04 
PDCD2L Not mapped in STRING PPP2R5D 58 0.00196229 
PDCD4 15 4.88E-04 PPP2R5E 50 5.99E-04 
PDCD6 10 5.33E-04 PPP5C 26 5.57E-04 
PDIA6 41 0.00249717 PPP6R3 10 4.05E-04 
PDS5A 31 3.75E-04 PRDX1 43 0.00195091 
PEF1 3 2.22E-05 PRDX4 26 7.04E-04 
PELO 9 3.11E-04 PRDX5 16 7.39E-04 
PEPD 8 0 PRG2 Not mapped in STRING 
PFAS 81 0.00941427 PRIM2 Not mapped in STRING 
PFDN2 21 9.61E-05 PRKAG1 28 0.00322919 
PFN2 18 3.90E-04 PRKDC 61 0.00567711 
PGAM5 3 0 PRMT1 31 0.00194359 
PGM3 10 1.37E-05 PRPF19 63 0.00932331 
PHB 31 0.00183159 PRPF38B 1 0 
PHF23 Not mapped in STRING PRPF8 60 0.00498235 
PHGDH 33 0.00123346 PRPS1 22 3.06E-04 
PI4KA 16 0.0017761 PRPSAP2 13 1.41E-04 
PIK3C2A 25 0.00362704 PRRC2A 4 6.52E-05 
PIK3R4 10 5.18E-04 PRRC2B 1 0 
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PIP Not mapped in STRING PSMA1 59 0.00324669 
PIP4K2C 6 2.52E-04 PSMA4 53 0.00404131 
PKM 60 0.00381676 PSMA7 45 4.91E-04 
PKM2 Not mapped in STRING PSMC1 48 0.00291621 
PKP4 3 3.08E-05 PSMC2 59 0.00224815 
PLCG1 17 0.00197279 PSMC3 53 0.00287866 
PLEC 56 0.0054181 PSMC4 52 0.00204496 
PLEC1 Not mapped in STRING PSMC5 53 0.00215172 
PM20D2 Not mapped in STRING PSMC6 64 0.00459512 
PNO1 32 9.60E-04 PSMD11 45 6.87E-04 
POLD2 21 2.88E-04 PSMD12 45 0.00210698 
POLDIP3 24 5.14E-04 PSMD14 81 0.00844395 
POLE 59 0.00290838 PSMD3 42 3.82E-04 
PSMD6 44 0.0010217 RPL5 94 0.00383517 
PSMD8 41 0.00122418 RPL6 74 0.00194139 
PSMD9 43 0.001028 RPL7 86 0.00367086 
PSME1 38 8.54E-04 RPL7A 81 0.00405323 
PSME2 38 9.32E-04 RPL7P32 Not mapped in STRING 
PSME3 40 0.00195273 RPL8 88 0.00233152 
PSMF1 36 3.41E-05 RPLP0 101 0.0072243 
PSMG1 16 1.01E-04 RPLP2 61 0.00100607 
PTBP1 47 0.00167229 RPN2 45 0.00106645 
PUM1 7 1.56E-04 RPP30 22 4.66E-05 
PURA 3 1.63E-05 RPRD2 5 5.18E-05 
PYCRL 3 0 RPS13 82 0.00216 
RAD50 40 0.00194645 RPS14 78 0.00167172 
RAD54L2 7 9.86E-05 RPS16 78 0.00165818 
RAE1 38 0.00189132 RPS17 46 1.11E-04 
RANBP2 96 0.01149267 RPS18 71 0.00174118 
RAPGEF6 Not mapped in STRING RPS19 69 8.95E-04 
RBBP4 31 0.00127374 RPS2 96 0.00386386 
RBBP7 31 0.00152103 RPS20 80 0.00549458 
RBM12B 3 5.32E-05 RPS21 60 6.71E-04 
RBM16 Not mapped in STRING RPS24 69 0.00144033 
RBM22 33 1.18E-04 RPS27 78 0.00346429 
RBM4 13 4.69E-04 RPS27A  Not mapped in STRING 
RBM6 Not mapped in STRING RPS27L 57 4.68E-04 
RC3H1 1 0 RPS3 99 0.00580479 
RC3H2 1 0 RPS3A 78 0.00264861 
RCC2 26 2.18E-04 RPS4X 82 0.00301733 
RCN2 Not mapped in STRING RPS6 90 0.0063992 
RFC2 31 0.00182988 RPS8 75 0.00227805 
RFC4 71 0.00464623 RPSAP12 Not mapped in STRING 
RFC5 45 0.00160218 RPSAP15 Not mapped in STRING 
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RG9MTD1 Not mapped in STRING RPSAP55 Not mapped in STRING 
RIC8A Not mapped in STRING RTN4IP1 7 1.25E-04 
RIF1 7 2.47E-05 RUVBL1 47 0.00242772 
RNASE3 2 0 RUVBL2 34 0.00151223 
RNF160 Not mapped in STRING S100A10 7 2.49E-04 
RNH1 7 5.38E-05 S100A9 14 6.48E-04 
RNMT 9 4.24E-04 SAAL1 Not mapped in STRING 
RPL12 74 0.00321762 SAPS3 Not mapped in STRING 
RPL15 75 0.00162371 SBF1 Not mapped in STRING 
RPL22 58 7.64E-04 SCAF8 6 1.05E-04 
RPL23 68 0.00113525 SCLY 10 2.04E-04 
RPL27 56 2.33E-04 SDCCAG3 Not mapped in STRING 
RPL36AP37 Not mapped in STRING SEC16A 4 7.14E-05 
RPL38 56 2.92E-04 SEC24B 9 3.10E-04 
RPL4 98 0.00391575 SERBP1 13 4.61E-04 
SERPINB6 6 2.10E-05 TCP1 108 0.00983764 
SF3A3 42 0.00153403 TFCP2 2 0 
SF3B1 61 0.00944436 TH1L 9 3.99E-05 
SF3B14 33 1.60E-04 THADA 6 0.0033768 
SF3B4 35 3.14E-04 THOC2 30 0.0042978 
SFRS7 Not mapped in STRING THOC3 19 0.00106172 
SIP1 Not mapped in STRING THUMPD3 1 0 
SKP1 63 0.00548102 TIMM50 9 8.06E-05 
SLC25A1 20 0.00172455 TIPRL 10 2.67E-04 
SLC25A11 1 0 TMPO 14 1.01E-04 
SLC25A3 27 6.63E-04 TNKS1BP1 8 1.13E-04 
SLC25A4 15 0.00338487 TNRC6B 7 3.09E-04 
SLC25A5 37 3.84E-04 TOE1 5 7.52E-05 
SLC25A6 31 4.07E-04 TP53 169 0.05376185 
SLC7A9 4 0 TPM1 25 0.00130876 
SLK 9 1.79E-04 TPM3 19 4.49E-04 
SMARCA4 60 0.00682904 TPM4 24 6.37E-04 
SMC2 32 6.96E-04 TPP1 2 1.01E-05 
SMC4 36 7.81E-04 TPR 45 0.00305962 
SNRNP200 50 0.00559067 TRAF2 31 7.67E-04 
SNRPB 64 0.00390637 TRAPPC2L 3 1.49E-04 
SNRPC 39 5.56E-04 TRIM65 Not mapped in STRING 
SNRPE 51 0.00129776 TRIP12 35 0.00199184 
SNX27 Not mapped in STRING TRIP13 26 4.83E-04 
SPAG9 1 0 TRIP6 12 3.32E-04 
SPTAN1 47 0.00907029 TRMT10C 6 1.41E-04 
SRM 9 7.48E-05 TRMT11 8 1.00E-04 
SRPRB 36 7.54E-04 TRMT112 8 0.00349947 
SRSF7 54 0.00246868 TROVE2 2 9.60E-06 
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STAG2 37 0.00189833 VIM 36 0.00587713 
STARD7 1 0 TRRAP 33 0.00245945 
STK25 9 3.76E-05 TSC1 21 7.30E-04 
STK4 6 8.79E-04 TSC2 27 0.00261116 
STRAP 19 8.51E-04 TSNAX 3 6.54E-05 
STUB1 36 0.00249913 TTC4 13 9.10E-04 
SUGT1 18 2.25E-04 TUBA1A 52 0.00273596 
SUPT5H 50 0.00729301 TUBA1C 49 0.00153618 
SYNCRIP 33 0.00243678 TUBA3D 31 9.44E-04 
SYNRG 4 0 TUBA4A 54 0.00171606 
TAB1 11 1.38E-04 TUBAL3 32 3.61E-04 
TARBP1 9 3.09E-04 TUBB 57 0.00237986 
TARDBP 19 0.00106513 TUBB1 40 6.36E-04 
TBC1D4 7 1.66E-06 TUBB2A 51 0.00184416 
TBCB 14 2.85E-05 TUBB2C Not mapped in STRING 
TBCE 15 3.40E-05 TUBB3 36 0.00176117 
TCEB2 25 0.00130656 TUBB4 Not mapped in STRING 
TUBB4B 59 0.00252014 TUBB4A 48 9.38E-04 
TUBB6 42 8.43E-04 WDR77 16 3.63E-04 
TUBG1 37 0.0016588 XIAP 24 8.08E-04 
TUFM 59 0.00298755 XPO1 101 0.01931212 
TXN 63 0.00555186 XPO5 29 0.00184956 
TXNDC5 36 0.00182089 XRN1 26 0.00142999 
U2AF1 57 0.00230364 YLPM1 1 0 
U2AF2 64 0.00495144 YRDC 2 0 
UBA1 39 0.00309404 YWHAB 41 0.00426707 
UBAP2 5 1.09E-04 YWHAE 39 0.00185874 
UBAP2L 6 2.89E-04 YWHAG 36 0.00185471 
UBB Not mapped in STRING YWHAQ 37 0.0023876 
UBC 150 0.03059425 YWHAZ 46 0.00400644 
UBE2L3 27 0.00134361 YY1 30 0.00234145 
UBE2O 13 0 ZC3H15 5 0.00337035 
UBR4 22 8.48E-04 ZC3HAV1L Not mapped in STRING 
UBR5 17 6.60E-04 ZCCHC11 5 3.68E-05 
UBXN1 9 1.75E-04 ZEB2 6 1.71E-05 
UCK2 6 9.41E-06 ZFYVE16 2 9.40E-07 
UGCGL1 Not mapped in STRING ZMYM4 3 0 
UGGT1 4 2.05E-05 ZNF318 Not mapped in STRING 
UPF1 66 0.00467004 ZNF362 Not mapped in STRING 
USP24 8 1.25E-04 ZNF609 Not mapped in STRING 
USP34 12 1.90E-04    
USP47 5 3.45E-05    
USP7 35 0.01004796    
USP9X 24 0.00180067    
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Appendix 2: Full list of GO term enrichment 
 
Merged name GO Biological process Pathway description Observed count FRD Pvalue 
Cell cycle GO.0007049 cell cycle 129 6.05E-32 
Cell cycle GO.0000278 mitotic cell cycle 105 7.56E-35 
Cell cycle GO.1903047 mitotic cell cycle process 98 7.3E-34 
Cell cycle GO.0022402 cell cycle process 115 3.91E-33 
Cell cycle GO.0031571 mitotic G1  DNA damage 
checkpoint 
27 1.78E-19 
Cell cycle GO.0044770 cell cycle phase transition 50 1.82E-19 
Cell cycle GO.0051439 regulation of ubiquitin-protein 
ligase activity involved in mitotic 
cell cycle 
29 1.96E-19 
Cell cycle GO.0007093 mitotic cell cycle checkpoint 37 2.64E-19 
Cell cycle GO.1901991 negative regulation of mitotic cell 
cycle phase transition 
36 4.85E-19 
Cell cycle GO.0044772 mitotic cell cycle phase transition 49 5.31E-19 
Cell cycle GO.1901988 negative regulation of cell cycle 
phase transition 
37 5.85E-19 
Cell cycle GO.0072431 signal transduction involved in 
mitotic G1  DNA damage 
checkpoint 
25 9.73E-19 
Cell cycle GO.0000075 cell cycle checkpoint 41 1.8E-18 
Cell cycle GO.0051437 positive regulation of ubiquitin-
protein ligase activity involved in 
regulation of mitotic cell cycle 
transition 
25 7.17E-18 
Cell cycle GO.0044774 mitotic DNA integrity checkpoint 29 9E-18 
Cell cycle GO.0006977 DNA damage response, signal 
transduction by p53 class 
mediator resulting in cell cycle 
arrest 
24 1.05E-17 
Cell cycle GO.0044773 mitotic DNA damage checkpoint 28 1.77E-17 
Cell cycle GO.1901990 regulation of mitotic cell cycle 
phase transition 
42 1.85E-17 
Cell cycle GO.1901987 regulation of cell cycle phase 
transition 
43 3.82E-17 
Cell cycle GO.2000134 negative regulation of G1/S 
transition of mitotic cell cycle 
28 5.44E-17 
Cell cycle GO.0010948 negative regulation of cell cycle 
process 
40 8.25E-17 
Cell cycle GO.0045930 negative regulation of mitotic cell 
cycle 
39 9.24E-17 
Cell cycle GO.0071158 positive regulation of cell cycle 
arrest 
25 1.02E-15 
Cell cycle GO.0051726 regulation of cell cycle 80 1.2E-15 
Cell cycle GO.0045786 negative regulation of cell cycle 52 5.6E-15 
Cell cycle GO.2000045 regulation of G1/S transition of 
mitotic cell cycle 
29 1.44E-14 
Cell cycle GO.0000082 G1/S transition of mitotic cell 
cycle 
32 2.35E-14 
Cell cycle GO.0071156 regulation of cell cycle arrest 26 3.21E-14 
Cell cycle GO.0007346 regulation of mitotic cell cycle 50 2.45E-13 
Cell cycle GO.0010564 regulation of cell cycle process 52 2.56E-12 
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Cell cycle GO.0045787 positive regulation of cell cycle 35 1.19E-09 
Cell cycle GO.0090068 positive regulation of cell cycle 
process 
31 1.25E-09 
Cell cycle GO.0007067 mitotic nuclear division 35 1.79E-08 
Cell cycle GO.0007077 mitotic nuclear envelope 
disassembly 
13 2.14E-08 
Cell cycle GO.0051301 cell division 40 2.12E-07 
Cell cycle GO.0000280 nuclear division 36 0.00000139 
Cell cycle GO.0000086 G2/M transition of mitotic cell 
cycle 
19 0.00000382 
Cell cycle GO.0000070 mitotic sister chromatid 
segregation 
9 0.00851 
Cell cycle GO.0007094 mitotic spindle assembly 
checkpoint 
6 0.0111 
Cell cycle GO.0010389 regulation of G2/M transition of 
mitotic cell cycle 
7 0.0163 
Cell cycle GO.0007084 mitotic nuclear envelope 
reassembly 
3 0.0498 
     
Chromatin structure GO.0006325 chromatin organization 39 0.000541 
Chromatin structure GO.0043044 ATP-dependent chromatin 
remodeling 
10 0.00224 
Chromatin structure GO.0016568 chromatin modification 31 0.00738 
Chromatin structure GO.0032508 DNA duplex unwinding 7 0.0201 
Chromatin structure GO.0006338 chromatin remodeling 13 0.0223 
Chromatin structure GO.0031497 chromatin assembly 11 0.0259 
Chromatin structure GO.0006333 chromatin assembly or 
disassembly 
12 0.0272 
     
DNA damage, repair 
and surveillance  
GO.0006284 base-excision repair 8 0.00299 
DNA damage, repair 
and surveillance  
GO.0031571 mitotic G1  DNA damage 
checkpoint 
27 1.78E-19 
DNA damage, repair 
and surveillance  
GO.0072422 signal transduction involved in 
DNA damage checkpoint 
26 2.38E-19 
DNA damage, repair 
and surveillance  
GO.0072431 signal transduction involved in 
mitotic G1  DNA damage 
checkpoint 
25 9.73E-19 
DNA damage, repair 
and surveillance  
GO.0044774 mitotic DNA integrity checkpoint 29 9E-18 
DNA damage, repair 
and surveillance  
GO.0006977 DNA damage response, signal 
transduction by p53 class 
mediator resulting in cell cycle 
arrest 
24 1.05E-17 
DNA damage, repair 
and surveillance  
GO.0006974 cellular response to DNA damage 
stimulus 
70 1.57E-17 
DNA damage, repair 
and surveillance  
GO.0044773 mitotic DNA damage checkpoint 28 1.77E-17 
DNA damage, repair 
and surveillance  
GO.0000077 DNA damage checkpoint 32 5.72E-17 
DNA damage, repair 
and surveillance  
GO.0031570 DNA integrity checkpoint 33 5.73E-17 
DNA damage, repair 
and surveillance  
GO.0072331 signal transduction by p53 class 
mediator 
26 1.45E-12 
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DNA damage, repair 
and surveillance  
GO.0006281 DNA repair 42 7.74E-10 
DNA damage, repair 
and surveillance  
GO.0071478 cellular response to radiation 15 0.00126 
DNA damage, repair 
and surveillance  
GO.0042769 DNA damage response, detection 
of DNA damage 
7 0.00205 
DNA damage, repair 
and surveillance  
GO.0006289 nucleotide-excision repair 10 0.00372 
DNA damage, repair 
and surveillance  
GO.0006297 nucleotide-excision repair, DNA 
gap filling 
5 0.00445 
DNA damage, repair 
and surveillance  
GO.0045738 negative regulation of DNA repair 4 0.00613 
DNA damage, repair 
and surveillance  
GO.0043517 positive regulation of DNA 
damage response, signal 
transduction by p53 class 
mediator 
4 0.0117 
DNA damage, repair 
and surveillance  
GO.0006283 transcription-coupled nucleotide-
excision repair 
7 0.0118 
DNA damage, repair 
and surveillance  
GO.2001020 regulation of response to DNA 
damage stimulus 
12 0.0193 
DNA damage, repair 
and surveillance  
GO.0006979 response to oxidative stress 21 0.0317 
DNA damage, repair 
and surveillance  
GO.0008630 intrinsic apoptotic signalling 
pathway in response to DNA 
damage 
8 0.034 
DNA damage, repair 
and surveillance  
GO.2000780 negative regulation of double-
strand break repair 
3 0.0388 
DNA damage, repair 
and surveillance  
GO.2001022 positive regulation of response to 
DNA damage stimulus 
7 0.0389 
DNA damage, repair 
and surveillance  
GO.0006302 double-strand break repair 11 0.0486 
     
DNA replication  GO.0051276 chromosome organization 64 1E-09 
DNA replication  GO.0051052 regulation of DNA metabolic 
process 
28 0.00000186 
DNA replication  GO.0071103 DNA conformation change 21 0.000077 
DNA replication  GO.0006260 DNA replication 20 0.000156 
DNA replication  GO.0006323 DNA packaging 15 0.0021 
DNA replication  GO.0006310 DNA recombination 17 0.00256 
DNA replication  GO.2001251 negative regulation of 
chromosome organization 
11 0.00375 
DNA replication  GO.0051053 negative regulation of DNA 
metabolic process 
10 0.00838 
DNA replication  GO.0051098 regulation of binding 19 0.00987 
DNA replication  GO.0051321 meiotic cell cycle 13 0.0162 
DNA replication  GO.0033260 nuclear DNA replication 5 0.0189 
DNA replication  GO.0006278 RNA-dependent DNA replication 4 0.0193 
DNA replication  GO.0006278 RNA-dependent DNA replication 4 0.0193 
DNA replication  GO.0006275 regulation of DNA replication 11 0.023 
DNA replication  GO.0071897 DNA biosynthetic process 9 0.023 
DNA replication  GO.0051053 DNA biosynthetic process 9 0.023 
DNA replication  GO.0070192 chromosome organization 
involved in meiosis 
6 0.0272 
DNA replication  GO.0070987 error-free translesion synthesis 4 0.0366 
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DNA replication  GO.0010032 meiotic chromosome 
condensation 
2 0.0465 
     
Telomere 
maintenance 
GO.0010833 telomere maintenance via 
telomere lengthening 
8 0.000323 
Telomere 
maintenance 
GO.0000723 telomere maintenance 10 0.0025 
Telomere 
maintenance 
GO.0032201 telomere maintenance via semi-
conservative replication 
5 0.00896 
Telomere 
maintenance 
GO.0000722 telomere maintenance via 
recombination 
5 0.0189 
     
Transcription & 
translation  
GO.0010608 posttranscriptional regulation of 
gene expression 
51 4.98E-19 
Transcription & 
translation  
GO.0006417 regulation of translation 43 1.73E-16 
Transcription & 
translation  
GO.0045899 positive regulation of RNA 
polymerase II transcriptional 
preinitiation complex assembly 
7 3.94E-07 
Transcription & 
translation  
GO.0010629 negative regulation of gene 
expression 
79 0.000001 
Transcription & 
translation  
GO.0045727 positive regulation of translation 12 0.0000539 
Transcription & 
translation  
GO.0006446 regulation of translational 
initiation 
12 0.0000834 
Transcription & 
translation  
GO.0006367 transcription initiation from RNA 
polymerase II promoter 
23 0.000114 
Transcription & 
translation  
GO.0006352 DNA-templated transcription, 
initiation 
24 0.000281 
Transcription & 
translation  
GO.0045892 negative regulation of 
transcription, DNA-templated 
58 0.000609 
Transcription & 
translation  
GO.1903507 negative regulation of nucleic 
acid-templated transcription 
58 0.00082 
Transcription & 
translation  
GO.0006366 transcription from RNA 
polymerase II promoter 
43 0.00218 
Transcription & 
translation  
GO.0016441 posttranscriptional gene silencing 7 0.00702 
Transcription & 
translation  
GO.0006283 transcription-coupled nucleotide-
excision repair 
7 0.0118 
Transcription & 
translation  
GO.0000122 negative regulation of 
transcription from RNA 
polymerase II promoter 
38 0.0218 
Transcription & 
translation  
GO.0010628 positive regulation of gene 
expression 
70 0.0225 
Transcription & 
translation  
GO.0010628 positive regulation of gene 
expression 
70 0.0225 
Transcription & 
translation  
GO.0040029 regulation of gene expression, 
epigenetic 
16 0.0272 
Transcription & 
translation  
GO.0006357 regulation of transcription from 
RNA polymerase II promoter 
69 0.0311 
Transcription & 
translation  
GO.0006369 termination of RNA polymerase II 
transcription 
6 0.0415 
     
Ubiquitination  GO.0031397 negative regulation of protein 
ubiquitination 
34 3.63E-20 
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Ubiquitination  GO.0051444 negative regulation of ubiquitin-
protein transferase activity 
29 5.39E-20 
Ubiquitination  GO.0051438 regulation of ubiquitin-protein 
transferase activity 
33 7.11E-20 
Ubiquitination  GO.0051439 regulation of ubiquitin-protein 
ligase activity involved in mitotic 
cell cycle 
29 1.96E-19 
Ubiquitination  GO.0031145 anaphase-promoting complex-
dependent proteasomal 
ubiquitin-dependent protein 
catabolic process 
27 1.34E-18 
Ubiquitination  GO.0051437 positive regulation of ubiquitin-
protein ligase activity involved in 
regulation of mitotic cell cycle 
transition 
25 7.17E-18 
Ubiquitination  GO.0051443 positive regulation of ubiquitin-
protein transferase activity 
27 1.85E-17 
Ubiquitination  GO.0031396 regulation of protein 
ubiquitination 
41 3.41E-17 
Ubiquitination  GO.2000058 regulation of protein 
ubiquitination involved in 
ubiquitin-dependent protein 
catabolic process 
26 5.13E-16 
Ubiquitination  GO.0031398 positive regulation of protein 
ubiquitination 
30 3.38E-13 
Ubiquitination  GO.0000209 protein polyubiquitination 32 9.09E-13 
Ubiquitination  GO.0000209 protein polyubiquitination 32 9.09E-13 
Ubiquitination  GO.0043161 proteasome-mediated ubiquitin-
dependent protein catabolic 
process 
39 2.08E-12 
Ubiquitination  GO.0006511 ubiquitin-dependent protein 
catabolic process 
45 3.02E-11 
Ubiquitination  GO.0016567 protein ubiquitination 45 8.53E-08 
Ubiquitination  GO.0032435 negative regulation of 
proteasomal ubiquitin-dependent 
protein catabolic process 
10 0.000323 
Ubiquitination  GO.0032434 regulation of proteasomal 
ubiquitin-dependent protein 
catabolic process 
15 0.000794 
Ubiquitination  GO.1901315 negative regulation of histone 
H2A K63-linked ubiquitination 
3 0.00087 
Ubiquitination  GO.0070534 protein K63-linked ubiquitination 6 0.0111 
Ubiquitination  GO.1902914 regulation of protein 
polyubiquitination 
4 0.0117 
Ubiquitination  GO.0036503 ERAD pathway 8 0.0133 
Ubiquitination  GO.0030433 ER-associated ubiquitin-
dependent protein catabolic 
process 
7 0.0357 
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